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Introduction
Proliferative vitreoretinopathy
proliferative vitreoretinopathy (pVR) occurs in approximately 10% of patients with 
rhegmatogenous retinal detachment (RRD) and is the major cause of failed retinal 
detachment surgery 1-3. Established pVR is characterized by the presence of subretinal, 
intraretinal, and/or epiretinal contractile fibroproliferative membranes that cause (re)
detachment of the retina with reduced or even complete loss of vision as a consequence 
(figure 1) 1-3. 
Established pVR can currently only be treated by (further) surgical intervention with its 
potential risks. A pharmacological strategy to treat pVR would therefore be preferable. 
Current treatment approaches are anti-inflammatory agents (steroids), anti-proliferative 
agents (Daunomycin, 5-fu, retinoid acid) and heparin 4-8. Although not clearly described 
in these studies, the likely rationale behind heparin therapy was to trap growth factors 
and prevent fibrin formation. However, only two of five studies involving heparin showed 
some benefit. 
The pathophysiology of PVR comprises inflammation, cellular proliferation and 
deregulated tissue remodeling 1, 9, 10. Although our knowledge on pVR development has 
increased during the last decades, more detailed insight into the cellular and molecular 
networks is absolutely required to identify and/or improve potential therapeutic 
strategies to prevent pVR in patients who are at risk. In order to investigate novel 
pathophysiological mechanisms we set up a series of experiments described in this 
thesis.
figure 1: fundus photographs of retinal detachments. Depicting a large retinal tear without 
fibroproliferative membranes (left) and an ablation with an epiretinal membrane (right).
Current insight in the pathophysiology of proliferative vitreoretinopathy
Inflammation and fibrosis represent central processes in the pathophysiology of PVR. 
Although far from completely understood pVR is the result of an intricate interplay 
between different cell types and soluble factors, including cytokines, growth factors, 
but also adhesion molecules. 
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Chapter 1 
Inflammation in PVR
Elevated levels of cytokines and chemokines, including chemokine (C-C motif) ligand 
(CCl)2, chemokine (C-X-C motif) ligand (CXCl)8, CXCl10, CXCl12, interleukin (Il)-6 and 
macrophage-colony stimulating factor (m-CSf), have been found in vitreous of patients 
with (established) pVR 11-19. These cytokines/chemokines recruit, activate and stimulate 
the differentiation of immune cells at sites of disturbed tissue homeostasis, while some 
(e.g. Il-6) also enhance vascular permeability 20-22. In line with this, increased vascular 
permeability is associated with pVR and leukocytes, primarily monocytes/macrophages, 
but also neutrophils, are present in vitreous and fibroproliferative membranes from 
patients with pVR, while B- and T-lymphocytes are present less frequently 1, 10, 23, 24. The 
presumed contribution of the different types of leukocytes i.e. monocytes, macrophages, 
neutrophils and lymphocytes to pVR development is discussed hereunder. 
Monocytes and macrophages
upon tissue injury monocytes are recruited from the systemic circulation into the 
damaged tissue where they differentiate into macrophages that contribute to 
removal of cellular debris and, when present, infectious agents 25. Instructed by the 
local environment, these macrophages can adopt either an m1 or m2-phenotype. 
The M1 phenotype is mostly associated with inflammatory responses. In contrast M2-
macrophages secrete cytokines and growth factors, including IL-10, fibroblast growth 
factor (fgf) and platelet-derived growth factor (pDgf) that stimulate healing processes 
26. unsuccessful healing attempts are associated with uncontrolled m2 skewing and 
consequently enhanced and prolonged production of growth factors 27. Therefore, an 
important role is ascribed to M2-macrophages in fibrosis development 28-31. monocytes 
and macrophages are abundantly present in vitreous and retinal tissue from pVR 
patients 1, 10, 24. following retinal detachment macrophages can be expected to contribute 
to removal of cellular debris that originated from the damaging insult. However, they 
are also reported as important producers of pro-fibrotic mediators such as PDGF, 
transforming growth factor (TGF)-β and vascular endothelial growth factor (VEGF) that 
have been found elevated in vitreous from patients with pVR 1, 9, 10, 32. Although to date 
no studies are available that examined m1 versus m2 skewing in pVR pathogenesis, m2-
macrophages are likely to be involved in the fibrotic response associated with PVR. For 
example, activated autologous peritoneal macrophages induced pVR when injected into 
rabbit’s eyes. These macrophages remained in the eye for a median period of 12 hours, 
a period probably sufficient to secrete the pro-fibrotic mediators mentioned above 
33. However, so far the mechanisms and molecules involved in monocyte recruitment 
and subsequent macrophage differentiation in PVR are still poorly understood, and are 
therefore not an attractive target for pharmacological intervention.  
Neutrophils
Neutrophils have been identified in vitreous and retinal membranes from patients with 
pVR 10, 32, 34. Their recruitment most likely involves the chemokine CXCl8 (Il-8), which is 
amongst the most potent neutrophil chemotactic factors and abundantly present in 
vitreous from pVR patients 34. Despite their presence the contribution of neutrophils to 
pVR development is hardly examined as well. They can be expected to contribute to 
removal of cellular debris, but on the other hand might further aggravate tissue damage 
via the release of proteases including matrix metalloproteases that are elevated in pVR 
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ocular fluids or possibly other enzymes such as elastase 35-37. moreover, neutrophils 
are an extremely rich source of cytokines and as such can be involved in shaping the 
inflammatory environment 38.
Lymphocytes
B-lymphocytes and T-lymphocytes are only occasionally present in vitreous from 
patients with RRD, established pVR and in pVR membranes 10, 23, 24, 32, 39. This suggests that 
lymphocytes only marginally contribute to pVR development. This is further supported 
by an  experimental animal study in which pVR development and severity was compared 
between wild-type (WT) mice and RAG1-deficient mice (lacking B- and T-lymphocytes). 
This study demonstrated that although T-lymphocytes were present in pVR lesions of 
the WT mice, PVR incidence and severity was similar between WT and RAG1-deficient 
mice 40. It can, however, not be excluded that lymphocytes, when present, contribute 
to the local inflammatory environment, for instance via the secretion of cytokines and 
growth factors such as IL-6 and TGF-β 34, 41. 
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Fibrosis in PVR
Fibrosis is often regarded as a deregulated healing attempt and is defined as excessive 
accumulation of extracellular matrix (ECm) components with an associated loss of 
normal tissue architecture, elasticity and function 42. Although a variety of different 
insults can result in fibrosis the formation and proliferation of so-called myofibroblasts is 
a common feature of fibrosis in all organ system 43.  Myofibroblasts are highly specialized 
fibroblast-like cells that exhibit contractile properties and high capacity to synthesize 
ECm molecules 44. Excessive ECM deposition and myofibroblast formation are evident 
histopathological features of pVR as well and will be discussed further below.  
Extracellular matrix molecules 
The fibrotic membranes in PVR contain a variety of ECM molecules that are normally 
absent or hardly present in the retina. The fibrillar collagen subtypes -I and -III are the 
most abundant, but also subtypes -II, -IV and -V have been detected in pVR membranes 
45, 46. Besides collagen, elastin, laminin, fibronectin and vitronectin have also been 
detected by immunohistochemistry in pVR membranes 47. The ECm composition of 
retinal fibroproliferative membranes can vary in the course of disease. For instance, 
fibronectin appears to be more abundant in membranes of short clinical duration while 
collagen content increases in time 45, 48, 49. moreover, the cellularity of the membranes 
decreases with clinical duration 9, 47. These changes in ECm composition and cellularity 
are comparable to those in healing and fibrosis in other organ systems 50.
Retinal pigment epithelial cells and myofibroblasts 
RpE cells form a monolayer between the photoreceptors and Bruch’s membrane and 
are considered as a part of the outer blood-retinal barrier (BRB). Highly specialized tight 
junction molecules between the RpE cells provide them with their barrier function (figure 
2) 51-53. RpE cells are in close contact with Bruch’s membrane at the lateral side while their 
apical side is separated from the neuroretina by subretinal spaces  51-53. One of the main 
functions of RpE cells is to regulate the ionic composition within the subretinal space, 
which provides the photoreceptors with an environment for proper functioning. The RpE 
cells also transport waste, water and nutrients from the subretinal space, and participate 
in the visual cycle 54-56. The RpE cells are a major source of ocular angioregulatory proteins 
like the anti-angiogenic pigment epithelium-derived factor (pEDf) and pro-angiogenic 
VEgf and thus play an important role in maintaining the ocular angiogenic homeostasis 
through a balanced production of these positive and negative regulatory factors 57.
During pathology RpE cells can lose their physiological properties and contribute to 
local inflammatory and fibrotic responses. RPE express many receptors that can bind 
cytokines, growth factors, pathogens and other ligands, but are themselves a rich 
source of cytokines and growth factors as well 58, 59. In pVR the RpE cells exert a clear pro-
fibrotic role. RPE cells are abundantly present in PVR membranes and de-differentiate 
into myofibroblasts by a process referred to as epithelial mesenchymal transition (EMT) 
1, 10. EmT is associated with loss of typical epithelial features (e.g. tight junction molecules 
like zonula occludens and E-cadherin) while mesenchymal features (e.g. α-smooth 
muscle actin (α-SMA) and fibronectin expression) that promote migratory capacity, 
invasiveness and resistance to apoptosis are acquired 60-62. Importantly, myofibroblasts 
exhibit a strong capacity to produce collagen molecules when stimulated with growth 
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factors, including PDGF and TGF-β 63, 64. In principle EmT represents a normal physiological 
response to tissue injury to promote wound closure and tissue repair 62. In normal healing 
processes EMT is tightly controlled, but in fibrosis EMT programs are not attenuated, 
resulting in persistent myofibroblast formation and excessive ECM accumulation 65. 
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RPE-derived myofibroblasts thus represent an important source of the fibroblast-like 
cells that accumulate in pVR membranes and are indicative of the deregulated healing 
attempt 66. Here myofibroblasts not only represent a major cell type involved in excessive 
ECm production, but the expression of α-SmA also provides these cells with contractile 
properties that cause pVR membrane contraction. This contraction contributes to 
further retinal detachment 45, 62, 67, 68. These data point at an important role for EmT of 
RPE cells in the fibrotic process of PVR, however there is only limited data available on 
which factors exactly drive EmT by human RpE. 
Other cell types 
The retina contains astrocytes and glial cells, amongst which müller cells that are the 
principal supporting glial cells of the retina 69-71. Retinal damage/detachment induces 
proliferation of astrocytes and glial cells and immunohistochemical studies identified 
astrocyte and glial cell markers in pVR membranes 72. These glial cells contribute to pVR 
membrane formation, mostly via collagen type-I production and myofibroblastic de-
differentiation 73, 74.
In tissue repair processes (myo)fibroblasts originate from several sources, including 
the earlier discussed EMT. However at sites of tissue inflammation/healing fibroblast-
like cells can also derive via recruitment and differentiation of circulating fibrocytes 75. 
fibrocytes are bone-marrow derived mesenchymal cells that circulate as peripheral 
blood mononuclear cells and express among others CD34, CD45, specific chemokine 
receptors as well as ECM molecules (e.g. collagen type-I and fibronectin) 75, 76. fibrocytes 
rapidly infiltrate sites of tissue damage where they participate in inflammation, healing 
and tissue remodeling, but they are also involved in fibrosis and as such they have been 
suggested to contribute to pVR development 77, 78. However, how fibrocyte recruitment 
and subsequent differentiation is regulated in PVR requires further studies.   
figure 2: Schematic overview of the 
many functions of RpE in normal 
polarized condition: providing a 
protective barrier, light absorption, 
contribution to the visual cycle, 
phagocytosis,  transepithelial 
transport of ions, nutrient secretion 
and immune modulation of the eye. 
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Growth factors in PVR development
Despite the variety of insults associated with fibrosis it is generally accepted that 
fibrosis is largely driven by excess presence of cytokines, growth factors and their 
receptors within the affected tissue where they stimulate (myo)fibroblast recruitment, 
proliferation, differentiation and ECM molecule production 79. In pVR the true initiating 
insult remains enigmatic, but certain gene polymorphisms, for instance in mouse double 
minute 2, human homolog of; p53-binding protein, (mDm2), tumor protein (Tp)53, 
mothers against decapentaplegic homolog (SmAD)7 and tumor necrosis factor (TNf) 
have been linked to pVR  development, although their exact contribution remains to 
be established 80-83. However, enhanced intraocular growth factor activity is clearly 
implicated in pVR pathogenesis 84-86. These growth factors derive from different sources. 
They may for instance originate from blood secondary to BRB breakdown or via local 
production by the various described cell types including glial cells, RpE cells, (myo)
fibroblasts and infiltrated immune cells 1, 10, 68, 84-86. A variety of growth factors, their 
receptors and signaling pathways have been found elevated in vitreous and membranes 
from pVR patients and are summarized in table 1 1, 87.  moreover, connective tissue growth 
factor (CTgf), which binds domains of growth factors and matrix metalloproteases, is 
downstream of various growth factors amongst which pDgf, Tgf-β and VEgf signaling, 
is also associated with pVR 84, 88-92. CTgf contributes to physiological wound healing 
and fibrosis by inducing ECM production 88, 91, 92. CTgf is highly expressed in human pVR 
membranes and partially co-localized with cytokeratin-positive RpE cells 89. furthermore 
a prominent accumulation of the N-terminal half of CTgf was found in the vitreous of 
patients with pVR 89.  Because PDGF, TGF-β and VEGF are thought to be amongst the 
most important growth factors involved in pVR they are discussed in more detail.    
Platelet-derived growth factor
pDgf is a family of polypeptides that exert broad functions, both in health and disease 
128. The pDgf family consists of the dimeric family members, pDgf-AA, -AB, -BB, -CC and 
–DD.   pDgf-AA and pDgf-BB are secreted in their active form after intracellular process-
ing, while pDgf-CC and pDgf-DD are secreted as latent molecules that require extracellu-
lar activation by proteases 129. PDGF molecules activate specific PDGF-receptor (PDGFR) 
dimers, being PDGFR-αα, PDGFR-αβ or PDGF-ββ dimers (table 1) 114, 130. pDgf is not only re-
leased by platelet degranulation following injury but is also produced by a variety of cell 
types, including macrophages, fibroblasts and RPE cells 110, 131. pDgf molecules stimulate 
chemotaxis and proliferation of different cell types including neutrophils, macrophages, 
fibroblasts, fibrocytes and smooth muscle cells at sites of injury 132, 133. pDgf also induces 
myofibroblast differentiation and stimulates ECM production 134, 135. pDgf-molecules are 
generally considered as key driving forces in fibrosis 136.
Of all growth factors measured to date, pDgf isoforms are amongst the ones most highly 
present in vitreous of patients and experimental animals with pVR, suggesting that they 
strongly contribute to disease pathogenesis 74, 89, 134. The pDgf molecules can be blood 
derived or originate from local production by glial cells, RpE cells and macrophages 14, 
137, 138. PDGF induces proliferation and myofibroblast differentiation by glial cells and RPE 
cells 113. Retinal glial cells express PDGFR-α and PDGFR-β chains, while RPE cells express 
the PDGFR-β chain at far higher levels than the PDGFR-α chain 114. In human vitreous 
samples as well as in experimental animal models PDGF-CC has been identified as 
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important contributor to pVR development 139, 140. However the clear involvement of RpE 
cells in PVR pathogenesis along with their predominant expression of PDGFR-β chains 
suggests a role for PDGF-BB and PDGF-DD that predominantly activate PDGFR-ββ dimers. 
Nevertheless the low expression of PDGFR-α chains by RPE does not exclude that PDGFR-
αβ dimer activation by PDGF-AB, PDGF-BB, PDGF-DD, and possibly PDGF-CC, or PDGFR-
αα dimer activation by PDGF-AA, PDGF-AB and PDGF-CC contribute to RPE activation in 
pVR 128. pDgf-BB has been shown stimulate EmT by RpE via pDgfR signaling and pDgfR 
activity has been observed in human epi- and subretinal membranes, although this was 
not confined to a specific cell type 114, 141-143. 
Growth factor Growth factor 
receptor
Target cells Cellular effect
epidermal growth 
factor (Egf)
Egf-receptor glial cells 93-95
RpE 96, 97
differentiation 98
migration 97
fibroblast growth 
factor (fgf)
fgf-receptor glial cells 99-101
RpE 99
differentiation 102
migration 102
proliferation 101, 102
heparin-binding 
Egf-like
growth factor (HB-
Egf)
Egf-receptor glial cells 93-95
RpE 96, 97
chemotaxis 95
differentiation 95
migration 97
proliferation 95
insulin-like growth 
factor (Igf)
Igf-receptor
insulin receptor
glial cells 103
RpE 104-107
migration 104-106
proliferation 104, 106, 107
pigment epithelium 
derived–
factor (pEDf)
pEDf-receptor RpE 108, 109 anti-migration 108, 109
platelet-derived 
growth
factor (pDgf)
pDgf-receptor fibroblast 110, 111
glial cells 103
RpE 110 112-114
chemotaxis 112, 113
differentiation 115
ECm production 116
proliferation 112
transforming growth 
factor – α (TGF-α)
Egf-receptor glial cells 93-95
RpE 96, 97
differentiation 98
migration 97
transforming growth 
factor – β (TGF-β)
TGF-β-receptor fibroblasts 117
RpE 118-120
differentiation 117, 118, 
120, 121
ECm production 88, 119
proliferation 118
vascular endothelial 
growth
factor (VEgf)
VEgf-receptor glial cells 122
RpE 122, 123
proliferation 124
hepatocyte growth 
factor (Hgf)
c-mET RpE125, 126 proliferation 125-127
migration 125, 127
Table 1: growth factors implicated in pVR
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Transforming growth factor-β
Transforming growth factor (Tgf)- β contains three isoforms, TGF-β1, TGF-β2 and TGF-β3  
TGF-β molecules are dimeric molecules that are initially secreted by the producing cells 
as a large latent complex that also contains two latency associated peptide (lAp) chains 
and a latent TGF-β binding protein (LTBP) 144. After secretion active TGF-β is released 
from the latent complex, mainly via the action of proteases for instance plasmin, matrix 
metalloproteases (mmp)-2 and -9, bone morphogenetic protein (Bmp)-1, but also other 
molecules such as thrombospondin 1, retinoic acid, αV integrins as well as reactive oxygen 
species and by an acidic environment (e.g. low pH) 145-149. After formation the active TGF-β 
molecules interact with a receptor complex forming a heterotetrameric combination 
containing two type-I TGF-β-receptors (TGF-βR-I) and two TGF-βR-II subunits 150. Besides 
TGF-βR-I and TGF-βR-II also TGF-βR-III is expressed. TGF-β-R-III is not a typical receptor 
as it is not able to transmit signaling by itself, but has a co-receptor function that can 
present TGF-β to a receptor complex consisting of TGF-βR-I and TGF-βR-II subunits 151-
154. TGF-β isoforms regulate cellular proliferation, differentiation, migration, survival, 
ECm production and are involved in embryonic development, angiogenesis, and wound 
healing 65, 155. Besides this, excessive TGF-β activity is a major contributor to fibrosis 
development 156-158.
Increased expression of TGF-β and TGF-βR has been detected in epiretinal membranes of 
patients with pVR 66, 159, 160. TGF-β has been demonstrated to induce proliferation and EMT 
by RpE 118, 161, 162. RpE express Tgf-β1 and Tgf-β2 of which Tgf-β2 is the dominantly expressed 
isotype, and Tgf-β2 is most often associated with pVR 
14, 67, 120, 163.  The importance of 
the TGF-β signaling pathway in PVR is further supported by in vitro and experimental 
animal models,  in which TGF-β or downstream signaling was inhibited, which prevented 
proliferation and EmT of RpE 164-167.
Vascular endothelial growth factor
In humans four VEgf isoforms are presented known as VEgf-A, -B, -C and -D 168. These 
isoforms signal through their receptors named VEgfR1, -2 and -3. VEgf-A binds VEgfR1 
and -2, VEgf-B binds VEgfR1, VEgf-C binds VEgfR2 and -3 while VEgf-D binds VEgfR3 
169. VEgfRs are distantly related to the pDgfR family but are unique with respect to their 
structure and signaling system. Signaling via VEgfR1 and VEgfR2 results in proliferation 
and migration of endothelial cells which is primarily involved in angiogenesis and 
increased vascular permeability, signaling via VEgfR3 stimulates lymphangiogenesis  170. 
In several vitreoretinal disorders intraocular VEgf concentration levels are elevated  87, 171, 
172. In exudative age-related macular degeneration and (proliferative) diabetic retinopathy 
the elevated levels of VEgf largely contribute to vascularization of the retina 173-175. VEgf 
is also abundantly present in vitreous and retinal tissue from patients with established 
pVR 1, 87, 172, 176, 177. However, retinal vascularization is not part of pVR pathogenesis. In RpE 
VEgf induces pEDf expression which is an anti-angiogenic factor which competes with 
VEgf for VEgfR binding and thus inhibits VEgfR signaling 178. moreover, in an animal 
pVR model in which VEgf was neutralized by Ranibizumab, membrane formation was 
reduced 179. VEGF stimulates the local fibrotic response in PVR via VEGFR-mediated 
transactivation of other growth factor receptors, including PDGFR-α 87, 123, 180. 
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Coagulation cascade activity in PVR
Coagulation cascade activation after tissue injury is crucial to facilitate the healing 
process. The coagulation cascade consists of a series of plasma proteins that are 
stepwise activated with the formation of a fibrin clot as final product. Two pathways of 
coagulation cascade activation are recognized, the intrinsic pathway and the extrinsic 
pathway, of which the extrinsic pathway (activated by vascular injury) is considered 
crucial for the initiation of fibrin formation while the intrinsic pathway is more involved 
in maintenance of fibrin formation (Figure 3) 181. At a certain point activation of the 
coagulation cascade results in the conversion of factor X into activated factor X (fXa). 
fXa then cleaves pro-thrombin to generate thrombin which converts soluble plasma 
fibrinogen into an insoluble fibrin clot, but also stimulates platelet aggregation and 
degranulation 182. The formed clot prevents blood from leaving the vessels and prevents 
pathogens from entering the blood stream 183. In addition the fibrin/platelet clot provides 
a scaffold for fibroblasts, macrophages and other cells to migrate on, thereby facilitating 
the healing process. Once the site of injury is closed, the formed clot is degraded by 
plasmin in a process referred to as fibrinolysis and normal blood flow is re-established 183. 
prothrombin thrombin
factor Xa factor Xfactor X
fibrinogen fibrin fibrinopeptides
+
factor IX factor IXa
factor XI factor XIa
factor XII factor XIIa
factor V factor Va
factor VIIa factor VII
tissue factor
trauma
intrinsic pathway
trauma
extrinsic pathway
common pathway
figure 3: Schematic overview of the
coagulation cascade. Both the 
intrinsic and the extrinsic pathway 
end up in the common pathway 
in which factor Xa converts 
prothrombin into thrombin that 
converts fibrinogen into fibrin.
uncontrolled activation of the coagulation cascade has been recognized to contribute 
to fibrosis in several organ systems 184, 185. Classically it was thought that this was related 
to the fibrin clot acting as matrix for fibroblasts and inflammatory cells to migrate and 
proliferate on as well as providing a reservoir function for binding and release of growth 
factors and cytokines 186. Along this line, fibrin deposits have been found in the eyes of 
PVR patients and it has been reported that RPE can use fibrin as scaffold supporting de-
differentiation and migration 9, 187. However, the observation that fibrinogen knock-out 
mice were not protected from bleomycin-induced lung fibrosis questions whether fibrin 
formation is truly a prerequisite for fibrosis to develop 188. 
fXa and thrombin, however, also directly activate cellular processes associated with 
healing through specific activation of proteinase-activated receptors (PARs), of which 
four different types exist: PAR1-4 189-191. pARs are g-coupled receptors of which signaling is 
initiated via proteolytic cleavage of the extracellular N-terminal part. The newly formed 
N-terminus binds to another extracellular part of the receptor, causing a conformational 
change that activates intracellular signaling via the g-coupled proteins (figure 4) 192. Each 
pAR has its own unique cleavage site that can be cleaved by various proteases of which 
thrombin by far has the highest affinity for these receptors, with the exception of PAR2 
(Table 2) 191, 193, 194. 
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pAR1 represents the major signaling receptor for thrombin and fXa to induce pulmonary 
fibroblast proliferation, cytokine/growth factor and ECM production, as well as 
myofibroblast differentiation 195 . Importantly, direct thrombin or fXa inhibition protects 
mice from bleomycin-induced lung fibrosis 196, 197. moreover, pAR1 knock-out mice are 
protected from bleomycin-induced lung inflammation and fibrosis 196, 198. Comparable 
observations have been made in animal models for fibrosis in other organs, for instance 
in the kidney and liver 185. Together these data suggest that fXa/thrombin induced pAR1 
signaling elicits cellular responses crucial for fibrosis to develop.       
RpE cells also express pARs, mostly pAR1 and pAR3 199. However to date only minimal 
data is present that these cells can be activated by thrombin and fXa. Thrombin and 
FXa have been described to induce expression of VEGF, FGF, PDGF and TGF-β as well as 
chemotaxis and proliferation of human RpE cells 199-203. In animal studies, with primary rat 
RPE, thrombin was described to induce stress fiber formation, proliferation, expression 
of adhesion molecules and increased expression of chemokines like CCl2 204-207. These 
observations together with the implication that the coagulation cascade is involved 
in PVR pathogenesis warrants further studies into the RPE activating effects of FXa 
and thrombin, especially because clinical applicable thrombin inhibitors are currently 
available.
Gα Gβ Gγ
Gα-1 Gα-12/13
ELK1 GATA
TBPNFκB
NFκB
cell survival
PI3K
Ras
Raf1
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Figure 4: Schematic overview of PAR1 signaling which resulting in various cellular effects like cell 
growth, differentiation, inflammation and migration.
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PAR1 PAR2
Activated protein C
Cathepsin g
factor Xa
granzyme A
Kallikrein 1, 4, 5, 6, 14
matrix metalloprotease 1
meizothrombin (desf1)
penicillium citrinum 13
plasmin
proatherocytin
Thrombin
Trypsin IV
Acrosin
Bacterial gingipains
Chitinase
granzyme A
Kallikrein 2, 4, 5, 6, 14
mast cell tryptase
matriptase/membrane-Type Serine protease 1
penicillium citrinum 13
peptidase 1, 2, 3
Tissue factor:factor Xa:factor VIIa
Transmembrane protease serine 2
Transmembrane protease serine 11D
Trypsin
Trypsin IV
PAR3 PAR4
Thrombin Bacterial gingipains
Cathepsin g
factor Xa
Kallikrein1, 14
mannon binding lectin serine peptidase 1
plasmin
Thrombin
Trypsin
Trypsin IV
Table 2: Agonists of protease-activated receptors
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Aim of this thesis
There is preliminary data that suggest involvement of the coagulation cascade in pVR, 
but at what stage of development and how this would contribute to pVR development 
is far from clear. The aims of this thesis are: a) to examine the effect of the coagulation 
proteins FXa and thrombin on pro-inflammatory and pro-fibrotic responses by human 
RpE cells, and b) to determine whether pVR development in patients is truly associated 
with increased intravitreal coagulation cascade activity, c) whether this activation of 
the intravitreal coagulation cascade contributes to RPE activation towards a fibrotic 
response and d) if the latter process can be blocked by the clinically available direct 
thrombin inhibitor dabigatran. 
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The effects of FXa and thrombin on RPE
Abstract
Background: Vitreoretinal disorders, including proliferative vitreoretinopathy (pVR), 
proliferative diabetic retinopathy (pDR) and exudative age-related macular degeneration 
(AmD), are a major cause of visual impairment worldwide and can lead to blindness when 
untreated. loss of blood-retinal barrier (BRB) integrity associated with vitreoretinal 
fibrin deposition, inflammation, fibrosis and neovascularization contribute to the 
pathophysiological processes in these disorders. Retinal pigment epithelial (RpE) cells 
are well recognized to contribute to vitreoretinal inflammation/fibrosis and are likely to 
encounter contact with coagulation factor upon loss of BRB integrity. 
Methods: An extensive study was performed in which we examined the effect of factor 
Xa and thrombin on the production of a broad panel of cytokines/chemokines and 
growth factors by RpE cells. for this purpose we used the ARpE-19 cell line as well as 
primary RpE cells, a glass slide based array that allows simultaneous detection of 120 
cytokines/chemokines and growth factors, ElISA and real-time-quantitative pCR. The 
involved signaling cascade was examined using specific inhibitors for protease activated 
receptor (pAR)-1, pAR-2 and nuclear factor kappa-B (Nf-κB). 
Results: factor Xa and thrombin regulated the production of cytokines and growth 
factors (including gm-CSf, Il-6, Il-8, mCp-3, pDgf-AA, pDgf-BB, TImp-1 and Tgf-α) that 
fit well in the pathobiology of vitreoretinal disease. Blocking studies revealed that the 
effects were mediated via PAR1 induced NF-κB activation. 
Conclusions: Our findings suggest that factor Xa and thrombin can drive vitreoretinal 
inflammation and fibrosis and should be considered as treatment targets in vitreoretinal 
disorders such as pVR, pDR and AmD.
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Introduction
Vitreoretinal disorders, including proliferative vitreoretinopathy (pVR), proliferative 
diabetic retinopathy (pDR) and age-related macular degeneration (AmD), are visual 
impairing diseases that affect millions of people and are potentially blinding when left 
untreated 1. The pathobiological process of these disorders comprises breakdown of 
the blood-retinal barrier (BRB) at some stage, with vitreoretinal inflammation, fibrosis 
in pVR, pDR and AmD, and neovascularization in AmD and pDR 1. Treatment options are 
limited so far, anti-VEGF treatment can be beneficial in case of PDR and AMD while PVR 
treatment mostly still depends on (recurrent) surgical intervention 1, 2.   
The retinal pigment epithelial (RpE) cell-layer (located between the neural retina and 
the choriocapillaries) controls, under normal physiological conditions, the integrity of 
the outer BRB 3. However, in case of an injurious event RpE cells can turn into important 
drivers of ocular inflammation and neovascularization via the production of cytokines 
and growth factors 2, 4. The production of these cytokines and growth factors can also 
contribute to retinal fibrosis by stimulating proliferation, migration and differentiation 
of RPE cells into extracellular matrix (ECM) protein producing myofibroblast-like cells 1. 
Breakdown of the outer BRB is associated with vascular damage/leakage and activation 
of the coagulation cascade with resultant formation of vitreoretinal fibrin deposits 1, 5. 
Factor Xa and thrombin are crucially important for fibrin formation but can also stimulate 
cellular responses involved in inflammation, tissue repair and fibrosis 6, 7. These latter 
effects are established through activation of cell-membrane expressed protease-
activated receptors (pARs), mainly pAR1 and pAR2 8. factor Xa and thrombin most likely 
come into contact with RPE in vitreoretinal disease, but direct cellular effects of factor Xa 
and thrombin on human RpE cell activity are only marginally explored so far. Thrombin 
has been shown to stimulate migration, proliferation, Il-8 and monocyte chemotactic 
protein (mCp)-1 production by RpE and to facilitate RpE monocyte interactions 9, 10. 
furthermore, thrombin has been described to increase mRNA expression of the B-chain 
of the pro-fibrotic dimeric molecule PDGF and to stimulate VEGF production by human 
RpE cells 10, 11. Data on the effect of factor Xa on RPE activity is even more scarce as it was 
only very recently reported that factor Xa can stimulate VEgf production by human RpE 
12.
To date, no detailed data is present on the effects of factor Xa and thrombin on the 
production of a broad panel of inflammatory and pro-fibrotic mediators that can be 
involved in retinal inflammation and fibrosis. Therefore, we here investigated the effect 
of factor Xa and thrombin on the production of a total of 120 inflammatory and pro-
fibrotic mediators by RPE cells, for which we used a human cytokine antibody glass-slide 
array. Several factors present on the antibody array were also examined by ElISA or real-
time quantitative-pCR. In addition, by using antagonists for pAR1, pAR2 and an inhibitor 
of the transcription factor Nf-κB the signaling pathway involved was examined. 
This study is the first to demonstrate that factor Xa and thrombin may fulfill a 
comprehensive role in driving inflammation and fibrosis in vitreoretinal diseases, and 
may thus be attractive therapeutic targets.   
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Materials and methods
Reagents
The human retinal pigment epithelial cell line (ARpE-19) was obtained from ATCC (ma-
nassas, VA, uS). ARpE-19 cells were cultured in DmEm/HAm’s f-12 1:1 medium (HyClo-
ne logan, uT, uS), containing 10% heat inactivated fetal calf serum (fCS) and penicillin/
streptomycin (all from BioWhittaker, Verviers, Belgium), hereafter referred to as RpE 
medium. for experiments ARpE-19 cells between passage 23-30 were used. A primary 
RpE cell culture was established from a surplus eye globe from a donor after enucleation 
for corneal transplantation, as described previously 13. for experiments primary RpE cells 
between passage 5-8 were used. under the used culture conditions the ARpE-19 and pri-
mary RPE cells were not pigmented. Human factor Xa, thrombin and the NF-κB inhibitor 
SC-514 were obtained from Calbiochem (la Jolla, CA, uS). pAR1 antagonist SCH79797 
was obtained from Tocris Bioscience (Bristol, uK) and pAR2 antagonist ENmD-1068 was 
obtained from ENZO life Sciences (Zandhoven, Belgium). Il-6 (lower limit of detecti-
on: 7.8 pg/ml) and Il-8 ElISA (lower limit of detection: 7.8 pg/ml) were obtained from 
Invitrogen (paisley, uK), granulocyte macrophage colony stimulating factor (gm-CSf) 
(lower limit of detection: 15.6 pg/ml), MCP-3 (lower limit of detection: 15.6 pg/ml), TGF-β1 
(lower limit of detection: 31.3 pg/ml) and tissue inhibitor of metalloproteinase (TImp)-1 
ElISA (lower limit of detection: 31.3 pg/ml) were obtained from R&D Systems (Abingdon, 
uK). 
Factor Xa and thrombin titration studies
ARpE-19 cells were seeded at 5 x 105 cells/well into six-well plates (Nunc; Roskilde, Den-
mark), serum-starved in RpE medium containing 1% fCS and allowed to adhere overnight. 
To determine the optimal concentration for further studies, ARpE-19 cells were initially 
stimulated for 24 hours with different concentrations factor Xa (0, 0.25, 0.5, 1.0 and 2.0 
u/ml) and thrombin (0, 1, 5 and 10 u/ml) and the culture supernatants were analyzed for 
Il-6 and Il-8 concentrations by ElISA according to the manufacturer’s instructions. 
Multiplex detection of 120 factors related to inflammation and fibrosis
ARpE-19 cells were seeded 5 x 105 cells/well into six-well plates, serum-starved in RpE 
medium containing 1% fCS and allowed to adhere overnight and thereafter stimulated with 
factor Xa (1 u/ml) or thrombin (5 u/ml) for 24 hours. Culture supernatants of 4 identical 
stimulations were pooled and analyzed on a Quantibody ® Human Cytokine Antibody 
Array 2000 (RayBiotech Inc; Norcross, gA, uS) according to manufacturer’s instructions. 
This approach allows simultaneous detection of 120 cytokines/chemokines and growth 
factors per sample. Briefly, the pooled culture supernatants were incubated on glass 
slide arrays spotted with antibodies directed against different cytokines/chemokines 
and growth factors, followed by incubation with a secondary biotin-labeled antibody 
and a tertiary Cy3-labeled streptavidin. The arrays were scanned (laser scanner: Tecan; 
mechelen, Belgium) and the cytokine concentrations in the samples were calculated. 
Quantifying analysis was performed with Imagene 8.0 (Biodiscovery Inc; El Segundo, CA, 
uS). A heatmap was created of the factors which expression changed  ≥ 2-fold within the 
linear range of the reference curves between any of the tested conditions (unstimulated, 
factor Xa stimulated and thrombin stimulated).
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Messenger RNA expression analysis by real-time quantitative PCR
RpE cells were seeded 5 x 105 cells/well into six-well plates, serum-starved in RpE 
medium containing 1% fCS and allowed to adhere overnight. Subsequently the cells were 
incubated for 4 hours (which we found optimal in initial time-course experiments) in the 
presence or absence of factor Xa (1 u/ml) or thrombin (5 u/ml). RNA was isolated using 
Isol-RNA lysis Reagent (5 prime; Hamburg, germany) and reverse transcribed into cDNA. 
Transcript levels of pDgf-A, pDgf-B, Tgf-α, Tgf-β1 and insulin like growth factor binding 
protein (IgfBp)-3 were determined by RQ-pCR (7700 pCR system; Applied Biosystems 
[ABI], foster City, CA, uS). In addition the mRNA expression levels of all four pAR family 
members (pAR1, pAR2, pAR3, and pAR4) were determined in unstimulated RpE cells. 
Messenger RNA expression of the RPE cell specific protein cellular retinaldehyde-binding 
protein (CRAlBp) was determined in RpE cells and the colon epithelial cell lines HT-29 
and Caco-2 (kindly provided by dr. Ron Smits, Erasmus mC, The Netherlands). Expression 
levels of the analyzed gene transcripts were normalized to the control gene Abelson 14. 
primer and probe combinations used are listed in table 1. 
 
Cytokine analysis by ELISA
RpE cells were seeded 5 x 105 cells/well into six-well plates, serum-starved in RpE 
medium containing 1% fCS and allowed to adhere overnight. Cells were subsequently 
stimulated with factor Xa (1 u/ml) or thrombin (5 u/ml) for 24 hours in fresh RpE medium 
containing 1% fCS. After stimulation supernatants were analysed for gm-CSf, Il-6, Il-8, 
mCp-3, Tgf-β1 and TImp-1 by ElISA according to manufacturer’s instructions. In order 
to determine total Tgf-β1 concentrations, inactive TGF-β1 was activated by addition of a 
1m HCl solution that was subsequently neutralized by adding a 1.2m NaOH/0.5m Hepes 
solution, according to the manufacturer’s instructions.
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Table 1: pCR primer and probe sequences
Gene Sequence fwd primer  (5`-3`) Sequence rev primer  (5`-3`) Sequence probe  (5`-3`)
ABl 14 TggAgATAACATCTAAgCATAACTAAAggT gATgTAgTTgCTTgggACCCA CCATTTTTggTTTgggCTTCACACCATT
CRAlBp ggTggACATgCTCCAggATT TACCATggCTggTggATgAA TTCCCAgCCCggTTCAAAgCCAT
IgfBp-3 52 ACgCACCgggTgTCTgA TgCCCTTTCTTgATgATgATTATC CCCAAgTTCCACCCCCTCCATTCA
pAR1 CggCggCTgCTgCT gggTTCCTgAgAAgAAATgACC CCAgAATCAAAAgCAACAAATgCCACC
pAR2 ggCCgCCATCCTgCTA gggATgTgCCATCAACCTTA CACCATCCAAggAACCAgTAgATCCTCTAAA
pAR3 ggCCTCCTgCTTCTgTTgC ggAACTCTTCAAAAgAATTTggg TgATACAAACAACTTggCAAAgCCAACCTT
pAR4 CTgCgTggATCCCTTCATCT CCTgCCCgCACCTTgTC TACTACgTgTCggCCgAgTTCAg
pDgf-A 53 CggggTCCATgCCACTAA ggggCCAgATCAggAAgTTg AgCTTCCTCgATgCTTCTCTTCCTCCg
pDgf-B 54 TCCCgAggAgCTTTATgAgATg CgggTCATgTTCAggTCCAAC AgTgACCACTCgATCCgCTCCTTTg
TGF-α gCCAggCCTTggAgAACAg AATCTgggCAgTCATTAAAATgg ACgTCCCCgCTgAgTgACCCg
TGF-β1 CgCgTgCTAATggTggAA AgAgCAACACgggTTCAggT CCACAACgAAATCTATgACAAgTTCAAgCAgA
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PAR and NF-κB inhibition studies
RpE cells were seeded at 5 x 105 cells/well into six-well plates, serum-starved in RpE 
medium containing 1% fCS and allowed to adhere overnight. Subsequently the cells 
were incubated with SC-514 (100 µm), SCH79797 (250 nm) or ENmD-1068 (100 µm) 
60 minutes prior to stimulation with factor Xa or thrombin. Depending on the type 
of analysis the cells were stimulated for 4 or 24 hours with factor Xa or thrombin and 
the effects of the inhibitors were determined via RQ-PCR or ELISA. The concentrations 
SCH79797, ENmD-1068 and SC-514 used, were non-toxic to RpE cells as determined by 
lactate dehydrogenase (lDH) release (Roche, mannheim, germany) and microscopic 
appearance of the cells. 
Statistical analysis
Data obtained with the cytokine array were considered of interest when a ≥ 2-fold 
change between any of the three culture conditions was measured. gm-CSf, IgfBp-3, 
Il-6, Il-8, mCp-3, pDgf-A, pDgf-B, Tgf-α, Tgf-β1 and TImp-1 mRNA or protein expression 
levels were analyzed using the paired Student’s t-test. A P-value < 0.05 was considered 
significant. 
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Gene Sequence fwd primer  (5`-3`) Sequence rev primer  (5`-3`) Sequence probe  (5`-3`)
ABl 14 TggAgATAACATCTAAgCATAACTAAAggT gATgTAgTTgCTTgggACCCA CCATTTTTggTTTgggCTTCACACCATT
CRAlBp ggTggACATgCTCCAggATT TACCATggCTggTggATgAA TTCCCAgCCCggTTCAAAgCCAT
IgfBp-3 52 ACgCACCgggTgTCTgA TgCCCTTTCTTgATgATgATTATC CCCAAgTTCCACCCCCTCCATTCA
pAR1 CggCggCTgCTgCT gggTTCCTgAgAAgAAATgACC CCAgAATCAAAAgCAACAAATgCCACC
pAR2 ggCCgCCATCCTgCTA gggATgTgCCATCAACCTTA CACCATCCAAggAACCAgTAgATCCTCTAAA
pAR3 ggCCTCCTgCTTCTgTTgC ggAACTCTTCAAAAgAATTTggg TgATACAAACAACTTggCAAAgCCAACCTT
pAR4 CTgCgTggATCCCTTCATCT CCTgCCCgCACCTTgTC TACTACgTgTCggCCgAgTTCAg
pDgf-A 53 CggggTCCATgCCACTAA ggggCCAgATCAggAAgTTg AgCTTCCTCgATgCTTCTCTTCCTCCg
pDgf-B 54 TCCCgAggAgCTTTATgAgATg CgggTCATgTTCAggTCCAAC AgTgACCACTCgATCCgCTCCTTTg
TGF-α gCCAggCCTTggAgAACAg AATCTgggCAgTCATTAAAATgg ACgTCCCCgCTgAgTgACCCg
TGF-β1 CgCgTgCTAATggTggAA AgAgCAACACgggTTCAggT CCACAACgAAATCTATgACAAgTTCAAgCAgA
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Results
The concentration-dependent effect of factor Xa and thrombin on IL-6 and IL-8 
production 
factor Xa and thrombin induced Il-6 and Il-8 secretion by ARpE-19 after 24 hours of 
stimulation in a concentration dependent manner. factor Xa induced maximal secretion 
of Il-6 and Il-8 at a concentration of ~1-2 u/ml, while the optimal level of stimulation for 
thrombin was at a concentration of ~5-10 U/ml (Figure 1). No significant difference was 
observed between 1 and 2 u/ml factor Xa for the level Il-6 and Il-8 production. Also no 
significant difference was observed between 5 and 10 U/ml thrombin with regard to IL-6 
and Il-8 production. Therefore for further studies factor Xa was used at a concentration 
of 1 u/ml and thrombin at a concentration of 5 u/ml. 
The effect of factor Xa and thrombin on a broad panel of cytokines and growth factors
Culture supernatants of factor Xa or thrombin stimulated ARpE-19 cells were analysed 
on quantitative human cytokine antibody arrays. All factors determined by cytokine 
antibody array analysis and the effect of factor Xa and thrombin on the production 
of these factors by ARpE-19 are given in supplemental table 1. The cytokine antibody 
array analysis revealed that factor Xa and thrombin both induced Il-6 and Il-8 (figure 
2A), confirming the data obtained by ELISA (Figure 1). Factor Xa further changed the 
expression of 8 other factors ≥ 2-fold; IgfBp-3, Il-9 and osteopontin (OpN) were 
downregulated compared to unstimulated cells, while gm-CSf, pDgf-BB, TImp-1, tumour 
necrosis factor receptor (TNf-R)I and Tgf-α were upregulated compared to unstimulated 
cells (figure 2A). Thrombin induced a ≥ 2-fold change in expression levels for 10 factors 
other than Il-6 and Il-8; OpN was downregulated compared to unstimulated cells, while 
bone morphogenic protein (Bmp)-7, gm-CSf, Il-17f, mCp-3 (CCl7), monokine induced by 
gamma interferon (mIg), osteoprotegerin (Opg), pDgf-AA, pDgf-BB, TImp-1 and TNf-RI 
were upregulated compared to unstimulated cells (figure 2A). 
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figure 1: ARpE-19 cells were 
stimulated for 24 hours with 
different concentrations factor Xa 
or thrombin. Il-6 (left panels) and 
Il-8 (right panels) concentrations 
were determined in the culture 
supernatants by ElISA. Data are 
presented as the mean value of 4 
independent experiments ± SEm. 
Statistical analysis was performed 
with the paired Student’s t-test. P < 
0.05 was considered significant. * = 
P < 0.05 and ** = P < 0.01, compared 
to unstimulated.
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figure 2: (A) ARpE-19 cells were 
stimulated for 24 hours with 
factor Xa (1 u/ml) or thrombin 
(5 u/ml). Culture supernatants 
of 4 identical stimulation 
experiments were pooled 
and analyzed on quantitative 
human cytokine antibody 
arrays. The heatmap represents 
cytokines and growth factors 
with ≥ 2-fold change between 
the culture conditions. (B) 
ARpE-19 cells were stimulated 
for 24 hours with factor Xa 
(1 u/ml) or thrombin (5 u/
ml) and gm-CSf, mCp-3 and 
TImp-1 concentrations in 
culture supernatants were 
determined by ElISA. Data 
are presented as the mean 
value from 4 independent 
experiments ± SEm. (C) ARpE-
19 cells were stimulated for 4 
hours with factor Xa (1 u/ml) or 
thrombin (5 u/ml) and IgfBp-3, 
pDgf-A, pDgf-B and Tgf-α 
mRNA expression levels were 
determined by RQ-pCR and 
normalized against the control 
gene ABl. Data are presented 
as the mean value from 8 
independent experiments 
± SEM. US = unstimulated. 
Statistical analysis was 
performed with the paired 
Student’s t-test. P < 0.05 
was considered significant. 
* = P < 0.05 and ** = P < 0.01, 
compared to unstimulated.
To confirm the findings of the cytokine antibody array, a set of independent experiments 
was performed to examine the effect of factor Xa and thrombin on cytokine/chemokine/
growth factor expression by ARpE-19 cells. for this purpose a selected set of factors for 
which ElISA systems and pCR primers and probes were available at our laboratory was 
used. In this independent set of experiments factor Xa significantly (P < 0.05) upregulated 
PDGF-A and PDGF-B mRNA expression by ARPE-19, while thrombin significantly (P < 0.05) 
upregulated the protein production of gm-CSf and mCp-3 as well as mRNA expression of 
pDgf-A and pDgf-B (figure 2B). Also the pattern of IgfBp-3 and Tgf-α mRNA expression 
and TImp-1 protein production by ARpE-19 after stimulation with factor Xa and thrombin 
(Figure 2B) paralleled the findings obtained with the cytokine antibody array.  
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The effect of factor Xa and thrombin on TGF-β1
The human cytokine antibody array analysis revealed that factor Xa slightly stimulated 
Tgf-β1 secretion (~1.5 times, supplemental table 1) and that thrombin had no effect. 
Because Tgf-β1 has been identified as an important stimulator of retinal fibrosis and the 
fact that the cytokine antibody array only detects Tgf-β1  in the active form, the effect 
of factor Xa and thrombin on total Tgf-β1 was also examined by RQ-pCR and ElISA. This 
showed that factor Xa and thrombin did not significantly enhance total TGF-β1 production 
by ARpE-19 cells (figure 3) 15.
Expression and activation of protease-activated receptors
previously Hollborn and colleagues demonstrated that primary human RpE cells express 
pAR1 and pAR-3 mRNA 10. To examine whether the ARpE-19 cells resemble this expression 
pattern the PAR mRNA expression profile was determined. This revealed that the ARPE-
19 cells mainly express pAR1 and pAR3 with only marginal pAR2 and pAR4 expression 
(Figure 4A). ARPE-19 cells exhibit thus a PAR mRNA expression profile similar to that 
of primary human RPE and are therefore representative to study the effects of factor 
Xa, thrombin and pAR signaling in human RpE. Because factor Xa and thrombin mainly 
signal via PAR1 and PAR2 specific antagonists were used to examine which PAR receptor 
mediated their effects in RPE. PAR1 inhibition significantly reduced the capacity of factor 
Xa and thrombin to induce Il-6, Il-8, mCp-3 and pDgf-B production (figure 4B and 4C). 
PAR1 inhibition also significantly reduced thrombin induced GM-CSF and PDGF-A and 
factor Xa induced Tgf-α production. The PAR1 antagonist alone had no effect on basal 
production levels of these factors (data not shown). PAR2 blockade did not significantly 
alter factor Xa or thrombin induced production of gm-CSf, Il-6, Il-8, mCp-3, pDgf-A, 
Tgf-α and TIMP-1 by ARPE-19 cells, nor did it affect basal production levels of these 
factors (data not shown), which is in line with the low pAR2 expression levels. 
The effect of factor Xa and thrombin on NF-κB signaling
The transcription factor Nf-κB initiates the transcriptional activation of many different 
cytokine/chemokine/growth factor genes 16. Therefore we examined whether activation 
of the Nf-κB signaling pathway was involved in mediating the effects of factor Xa 
and thrombin in RpE. The Nf-κB inhibitor SC-514 significantly reduced factor Xa and 
thrombin induced production of the pro-inflammatory mediators IL-6, IL-8 and MCP-
3 as well as thrombin-induced gm-CSf production by ARpE-19 (figure 5A). moreover, 
SC-514 significantly reduced factor Xa and thrombin induced production of the pro-
fibrotic mediators PDGF-A and PDGF-B, as well as TGF-α (figure 5B). Although factor 
Xa and thrombin marginally induced expression of the pro-fibrotic factor TIMP-1, it was 
consistently reduced by SC-514 (Figure 5B). SC-514 alone had no significant effect on the 
basal production of these factors (data not shown).    
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The effect of factor Xa and thrombin on primary RPE
The primary RPE cell culture established expressed the mRNA encoding the RPE specific 
protein CRAlBp, comparable to ARpE-19 but in contrast to the colon epithelial cell lines 
HT-29 and Caco-2 that did not express CRALBP mRNA (Figure 6A), thus confirming their 
RpE origin. The primary RpE cells primarily expressed pAR1 and pAR3, thus resembling 
the pAR expression pattern of ARpE-19 (figure 4A) and other primary RpE 10. In line 
with the results found with ARPE-19, PAR1 inhibition significantly reduced factor Xa and 
thrombin induced expression of Il-6, Il-8 and pDgf-B in primary RpE, while this inhibition 
was non-significant for PDGF-A (Figure 6C and 6D). Also inhibition of the NF-κB pathway 
significantly reduced IL-6, IL-8, PDGF-A and PDGF-B expression induced by factor Xa or 
thrombin in primary RpE (figure 6C and 6D).  
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stimulated for 4 hours with factor 
Xa (1 u/ml) or thrombin (5 u/ml) 
and the Tgf-β1 mRNA expression 
level was determined by RQ-pCR 
and normalized against the control 
gene ABl. Data are presented as 
the mean value from 4 independent 
experiments ± SEm. (B) ARpE-
19 cells were stimulated for 24 
hours with factor Xa (1 u/ml) or 
thrombin (5 u/ml) and total Tgf-β1 
concentrations were determined in 
culture supernatants by ElISA. Data 
are presented as the mean value of 
5 independent experiments ± SEm. 
US = unstimulated. 
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Discussion
RPE cells contribute to vitreoretinal inflammation, fibrosis and neovascularization 
in disorders such as AmD, pDR and pVR 1, 2, 4. Intraocular activation of the coagulation 
cascade is associated with vitreoretinal disease, and our study it the first that examined 
the effects of factor Xa and thrombin on the production of an extensive panel of 
inflammatory and pro-fibrotic mediators by RPE cells 1, 5. We demonstrate that factor Xa 
and thrombin promote the production of several different cytokines, chemokines and 
growth factors by RPE cells and may thus play a comprehensive role in the inflammatory 
and fibrotic component of vitreoretinal (proliferative) disease.   
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figure 4: (A) pAR1, pAR2, pAR3 and pAR4 mRNA expression in ARpE-19 cells were determined by 
RQ-pCR and normalized against the control gene ABl. Data are presented as the mean value of 9 
independent experiments ± SEm. ARpE-19 cells were stimulated for 24 hours with factor Xa (1 u/
ml) or thrombin (5 u/ml) in the absence or presence of the pAR1 antagonist SCH79797 (250 nm) 
or the pAR 2 antagonist ENmD-1068 (100 µm). gm-CSf, Il-6, Il-8 and mCp-3 (B) and TImp-1 (C) 
concentrations is culture supernatants were determined by ElISA. Data are presented as the mean 
value of 5 independent experiments ± SEm. (C) ARpE-19 cells were stimulated for 4 hours with 
factor Xa (1 u/ml) or thrombin (5 u/ml) in the absence or presence of the pAR1 antagonist SCH79797 
or the pAR2 antagonist ENmD-1068 and the pDgf-A, pDgf-B and Tgf-α mRNA expression levels 
were determined by RQ-pCR and normalized against the control gene ABl. Data are presented as 
the mean value of 5 independent experiments ± SEm. Statistical analysis was performed with the 
paired Student’s t-test. P < 0.05 was considered significant. * = P < 0.05 and  ** = P < 0.01.
To examine the effect of factor Xa and thrombin on the production of inflammatory and 
pro-fibrotic mediators by RPE we used a cytokine antibody array that simultaneously 
detects 120 cytokines/chemokines/growth factors. We also examined the effect of 
factor Xa and thrombin on the production of a set of factors identified with the cytokine 
antibody array by ElISA or RQ-pCR. This revealed a high level of concordance between 
expression patterns detected with the different techniques. From this we conclude 
that the cytokine antibody array is a reliable technique for multiplex analysis of culture 
supernatants and therefore several of the factors indentified with the cytokine antibody 
array technique will hereunder be discussed in relation to inflammation, fibrosis and 
vitreoretinal (proliferative) disorders. 
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Inflammation involves recruitment, activation and differentiation of immune cells, 
processes in which cytokines play a prominent role. factor Xa and thrombin both 
stimulated the production of immune cell recruiting and activating cytokines gm-CSf, 
Il-6, Il-8, Il-17f, mCp-3 and mIg by RpE. Il-6 recruits and activates B-lymphocytes and 
stimulates plasma cell differentiation as well as immunoglobulin production, while IL-8 
is powerful neutrophil chemoattractant 17, 18. Thrombin also enhanced the production of 
Il-17f. The Il-17 family consists of distinct subclasses of cytokines: Il-17A-Il-17f, of which 
Il-17A and Il-17f share the most (~60%) homology. Il-17 stimulates the production of 
cytokines such as Il-8, thereby facilitating neutrophil recruitment 19. mIg production 
was especially enhanced by thrombin and recruits NK cells and T-lymphocytes into 
inflammatory foci 20. Thrombin also stimulated the production of mCp-3 and gm-
CSf which are chemoattractants for monocytes and macrophages, while gm-CSf 
also stimulates differentiation of monocytes into macrophages 21. B-lymphocytes, 
T-lymphocytes, monocytes, macrophages and neutrophils are abundantly present in 
infiltrates of AMD, PDR and PVR 2, 4, 22-27. Collectively, our data demonstrate that factor Xa 
and thrombin induce cytokine/chemokine production by RpE and may thus play a role 
in inflammatory cell recruitment, activation and differentiation in vitreoretinal disease.
Inflammatory responses are generally controlled by counter regulatory anti-inflammatory 
molecules, such as soluble cytokine receptors and anti-inflammatory cytokines 28. 
Thrombin stimulated Opg secretion by RpE while both factor Xa and thrombin enhanced 
TNf-RI secretion. Opg acts as decoy receptor for receptor activator of nuclear factor 
kappa-B ligand (RANKl) 29. The RANK/RANKl/Opg system is well recognized for its role 
in bone metabolism, but is also involved in the regulation of inflammation and immunity. 
T-lymphocytes produce RANKl which stimulates RANK-expressing immune cells, such 
as monocytes/macrophages and dendritic cells, to secrete pro-inflammatory cytokines/
chemokines 29. Opg also acts as a soluble decoy receptor for TNf-related apoptosis 
inducing ligand (TRAIl) and can thereby prevent apoptosis induction 29. Soluble TNf-RI 
acts as an anti-inflammatory cytokine that neutralizes TNF-α activity 30. Thrombin and 
especially factor Xa downregulated Il-9 secretion by RpE. The functional activities of 
Il-9 are far from clear but it has been suggested to promote survival of for instance 
T-lymphocytes, mast cells, epithelial cells and neurons. possibly improved survival under 
the influence of IL-9 might explain diverse IL-9 mediated effects such as enhanced 
chemokine expression by epithelial cells and antibody production by plasma cells 31. 
The increased Opg and soluble TNf-R1 production by RpE upon thrombin stimulation 
and the decrease in Il-9 production upon factor Xa stimulation may thus represent anti-
inflammatory mechanisms.
Recruitment, activation and differentiation of ECM-producing cells is central to the 
development of fibrosis and is driven by a host of mediators 32. Our study demonstrates 
that factor Xa and thrombin activate RpE to produce several well recognized pro-
fibrotic mediators. Factor Xa enhanced the production of TIMP-1 by RPE. TIMP’s are the 
major endogenous inhibitors of ECm-degrading matrix-metalloproteinases (mmp), and 
decreased MMP-activity due to increased TIMP levels contribute to fibrosis 33. In line with 
this, increased TImp-1 levels have been described in pVR and correlated positively with 
disease severity 34. The different PDGF isoforms stimulate migration, proliferation and 
ECM synthesis by various cell types, including epithelial cells and fibroblasts, thereby 
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contributing to fibrosis 35. pDgf and (activated) pDgf-receptors have been found in 
epiretinal membranes from patients with proliferative retinopathies and pDgf receptor 
inhibition reduces experimental pVR 34, 36-39. Our results demonstrate that thrombin and 
factor Xa collectively stimulate the formation of the pro-fibrotic PDGF-AA, PDGF-AB 
and PDGF-BB dimers by RPE cells. The stimulatory effect of thrombin on PDGF-B mRNA 
expression by RpE is in line with previous observations 10. Our studies are however the 
first to demonstrate that factor Xa enhances PDGF-B mRNA and PDGF-BB production 
and that thrombin also stimulates pDgf-A mRNA and pDgf-AA production by RpE. Tgf-β1 
stimulates ECM production and myofibroblastic differentiation and increased levels are 
present in epiretinal pVR membranes 15, 40. We found no significant effect of thrombin 
on Tgf-β1 mRNA expression nor Tgf-β1 secretion by RpE after 24 hours of stimulation, 
which is in line with previous observations 10. production of Bmp7, a suppressor of 
Tgf-β1 signaling 
41, was however increased by thrombin. Factor Xa also did not affect 
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figure 5: ARpE-19 cells were 
stimulated for 24 hours with factor 
Xa (1 u/ml) or thrombin (5 u/ml) 
in the absence or presence of the 
Nf-κB inhibitor SC-514 (100 µm). 
gm-CSf, Il-6, Il-8 and mCp-3 (A) 
and TImp-1 (B) concentrations 
in culture supernatants were 
determined by ElISA. Data are 
presented as the mean value of 4 
independent experiments ± SEm. 
(B) ARpE-19 cells were stimulated 
for 4 hours with factor Xa (1 u/ml) 
or thrombin (5 u/ml) in the absence 
or presence of the Nf-κB inhibitor 
SC-514 (100 µm). pDgf-A, pDgf-B 
and Tgf-α mRNA expression levels 
were determined by RQ-pCR and 
normalized against the control 
gene ABl. Data are presented as 
the mean value of 5 independent 
experiments ± SEm. Statistical 
analysis was performed with the 
paired Student’s t-test. P < 0.05 was 
considered significant. * = P < 0.05 
and ** = P < 0.01.
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Tgf-β1 production, but did stimulate the production of Tgf-α. Tgf-α shares considerable 
homology with epidermal growth factor (Egf) and binds the Egf-receptor 42. A role 
for both Tgf-α and EGF-R signaling has been implicated in the pathogenesis of fibrosis 
43, 44. IGF-I is implicated in the pathogenesis of fibrosis, and IGF-I and IGF-II stimulate 
processes such as proliferation, migration and contraction by RpE cells 45-47. Igf activity 
is controlled by the IGFBP family, which contains six different members 48. factor Xa and 
thrombin modulated the production of IgfBp-2, IgfBp-3 and IgfBp-6 by RpE in opposite 
directions. IgfBp-2 and IgfBp-3 are present in normal vitreous and neutralize Igf-I and 
Igf-II induced RpE and müller cell contraction 49. Although factor Xa and thrombin 
did not influence IGF-I production by RPE by itself (Supplemental table 1) they can be 
expected to modulate Igf activity, RpE cell contractility, proliferation and migration by 
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figure 6: (A) CRAlBp mRNA 
expression was determined on 
ARpE-19, primary RpE, HT-29 
and Caco-2 cells by RQ-pCR and 
normalized against the control 
gene ABl. Data are presented as 
the mean value of 6 independent 
experiments ± SEm (B) pAR1, 
pAR2, pAR3 and pAR4 mRNA 
expression was determined in 
primary RpE cells by RQ-pCR and 
normalized against the control 
gene ABl. Data are presented as 
the mean value of 5 independent 
experiments ± SEm. (C) primary 
RpE cells were stimulated for 24 
hours with factor Xa (1 u/ml) or 
thrombin (5 u/ml) in the absence 
or presence of the pAR1 antagonist 
SCH79797 (250 nm) or the Nf-
κB inhibitor SC-514 (100 µm). Il-6 
and Il-8 concentrations in culture 
supernatants were determined 
by ElISA. Data are presented as 
the mean value of 5 independent 
experiments ± SEm. (D) primary 
RpE cells were stimulated for 4 
hours with factor Xa (1 u/ml) or 
thrombin (5 u/ml) in the absence 
or presence of the pAR1 antagonist 
SCH79797 (250 nm) or the Nf-κB 
inhibitor SC-514 (100 µm). pDgf-A 
and pDgf-B mRNA expression 
levels were determined by RQ-pCR 
and normalized against the control 
gene ABl. Data are presented as 
the mean value of 5 independent 
experiments ± SEm. Statistical 
analysis was performed with the 
paired Student’s t-test. P < 0.05 was 
considered significant. * = P < 0.05 
and ** = P < 0.01.
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affecting IGFBP production. Moreover, certain IGFBP-subtypes can directly stimulate 
fibrotic processes, including epithelial-mesenchymal transition and ECM production 50. 
Our data demonstrate that factor Xa and thrombin induce the production of pro-fibrotic 
mediators by RPE and may thus contribute to fibrotic processes involved in proliferative 
vitreoretinal disorders.
The blocking experiments with specific PAR antagonists revealed that the effects of 
factor Xa and thrombin on inflammatory and pro-fibrotic mediator production by RPE 
were mediated by PAR1. NF-κB inhibition also abrogated the effects of factor Xa and 
thrombin on inflammatory and pro-fibrotic mediator production by RPE, indicating that 
factor Xa and thrombin exert their effect via PAR1 mediated activation of the NF-κB 
signaling pathway.
Thrombin generally stimulated the production of pro-inflammatory cytokines/
chemokines and growth factors by RpE more strongly than factor Xa. We regard it 
unlikely that this is related to the higher thrombin concentration used as our initial 
titration experiments revealed no further significant increase in IL-6 or IL-8 production 
when RpE were stimulated with higher concentrations of factor Xa (2 u/ml) (figure 
1). Moreover, thrombin has a much higher affinity for PAR1 than factor Xa 51. Our data 
therefore strongly suggest that thrombin more potently stimulates inflammatory and 
fibrotic responses by RPE than factor Xa. 
In conclusion, this study demonstrates that both factor Xa and thrombin activate RpE 
cells to produce cytokines/chemokines and growth factors that can attract and activate 
immune cells and induce fibrotic responses. Factor Xa and thrombin may thus contribute 
to retinal inflammation and fibrosis in vitreoretinal diseases like exudative AMD, PDR 
and PVR. Given the availability of clinically applicable anti-coagulants, these findings may 
form the basis of clinical studies to try and prevent the development of (proliferative) 
vitreoretinal disorders.
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Supplemental table 1
All cytokines/chemokines and growth factors detectable with the quantitative human cytokine 
antibody array are given in the first column. 
The concentration of these factors detected in culture supernatants form ARpE-19 cells in unsti-
mulated situation (uS) or after 24 hour stimulation with factor Xa (1 u/ml) or thrombin (5 u/ml) 
is indicated in the second, third and fourth columns, respectively. The fourth and fifth columns 
indicate the lower and upper limits of detection, respectively. Cytokines/chemokines and growth 
factor concentrations are in (pg/ml).
US factor Xa thrombin lower detection 
limit
upper detection 
limit
6Ckine 121.2 95.5 88.8 42.6 80,000
Axl 29.4 31.7 39.3 3.5 8,000
BTC 26.2 16.7 13.3 10.8 40,000
CCl28 142.7 114.0 99.8 34.0 80,000
CTACK 23.7 21.1 22.2 10.8 100,000
CXCl16 5,572.0 5,000.0 5,812.0 10.6 40,000
ENA-78 33.2 24.1 26.8 7.8 20,000
Eotaxin-3 61.6 38.0 48.7 16.2 40,000
gCp-2 16.4 11.8 8.6 9.2 20,000
gRO 15.5 15.4 26.1 0.6 2,000
HCC-1 0.4 0.6 0.3 2.1 8,000
HCC-4 9.4 10.0 9.5 5.1 20,000
Il-9 338.6 164.0 259.2 66.7 400,000
Il-17f 0.0 1.1 0.0 33.5 200,000
Il-18 Bpa 143.0 126.9 124.9 36.6 120,000
Il-28A 31.5 20.0 19.3 7.9 20,000
Il-29 424.4 293.9 295.8 90.4 200,000
Il-31 48.4 46.1 44.3 18.8 80,000
Ip-10 18.6 12.0 14.8 5.4 20,000
I-TAC 25.2 25.1 14.5 4.3 20,000
lIf 86.0 70.3 107.1 9.4 26,000
lIgHT 35.5 21.7 21.6 9.9 20,000
lymphot-
actin
7.6 7.6 3.7 8.8 200,000
mCp-2 5.2 4.6 1.5 1.3 4,000
mCp-3 309.5 376.6 972.8 1.6 8,000
mCp-4 0.9 1.7 0.5 2.5 20,000
61
The effects of FXa and thrombin on RPE
2
US factor Xa thrombin lower detection 
limit
upper detection 
limit
mDC 23.5 23.6 13.3 8.8 20,000
mIf 8,728.9 7,310.8 8,134.5 3.8 8,000
MIP-3α 15.9 15.1 17.8 3.2 8,000
MIP-3β 75.5 49.8 47.7 14.8 40,000
mpIf-1 15.0 13.8 15.0 4.1 20,000
MSPα 350.8 274.6 272.6 44.6 200,000
NAp-2 8.9 5.4 1.4 3.2 8,000
OpN 10,713.2 3,017.4 478.5 58.0 200,000
pARC 19.2 12.4 13.1 2.5 8,000
pf4 3.3 1.7 1.9 6.8 200,000
SDF-1α 10.6 6.3 2.4 4.9 20,000
TARC 18.2 10.1 9.5 3.2 20,000
TECK 170.8 120.8 42.4 111.4 200,000
TSlp 2.6 0.9 0.3 5.2 20,000
BlC 3.3 4.5 2.0 2.1 4,000
Eotaxin 8.9 10.0 8.6 2.6 8,000
Eotaxin-2 1.9 1.9 1.4 1.1 2,000
g-CSf 3.9 7.1 10.6 11.8 40,000
gm-CSf 36.3 91.6 345.0 0.6 2,000
I-309 6.2 4.1 4.5 4.8 8,000
ICAm-1 685.8 973.4 1296.3 22.2 200,000
IFN-γ 6.9 7.4 6.6 2.1 4,000
IL-1α 5.5 5.3 5.8 2.1 4,000
IL-1β 0.7 1.3 0.5 0.6 2,000
IL-1Rα 11.2 14.9 11.8 0.7 4,000
Il-2 9.7 11.3 12.0 1.8 4,000
Il-4 2.4 2.7 4.3 1.3 4,000
Il-5 10.6 12.8 11.0 3.6 8,000
Il-6 2864.4 4596.9 8387.7 2.4 4,000
Il-6sR 1.2 3.1 1.4 3.4 20,000
Il-7 12.4 12.2 11.8 5.2 8,000
Il-8 1482.7 1941.8 3057.8 0.5 1,000
Il-10 2.4 2.6 3.5 2.7 8,000
Il-11 51.2 62.1 98.0 13.0 40,000
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US factor Xa thrombin lower detection 
limit
upper detection 
limit
Il-12p40 8.1 9.9 12.8 7.5 20,000
Il-12p70 0.7 0.7 0.9 0.4 1,000
Il-13 1.9 2.1 2.5 0.8 2,000
Il-15 18.7 19.8 22.2 5.3 8,000
Il-16 12.2 13.8 17.8 4.0 10,000
Il-17 34.2 46.4 69.8 3.4 8,000
mCp-1 3632.9 3637.6 6075.6 1.6 4,000
mCSf 10.0 4.1 17.6 2.3 8,000
mIg 24.8 26.6 57.9 1.7 10,000
MIP-1α 11.3 35.3 20.1 4.5 20,000
MIP-1β 0.8 0.0 1.3 0.8 2,000
MIP-1δ 0.1 0.1 0.1 1.4 20,000
pDgf-BB 1.9 7.4 34.5 0.9 4,000
RANTES 0.8 0.9 1.1 5.4 40,000
TImp-1 10946.6 24790.4 22610.0 4.6 80,000
TImp-2 32284.1 45967.7 33046.2 11.6 80,000
TNF-α 8.8 16.2 12.3 1.5 4,000
TNF-β 3.0 4.3 2.8 6.4 40,000
TNf RI 966.8 2292.5 3273.2 8.7 80,000
TNf RII 0.0 0.0 0.0 3.7 80,000
AR 30.6 22.6 35.8 9.8 20,000
BDNf 16.4 29.9 25.5 2.3 4,000
bfgf 141.7 119.9 167.8 22.4 40,000
Bmp-4 40.4 39.3 25.1 33.5 200,000
Bmp-5 333.8 316.6 498.2 94.6 200,000
Bmp-7 123.2 163.5 258.2 28.5 80,000
b-Ngf 3.9 5.2 7.2 3.4 20,000
Egf 0.4 0.6 0.3 0.2 400
Egf R 913.8 1146.9 800.3 6.3 20,000
Eg-VEgf 1.8 2.2 2.1 2.1 20,000
fgf-4 362.3 438.0 241.3 84.9 200,000
fgf-7 3.1 1.8 4.5 5.5 20,000
gDf-15 0.4 2.6 0.8 0.8 4,000
gDNf 9.3 10.2 3.2 4.8 8,000
gH 17.3 21.5 8.0 7.0 20,000
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US factor Xa thrombin lower detection 
limit
upper detection 
limit
HB-Egf 15.0 14.1 12.3 6.0 20,000
Hgf 4.8 8.7 2.8 3.7 8,000
IgfBp-1 57.4 71.2 69.8 5.4 10,000
IgfBp-2 81.7 57.9 140.8 14.7 40,000
IgfBp-3 324907.4 101131.9 419231.5 156.8 400,000
IgfBp-4 142.3 259.4 88.6 70.4 400,000
IgfBp-6 57717.9 66115.3 32503.4 41.3 200,000
Igf-I 25.8 30.5 35.1 6.5 40,000
Insulin 90.0 94.3 2.7 7.2 40,000
mCf R 5.2 27.4 7.6 21.0 80,000
Ngf R 4.5 14.0 2.6 6.3 20,000
NT-3 64.1 43.4 22.6 32.0 80,000
NT-4 3.5 3.5 7.9 2.0 20,000
Opg 1926.9 3220.8 5675.7 2.3 8,000
pDgf-AA 658.4 414.5 1051.6 4.6 20,000
pIgf 0.6 3.4 0.3 2.8 8,000
SCf 0.0 0.2 0.1 1.9 20,000
SCf R 2.5 11.8 5.5 11.2 40,000
TGF-α 612.7 1728.0 716.6 1.1 20,000
TGF-β1 155.3 222.6 186.6 85.7 200,000
TGF-β3 8.4 10.3 4.1 24.7 80,000
VEgf 12550.2 12544.0 17015.9 6.9 20,000
VEgf R2 35.0 50.4 33.3 8.1 20,000
VEgf R3 7.9 60.8 3.6 25.8 80,000
VEgf-D 18.0 18.3 20.6 4.7 40,000
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Thrombin induces EmT by RpE
Abstract
Purpose: De-differentiation of retinal pigment epithelial (RPE) cells into mesenchymal 
cells (epithelial-mesenchymal transition; EmT) and associated collagen production 
contributes to development of proliferative vitreoretinopathy (pVR). In patients with 
pVR, intraocular coagulation cascade activation occurs and may play an important 
initiating role. Therefore we examined the effect of the coagulation proteins factor Xa 
and thrombin on EmT and collagen production by RpE cells.
Methods: RPE cells were stimulated with factor Xa or thrombin and the effect on zonula 
occludens ( ZO)-1, α-smooth muscle actin (α-SmA), collagen and platelet-derived growth 
factor (PDGF)-B were determined by RQ-PCR, immunofluorescence microscopy and 
HplC and ElISA for collagen and pDgf-BB in culture supernatants, respectively. pDgf-
receptor activation was determined by phosphorylation analysis and inhibition studies 
using the pDgf-receptor tyrosine kinase inhibitor Ag1296.
Results: Thrombin reduced ZO-1 gene expression (P < 0.05) and enhanced expression 
of the genes encoding α-SMA and the pro-alpha1 chain of collagen type-1 (P < 0.05), 
indicating EmT. Also ZO-1 protein expression declined upon thrombin stimulation while 
production of α-SmA and collagen increased. In contrast to thrombin, factor Xa hardly 
stimulated EmT by RpE. Thrombin clearly induced pDgf-BB production and pDgf-Rβ 
chain phosphorylation in RPE. Moreover AG1296 significantly blocked the effect of 
thrombin on EmT and collagen production.
Conclusion: Our findings demonstrate that thrombin is a potent inducer of EmT by RpE 
via autocrine activation of pDgf-receptor signaling. Coagulation cascade-induced EmT 
of RPE may thus contribute to the formation of fibrotic retinal membranes in PVR and 
should be considered as treatment target in pVR. 
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Introduction
proliferative vitreoretinopathy (pVR) is a complication that is characterized by the 
formation of fibroproliferative membranes in the retina and develops in approximately 
10% of patients that undergo surgery for rhegmatogenous retinal detachment. The 
fibroproliferative membranes, which primarily contain differentiated retinal pigment 
epithelial (RPE) cells, fibroblasts, glial cells, immune cells and extracellular matrix (ECM), 
have contractile properties which causes re-detachment of the retina 1-5. 
Epithelial-mesenchymal transition (EMT) is a de-differentiation process in which 
epithelial cells lose typical epithelial features and acquire mesenchymal features that 
promote migratory capacity, invasiveness, elevated resistance to apoptosis and strongly 
enhanced capacity to produce ECm components 5, 6. EmT is for instance associated with 
reduced expression of epithelial proteins, such as the tight junction proteins (e.g. zonula 
occludens (ZO)-1) and adherent junction proteins (e.g. E-cadherin) and enrichment of 
mesenchymal proteins like α-smooth muscle actin (α-SMA), fibronectin and collagen 
6, 7. EmT or EmT-like processes have been implicated in  the development of organ 
fibrosis, for instance in lungs, liver and kidney, but also the lens of the eye 6, 8. It has 
been recognized that RpE cells undergo EmT in pVR membranes and as such are  major 
contributors to the excessive ECm deposition in these membranes 4, 9-11. moreover, the 
associated upregulation of α-SmA contributes to membrane contractility 2, 4. Although 
these data point at an important role for EMT by RPE cells in the fibrotic process of PVR 
there is only limited data available on factors that drive EmT by human RpE. It has been 
demonstrated that platelet-derived growth factor (PDGF) induces α-SMA expression by 
human RpE and that pDgf-receptor inhibition prevents EmT and pVR development in 
experimental animal models 12-15. A better insight into the process of EmT by human RpE 
is not only crucial to delineate pVR pathology but is also required to improve treatment 
strategies, especially since satisfying treatment to prevent pVR development is currently 
lacking.
Tissue damage results in activation of the extrinsic coagulation pathway with tissue factor 
dependent activation of factor X to factor Xa. factor Xa is subsequently involved in the 
conversion of pro-thrombin into thrombin, which in turn converts soluble fibrinogen into 
insoluble fibrin 16. In addition to their role in coagulation, factor Xa and thrombin influence 
several cellular responses that have important roles in inflammation, tissue repair and 
wound healing, but that also contribute to fibrogenesis. They can for instance activate 
endothelial cells, promote chemotaxis of inflammatory cells, stimulate proliferation of 
fibroblasts, smooth muscle cells and epithelial cells and induce the production of ECM 
components such as collagen 16-21. These cellular effects of factor Xa and thrombin are 
mostly mediated via activation of the cell surface expressed protease activated receptor 
(pAR)1 and pAR2 16.
pVR development is associated with breakdown of the blood-retinal barrier and activation 
of coagulation as evidenced by the deposition of fibrin in the retina and vitreous in PVR 
patients 22-24.  In line with this, Ricker et al demonstrated that subretinal fluids from 
patients with rhegmatogenous retinal detachment exhibited high capacity to generate 
thrombin activity in a tissue factor dependent manner 25. Taken together, this suggests 
that RpE cells are likely to encounter direct contact with coagulation proteins during pVR 
development. previous studies by us and others have demonstrated that factor Xa and 
thrombin can stimulate the production of cytokines/chemokines, pro-fibrotic and pro-
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angiogenic factors by human RpE via pAR1 activation 26-30. moreover, there are indications 
that thrombin induces EmT by rat RpE through transcriptional repression of the epithelial 
marker E-cadherin and induction of actin stress fibre formation 31, 32. However, so far it is 
unknown whether factor Xa and thrombin can induce EmT and collagen production by 
human RpE. 
In this study we examined the effects of factor Xa and thrombin on EMT by the 
human RpE cell line ARpE-19, as well as in primary human RpE cells. We demonstrate 
that thrombin stimulates EMT by RPE, as reflected by reduced expression of ZO-1 and 
enhanced α-SmA expression and collagen production. furthermore we demonstrate 
that thrombin stimulates platelet-derived growth factor receptor (pDgf-R)β activity in 
RpE, most likely via autocrine release of pDgf-BB, and that inhibition of this reverses 
the effects of thrombin on ZO-1, α-SmA and collagen production. Our data indicate that 
thrombin is a strong inducer of EmT by RpE via activation of pDgf-receptor signaling.    
Thrombin induces EmT by RpE
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Materials and methods
Cell cultures
The human retinal pigment epithelial cell line ARpE-19 was obtained from ATCC 
(manassas, VA, uS). ARpE-19 cells between passages 23-30 were used for experiments. 
ARpE-19 and primary RpE cells were cultured in RpE medium (DmEm/HAm’s f-12 1:1 
medium (HyClone logan, uT, uS), containing 10% heat inactivated fetal calf serum (fCS) 
and penicillin/streptomycin (all from BioWhittaker, Verviers, Belgium)) 26. The cells were 
maintained under standard cell culture conditions at 37 oC in humidified air with 5% CO2.
Real-time quantitative PCR analysis 
ARpE-19 cells were seeded into six-well plates at a density of 5 x 105 cells/well in RpE 
medium containing 1% fCS and allowed to adhere overnight. Subsequently the cells were 
incubated for 0, 12, 24, 36 or 48 hours in the presence or absence of human factor Xa (1 
u/ml) or thrombin (5 u/ml) (Calbiochem, la Jolla, CA, uS) (the concentrations used are 
based on findings in a previous study 26) in RpE medium containing 1% fCS for analysis 
of ACTA2 (encoding for α-SmA) and COL1A1 (encoding for the pro-alpha1 chain of type I 
collagen) transcript levels. for analysis of TJP1 (encoding for ZO-1) transcript levels ARpE-
19 cells were seeded into six-well plates at a density of 5 x 105 cells/well in RpE medium 
containing 1% fCS. Cells were allowed to adhere overnight followed by an additional 7-9 
days in order to enable tight junction formation, while refreshing medium containing 1 
% fCS every 3-4 days. Subsequently the cells were incubated for 0, 12, 24, 36 or 48 hours 
in the presence or absence of human factor Xa (1 u/ml) or thrombin (5 u/ml) in RpE 
medium containing 1% fCS. RNA was isolated using a genEluteTm mammalian Total RNA 
miniprep Kit (Sigma; St. louis, mO, uS) and reverse transcribed into cDNA 33. Transcript 
levels of ACTA2, COL1A1, and TJP1 were determined by RQ-pCR (7700 pCR system; Applied 
Biosystems [ABI], foster City, CA, uS). PDGFRA (pDgf-Rα chain) and PDGFRB (pDgf-
Rβ chain) mRNA expression levels were determined in unstimulated ARpE-19 cells. In 
addition, ARpE-19 cells were stimulated with factor Xa (1 u/ml) or thrombin (5 u/ml) for 
0, 1, 2, 4, 6 or 8 hours and the effect on PDGFB mRNA expression level was determined. 
Expression levels of the analyzed gene transcripts were normalized to the control gene 
ABL (Abelson) 33. primer and probe combinations used are listed in table 1. 
Fluorescent immunocytochemistry
for analysis of α-SmA protein expression, ARpE-19 cells were cultured on 12 mm cover 
slips for 2-3 days in RpE medium containing 0.5% fCS. The cells were stimulated with 
factor Xa (1 u/ml), thrombin (5 u/ml) or remained unstimulated for an additional 48 
hours. Thereafter, cells were washed twice with PBS and fixed with 4% paraformaldehyde 
for 10 min. After washing twice with PBS, fixed cells were incubated with glycine (300 
mm) for 5 minutes and then permeabilized with pBS containing 0.1% Triton X-100 for 10 
min. Cells were then washed twice with pBS containing 0.1% Tween 20, incubated with 
pBS containing 1% fatty acid free BSA and 0.1% Tween 20 for 1 hour and then incubated 
overnight with rabbit anti-human-α-SMA primary antibody (clone E184, 04-1094; 
millipore, Billerica, mD, uS) at 4 oC. Thereafter, cells were washed three times with pBS 
containing 0.1% Tween 20 and subsequently incubated for 1 hour with Alexa fluor594-
conjugated chicken anti-rabbit secondary antibody (Invitrogen, paisley, uK) in pBS 
containing 1% BSA, 0.1% Tween 20 and 10% human serum. following secondary antibody 
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incubation, cells were washed six times with pBS containing 0.1% Tween 20 and then 
incubated with the nuclear stain DApI (Invitrogen) for 10 min. Cells were analyzed by 
fluorescence microscopy. 
for analysis of ZO-1 protein expression, ARpE-19 cells were cultured on 12 mm cover 
slips for 7-9 days in RpE medium containing 1% fCS to allow formation of tight junctions. 
Stimulation and staining of the cells were conducted as described above, using overnight 
incubation with Alexa fluor488-conjugated mouse-anti-human ZO-1 primary antibody 
(clone ZO-1-1A12, 339188; Invitrogen) at 4 oC, followed by DApI staining.
for analysis of collagen type 1 expression, ARpE-19 cells were cultured on 12 mm 
cover slips for 2-3 days in RpE medium containing 0.5% fCS. Twenty-four hours prior to 
stimulation and during the 48 hour stimulation period 50 µg/ml ascorbic acid and 200 µm 
L-Proline (Sigma) was added to the culture medium. After the first 24 hours again 50 µg/
ml ascorbic acid and 200 µm l-proline was added to the cell cultures. Here the cells were 
incubated overnight with a mouse-anti-human collagen type 1 primary antibody (clone 
5D8-g9, mAB3391; millipore) at 4 oC,  1 hour incubation with fITC-conjugated rabbit anti-
mouse secondary antibody (Dako, Heverlee, Belgium) and finally stained with DAPI. 
Collagen measurement in culture supernatants
ARpE-19 cells were seeded into six-well plates at a density of 1 x 105 cells/well in RpE 
medium containing 1% FCS and allowed to grow till 100% confluence. Twenty-four hours 
prior to stimulation 50 µg/ml ascorbic acid and 200 µm l-proline was added to the 
culture media. Subsequently the cells were incubated in fresh RpE medium containing 
1% fCS, 50 µg/ml ascorbic acid and 200 µm l-proline for 24 or 48 hours in the presence 
or absence of factor Xa (1 u/ml) or thrombin (5 u/ml). In case of 48 hour incubation 50 
µg/ml ascorbic acid and 200 µm l-proline was again added to the cell cultures after the 
first 24 hours of incubation. Following stimulation, the cells and medium were harvested 
together and proteins were ethanol-precipitated in 67% ethanol 21. Collagen was assessed 
by measuring hydroxyproline levels in proteins by high-pressure liquid chromatography, 
as previously described 21. The amount of collagen present in the culture supernatants 
was calculated based on the fact that collagen contains 12.2% w/w hydroxyproline and 
expressed relative to the amount produced by unstimulated cells 34.
Detection of PDGF receptors and PDGF receptor phosphorylation
In order to determine protein expression levels of the pDgf-Rα and pDgf-Rβ chains in 
ARPE-19 cells,  unstimulated cells were lysed in protein lysis buffer (20 mM Tris pH 8.0, 137 
mm NaCl, 10 mm EDTA, 100 mm Naf, 1% Np-40, 10% glycerol and protease inhibitors). Equal 
amounts of protein (25 µg) were loaded on SDS-pAgE and blotted onto a nitrocellulose 
membrane. Western blots were stained with rabbit-anti human pDgf-Rα (clone C-20, 
SC-338), rabbit-anti human pDgf-Rβ (clone p-20, SC-339) (Santa Cruz Biotechnologies, 
Heidelberg, germany) or mouse-anti human β-actin (clone AC-15, AB6276; Abcam, 
Cambridge, uK) antibodies. In order to assess pDgf-receptor phosphorylation, cultures 
were stimulated with factor Xa (1 u/ml), thrombin (5 u/ml), pDgf-BB (50 ng/ml) (R&D 
Systems, minneapolis, mN, uS) as positive control, or remained unstimulated for 8 
hours in RPE medium containing 1% FCS. Hereafter cells were lysed in protein lysis buffer 
and cell lysates (~500 µg) were used for immunoprecipitation using an anti-pDgf-R 
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antibody as described 35. Immune complexes were collected with a mixture of protein 
A- and g-Sepharose (Sigma) and the level of pDgf-Rβ phosphorylation was determined 
by using an anti-phospho-tyrosine antibody (#9411; Cell Signaling, Danvers, mA, uS) as 
described 35 and quantified by densitometric analysis (ImageQuant TL; GE Healthcare, 
freiburg, germany). 
PDGF-BB detection in culture supernatants
ARpE-19 cells were seeded into six-well plates at a density of 5 x 105 cells/well in RpE 
medium containing 1% fCS and allowed to adhere overnight. Subsequently the cells 
were incubated for 24 hours in the presence or absence of human factor Xa (1 u/ml) 
or thrombin (5 u/ml) in RpE medium containing 1% fCS. Supernatants were harvested 
and pDgf-BB levels were measured using a pDgf-BB ElISA (R&D Systems) according 
manufacturer’s instructions.
PDGF receptor inhibition studies
RpE cells were seeded into six-well plates at a density of 5 x 105 cells/well in RpE 
medium containing 1% fCS and allowed to adhere overnight. Hereafter the cells were 
incubated with RpE medium containing 10 µm of the pDgf-receptor tyrosine kinase 
inhibitor Ag1296 (Calbiochem) for 60 minutes and subsequently stimulated for 12 hours 
with factor Xa (1 u/ml), thrombin (5 u/ml) or pDgf-BB (50 ng/ml) as positive control. 
In order to determine the effect of AG1296 on TJP1 mRNA expression the seeded 
cells were cultured for 7-9 days in RpE medium containing 1% fCS. Hereafter the cells 
were incubated with fresh RpE medium containing 10 µm Ag1296 for 60 minutes and 
subsequently stimulated for 24 hours with factor Xa (1 u/ml), thrombin (5 u/ml) or pDgf-
BB (50 ng/ml). The effect of AG1296 on ACTA2, TJP1 and COL1A1 mRNA expression was 
determined by RQ-pCR. The Ag1296 concentration used was non-toxic to RpE cells as 
determined by lactate dehydrogenase (lDH) release (Roche, mannheim, germany) and 
microscopic appearance of the cells.
Statistical analysis
Data were analysed using the Kruskal-Wallis (One-way ANOVA) test followed by the 
paired Student’s t-test when applicable. A P-value < 0.05 was considered significant. 
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Results
The effect of factor Xa and thrombin on α-SMA and ZO-1 expression by RPE 
factor Xa and thrombin enhanced ACTA2 mRNA expression by ARpE-19, with maximal 
levels at 12 hours following stimulation and with thrombin significantly (P < 0.05) being 
more potent (figure 1A). In line with this, 48 hours stimulation with thrombin clearly 
enhanced the expression of α-SMA filaments in ARPE-19, while this was less evident for 
factor Xa (figure 1B). TJP1 mRNA expression was significantly (P < 0.05) reduced 24 hours 
after thrombin stimulation and was still reduced at 48 hours. factor Xa also appeared to 
decrease TJP1 mRNA expression, but this effect did not reach significance (Figure 1C). 
forty-eight hours stimulation with thrombin also clearly reduced ZO-1 protein expression 
by ARpE-19, while this was not observed with factor Xa (figure 1D). Taken together, 
these results show that thrombin strongly enhances α-SmA expression and reduces ZO-1 
expression by ARPE-19 cells while the expression of these proteins is hardly influenced 
by factor Xa.
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figure 1:  (A) ARpE-19 cells were stimula-
ted for 0, 12, 24, 36 and 48 hours with fac-
tor Xa (1 u/ml) or thrombin (5 u/ml) and 
the ACTA2 mRNA expression level was 
determined by RQ-pCR and normalized 
against the control gene ABl. (B) ARpE-
19 cells were stimulated for 48 hours with 
factor Xa (1 u/ml) or thrombin (5 u/ml) 
and the cells were fixed and stained with 
anti-alpha smooth muscle actin (primary 
antibody (rabbit anti-human) and Alexa 
fluor594-conjugated secondary antibo-
dy (chicken anti-rabbit)). The nuclei were 
stained with DApI. (C) ARpE-19 cells were 
stimulated for 0, 12, 24, 36 and 48 hours 
with factor Xa (1 u/ml) or thrombin (5 u/
ml) and the TJp1 mRNA expression level 
was determined by RQ-pCR and norma-
lized against the control gene ABl. (D) 
ARpE-19 cells were stimulated for 48 
hours with factor Xa (1 u/ml) or throm-
bin (5 U/ml) and the cells were fixed and 
stained with Alexa fluor488-conjugated 
anti-ZO-1 antibody (mouse anti-human). 
The nuclei were stained with DApI. RQ-
pCR data are presented as the mean va-
lue from 4 independent experiments ± 
SEm. Statistical analysis was performed 
with the Kruskal-Wallis (One-way ANO-
VA) test followed by the paired Student’s 
t-test when applicable. P < 0.05 was con-
sidered significant. * = P < 0.05 compared 
to t = 0h. Immunofluorescence pictures 
are representative for 3 independent ex-
periments.
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The effect of factor Xa and thrombin on collagen production by RPE
Factor Xa and thrombin stimulation resulted in significantly (P < 0.05 and P < 0.01, 
respectively) elevated levels of COL1A1 mRNA following 12 hours after stimulation. for 
thrombin this elevation was sustained up to at least 36 hours following stimulation 
and returned to base-line level 48 hours following stimulation (figure 2A). moreover, 
collagen type 1 protein expression was clearly enhanced after 48 hours of thrombin 
stimulation, while this was not the case for factor Xa (Figure 2B). These findings were 
confirmed by the collagen levels detected in the culture supernatants, demonstrating 
a significant (P < 0.05) increase in collagen secretion by RpE after 48 hours of thrombin 
stimulation (figure 2C). Collectively this data demonstrates that thrombin strongly 
enhances collagen production by RpE cells.
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figure 2: (A) ARpE-19 cells were stimu-
lated for 0, 12, 24, 36 and 48 hours with 
factor Xa (1u/ml) or thrombin (5 u/ml) 
and the COl1A1 mRNA expression level 
was determined by RQ-pCR and norma-
lized against the control gene ABl. (B) 
ARpE-19 cells were stimulated for 48 
hours with factor Xa (1 u/ml) or throm-
bin (5 U/ml) and the cells were fixed 
and stained with anti-collagen type 1 
primary antibody (mouse anti-human) 
and  fITC-conjugated secondary antibo-
dy (rabbit anti-mouse). The nuclei were 
stained with DApI. (C) ARpE-19 cells were 
stimulated for 24 or 48 hours with factor 
Xa (1 u/ml) or thrombin (5 u/ml) and af-
ter stimulation the cells numbers were 
determined and hydroxyproline content 
in the culture supernatants was deter-
mined by HplC. RQ-pCR and HplC data 
are presented as the mean value from 
4-5 independent experiments ± SEm. 
Statistical analysis was performed with 
the Kruskal-Wallis (One-way ANOVA) test 
followed by the paired Student’s t-test 
when applicable. P < 0.05 was conside-
red significant. * = P < 0.05 and ** = P < 
0.01 compared to t = 0h or unstimulated 
(US). Immunofluorescence pictures are 
representative for 3 independent expe-
riments.
The effect of factor Xa and thrombin on PDGF receptor phosphorylation
PDGF-isoforms can stimulate α-SMA expression and collagen production by various 
cell types, including RpE 13, 36, 37. previously we found that factor Xa but much stronger 
thrombin stimulated the production of pDgf-AA, pDgf-AB and pDgf-BB by RpE cells 
(ARPE-19 and primary RPE), and here we identified thrombin as a potent inducer of 
EmT by RpE 26. Collectively, these data suggest that thrombin may exert its EMT effect 
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in RpE in an indirect manner that involves activation of pDgf-receptor signaling. pDgf 
molecules signal via homodimeric or heterodimeric receptors consisting of pDgf-Rα and/
or pDgf-Rβ chains 38. Therefore we first examined PDGF-receptor chain expression in 
ARpE-19. Analysis of mRNA and protein expression of the pDgf-Rα and pDgf-Rβ chains 
revealed that ARpE-19 cells abundantly express pDgf-Rβ chains, but hardly express 
pDgf-Rα chains (figure 3A). Similar results were found in primary RpE (data not shown). 
This suggests that pDgf signaling in ARpE-19 will most likely predominantly occur via 
pDgf-Rβ homodimers. pDgf-BB can signal via pDgf-Rβ-homodimers, while pDgf-AB 
and AA signal via PDGF-Rα containing dimers 38. As expected stimulation of ARpE-19 with 
PDGF-BB resulted in significant (P < 0.05)  phosphorylation of pDgf-Rβ chains, indicating 
receptor activation (Figure 3B). In ARPE-19 cells, factor Xa hardly stimulated PDGF-Rβ 
chain phosphorylation, while thrombin significantly (P < 0.05)  stimulated resulted pDgf-
Rβ chain phosphorylation (Figure 3B). 
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figure 3:  (A) pDgfRA and pDgfRB mRNA 
expression levels in unstimulated ARpE-
19 cells were determined by RQ-pCR and 
normalized against the control gene ABl. 
Data are presented as the mean value of 
4 independent experiments ± SEm. pD-
GF-Rα, PDGF-Rβ and β-actin protein ex-
pression levels in unstimulated ARpE-19 
cells were determined by Western Blot. 
(B) ARpE-19 cells were stimulated for 8 
hours with or without factor Xa (1 u/ml), 
thrombin (5 u/ml) or pDgf-BB (50 ng/
ml). Total lysates from these stimulated 
cells were used for immunoprecipitation 
using an anti-PDGF-Rβ antibody. Immune 
complexes were collected with a mixtu-
re of protein A- and g-Sepharose and the 
PDGF-Rβ levels were determined. Levels 
of PDGF-Rβ phosphorylation were deter-
mined by using an anti-phospho-tyrosine 
antibody. The depicted western blot is 
representative for 3 independent expe-
riments. Densitometric analysis was per-
formed and the P-Tyr-100/PDGF-Rβ ratio 
was determined. Data are presented as 
the mean value from 3 independent ex-
periments ± SEm. (C) ARpE-19 cells were 
stimulated for 0, 1, 2, 4, 6 and 8 hours 
with factor Xa (1u/ml) or thrombin (5 u/
ml) and the pDgfB mRNA expression 
levels were determined by RQ-pCR and 
normalized against the control gene ABl. Data are presented as the mean value from 4 indepen-
dent experiments ± SEm. ARpE-19 cells were stimulated for 24 hours with or without factor Xa 
(1u/ml) or thrombin (5 u/ml) and pDgf-BB protein expression levels were determined. Data are 
presented as the mean value from 4 independent experiments ± SEm.  Statistical analysis was 
performed with the Kruskal-Wallis (One-way ANOVA) test followed by the paired Student’s t-test 
when applicable. P < 0.05 was considered significant. * = P < 0.05 and ** = P < 0.01 compared to t 
= 0h or US. US = unstimulated.
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Table 1: pCR primer and probe sequences
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figure 4: ARpE-19 cells and primary 
RpE were stimulated for 12 (ACTA2 
and COl1A1) or 24 hours (TJp1) with 
factor Xa (1 u/ml),  thrombin (5 u/ml) 
or pDgf-BB (50 ng/ml) in the absence 
or presence of the inhibitor Ag1296 (10 
µm). ACTA2, TJp1 and COl1A1 mRNA 
expression levels were determined by 
RQ-pCR and normalized against the 
control gene ABl. Data are presented 
as the mean value from 5-6 independent 
experiments ± SEm. Statistical analysis 
was performed with the Kruskal-Wallis 
(One-way ANOVA) test followed by the 
paired Student’s t-test when applicable. 
P < 0.05 was considered significant. * = P 
< 0.05 and ** = P < 0.01 compared to t = 
0h. US = unstimulated.
Gene Sequence fwd primer  (5`-3`) Sequence rev primer  (5`-3`) Sequence probe  (5`-3`)
ABl 26 TggAgATAACATCTAAgCATAACTAAAggT gATgTAgTTgCTTgggACCCA fAm-CCATTTTTggTTTgggCTTCACACCATT-TAmRA
ACTA2 CCgACCgAATgCAgAAggA ACAgAgTATTTgCgCTCCggA fAm-ATCACggCCCTAgCACCCAgCA-TAmRA
COl1A1 ACTggCCCCCCTggTCC gggCTCTCCAgCAgCACCTT fAm-CCggACCCCCAggCCCACCT-TAmRA
pDgfB 26 TCCCgAggAgCTTTATgAgATg CgggTCATgTTCAggTCCAAC fAm-AgTgACCACTCgATCCgCTCCTTTg-TAmRA
pDgfRA 58 TgAAggCAggCACATTTACATCTA TACAggAgTCTCgggATCAgTTg fAm-TgCCAgACCCAgATgTAgCCTTTgTACCTC-TAmRA
pDgfRB 58 ggggACAgggAggTggATT ATTCCCgATCACAATgCACA fAm-TCTACAgACTCCAggTgTCATCCATCAACgTC-TAmRA
TJp1 gAgACgCTggAACTgACCAA TgTTTgTCTTgATCTATgATTTgCTT fAm-AgCTCTggCATTATTCgCCTgCATACA-TAmRA
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The effect of factor Xa and thrombin on PDGF-BB production
Next we examined whether the lower level of PDGF-Rβ phosphorylation induced by 
factor Xa as compared to thrombin related to kinetic differences in PDGF-BB induction. 
Hereto, ARPE-19 cells were stimulated with factor Xa and thrombin for different time 
points and the effect on PDGFB mRNA expression was determined. This revealed that 
factor Xa and thrombin enhanced PDGFB mRNA expression in a time depending manner, 
being maximal and significant (thrombin P < 0.01, factor Xa P < 0.05)  4 hours after 
stimulation with thrombin being the most potent (figure 3C).  In line with this, 24 hour 
thrombin stimulation resulted in a significant (P < 0.05)  increase in pDgf-BB secretion 
by ARPE-19 cells, while the increase induced by factor Xa was not significant (Figure 3C). 
These data combined demonstrate that thrombin is the more potent inducer of pDgf-BB 
expression. 
The effect of PDGF-receptor inhibition on the regulation of α-SMA, ZO-1 and collagen 
type 1 expression by  factor Xa and thrombin
In order to examine whether the effect of thrombin on α-SmA, ZO-1 and collagen type 
1 expression by RpE depends on pDgf-receptor activation we performed inhibition 
studies with the pDgf-receptor tyrosine kinase inhibitor Ag1296, which potently inhibits 
signaling of human PDGF-Rα and –Rβ. PDGF-BB significantly (P < 0.05) enhanced ACTA2 
and COL1A1 mRNA expression by both ARPE-19 and primary RPE. PDGF-BB significantly 
(P < 0.05) reduced TJP1 mRNA levels in the ARpE-19 cells, but not in the primary RpE 
cells. The effects of PDGF-BB on ACTA2, TJP1 and COL1A1 mRNA levels were completely 
reversed (P < 0.05)  by Ag1296 (figure 4). In line with previous results (figures 1 and 
2) thrombin significantly (P < 0.05) enhanced ACTA2 and COL1A1 mRNA expression and 
reduced TJP1 mRNA expression by ARPE-19. Comparable effects for thrombin on ACTA2, 
COL1A1 and TJP1 mRNA levels were observed in primary RPE (Figure 4). These effects of 
thrombin were significantly (P < 0.05) blocked by Ag1296. Also the factor Xa stimulated 
increase in ACTA2 and COL1A1 mRNA levels in ARpE-19 and primary RpE cells was blocked 
by Ag1296.  
3
Gene Sequence fwd primer  (5`-3`) Sequence rev primer  (5`-3`) Sequence probe  (5`-3`)
ABl 26 TggAgATAACATCTAAgCATAACTAAAggT gATgTAgTTgCTTgggACCCA fAm-CCATTTTTggTTTgggCTTCACACCATT-TAmRA
ACTA2 CCgACCgAATgCAgAAggA ACAgAgTATTTgCgCTCCggA fAm-ATCACggCCCTAgCACCCAgCA-TAmRA
COl1A1 ACTggCCCCCCTggTCC gggCTCTCCAgCAgCACCTT fAm-CCggACCCCCAggCCCACCT-TAmRA
pDgfB 26 TCCCgAggAgCTTTATgAgATg CgggTCATgTTCAggTCCAAC fAm-AgTgACCACTCgATCCgCTCCTTTg-TAmRA
pDgfRA 58 TgAAggCAggCACATTTACATCTA TACAggAgTCTCgggATCAgTTg fAm-TgCCAgACCCAgATgTAgCCTTTgTACCTC-TAmRA
pDgfRB 58 ggggACAgggAggTggATT ATTCCCgATCACAATgCACA fAm-TCTACAgACTCCAggTgTCATCCATCAACgTC-TAmRA
TJp1 gAgACgCTggAACTgACCAA TgTTTgTCTTgATCTATgATTTgCTT fAm-AgCTCTggCATTATTCgCCTgCATACA-TAmRA
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Discussion
EMT contributes to fibrotic processes, including those occurring in the retina of patients 
with pVR 2, 13, 39, 40. Blood-retinal barrier breakdown and associated activation of the 
coagulation cascade contributes to pVR development 25, 41. Here we demonstrate that 
the coagulation protein thrombin is a strong inducer of EmT by human RpE and that 
factor Xa does this to a far lesser extent. 
 EmT occurs in response to injury to promote wound closure and tissue regeneration. 
However in fibrosis, which can be regarded as a dysregulated healing attempt, EMT 
programs are not attenuated, thereby contributing to excessive matrix production 
42. We found that thrombin  downregulated the expression of epithelial tight junction 
protein ZO-1 while expression of the contractile protein α-SMA was enhanced. This 
transformation of RPE cells into contractile myofibroblast like cells allows migration into 
the vitreous where they contribute to pVR membrane formation and the contractile 
properties of these membranes 5, 7. Myofibroblast like cells appear to be the main 
cell type responsible for collagen accumulation in fibrosis 43, 44. In line with this, we 
found that thrombin-induced downregulation of ZO-1 and upregulation of α-SMA was 
accompanied by enhanced production of collagen, which is one of the main constituents 
of pVR membranes 45. The effects of factor Xa on EMT and collagen production were 
less pronounced. We regard this unlikely to be related to the concentration used as we 
previously observed that 1u/ml factor Xa generated maximal pAR1 activation in RpE 26. 
Activation of RpE by thrombin may thus represent a major route of coagulation factor-
driven EmT in pVR.      
Fibrin clots have been suggested to contribute to fibrosis in general by providing ECM 
producing cells with a scaffold for adherence, proliferation and ECM production 22, 28. 
Along this hypothesis, retinal fibrin deposition has been suggested to promote RPE cell 
proliferation, differentiation and collagen synthesis in PVR 25, 41. However, experiments 
in fibrinogen knock-out mice revealed that bleomycin-induced lung fibrosis was not 
diminished, while direct blockade of PAR1 did inhibit bleomycin-induced lung fibrosis in 
mice 46, 47. These data indicate that fibrin deposition is not per se required for fibrosis 
development and that especially the cell mediated effects of thrombin and factor Xa 
contribute to fibrosis development in this model. Here we demonstrate that especially 
thrombin induces EmT and collagen production by human RpE, while others have shown 
that thrombin stimulates human RpE cell migration and rat RpE cell proliferation 28, 48. 
moreover, we and others found that factor Xa and thrombin stimulate the production of 
several cytokines and growth factors by RpE via pAR1 activation 26-30. Therefore the direct 
receptor-mediated cellular effects that thrombin and factor Xa elicit in RPE by activation 
of pAR1 may play an important role in pVR development.  
pDgf-receptor activity has been observed in human pVR membranes and pDgf has been 
found to stimulate EmT by RpE 10, 13, 49, 50. pDgf-receptor chains dimerize into functional 
signaling units upon ligand binding 38. Here we found that ARpE-19 as well as primary RpE 
predominantly express the PDGF-Rβ chain, which is in line with previous observations 51. 
Consequently RPE cells can be expected to predominantly form PDGF-Rβ homodimers, 
which is activated by pDgf-BB 38. In our current study we confirm our previous finding 
that thrombin induces pDgf-BB production by RpE more potent than factor Xa 26.  In 
line with this we here demonstrate that thrombin clearly enhances PDGF-Rβ chain 
phosphorylation (activation) in ARpE-19, while factor Xa does this to a far lesser extent. 
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Moreover, the effects of factor Xa and thrombin on ACTA2, TJP1 and COL1A1 mRNA 
expression were blocked by the pDgf-receptor tyrosine kinase inhibitor Ag1296. Thus 
thrombin, and to a lesser extent factor Xa, most likely induce EMT by RPE via PDGF-Rβ 
signaling initiated via autocrine release of pDgf-BB. Despite of low expression of pDgf-
Rα by RPE cells, activation of this receptor is considered important to PVR development 
50, 52. We can not exclude involvement of  PDGF-Rα in our study as it can be activated 
by pDgf-A and pDgf-B chain containing pDgf-dimers that are induced by factor Xa 
and thrombin in RPE (this study), while AG1296 also blocks PDGF-Rα activation 26, 38. 
Transactivation of PDGF- Rα via other growth factor receptors, for instance the FGF- or 
Egf- receptor can also  not be excluded 53, 54. Although, we consider this unlikely since we 
previously demonstrated that thrombin nor factor Xa stimulate fgf and Egf production 
by RpE 26. Nevertheless, our data clearly indicate that that the stimulatory effects of 
thrombin on EMT of RPE involves PDGF-Rβ activation. 
Factor Xa had a far  less pronounced effect on EMT, collagen production and PDGF-Rβ 
phosphorylation by RpE than thrombin in our studies. Whether this relates to the fact 
that factor Xa requires cofactors such as tissue factor, endothelial protein C receptor or 
annexin 2 for efficient PAR1 cleavage and a relative absence of such factors in our culture 
system is unclear 55-57. However, we found that factor Xa stimulates pDgf-BB secretion 
by ARpE-19 to a lesser extent than thrombin and that factor Xa less potently but with 
comparable kinetics to thrombin enhanced PDGFB mRNA expression in ARpE-19. This 
indicates that production of a certain amount of pDgf and subsequent level of pDgf-
receptor activation has to be achieved by the coagulation factor to efficiently induce 
EmT by RpE.
Collectively, our previous and current findings demonstrate that coagulation cascade 
activity can induce EmT of RpE via autocrine pDgf-receptor signaling (figure 5) 26. 
Inhibition of thrombin activity or its activator factor Xa by using clinically applicable 
anti-coagulants may therefore be considered in the treatment of pVR. Alternatively 
targeting of the downstream PDGF-receptor signaling cascade with specific PDGF-
receptor targeting tyrosine kinase inhibitors or the use of pAR1 antagonists may also be 
of therapeutic interest.           
Thrombin induces EmT by RpE
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figure 5: Schematic summary of the activation of RpE by factor Xa and thrombin resulting in EmT. 
Factor Xa and thrombin activate PAR1 which results in NF-κB signaling and the secretion of a broad 
panel of pro-inflammatory cytokines and growth factors, including PDGF-BB 26. The secreted pD-
GF-BB  binds an PDGF-Rβ chain resulting in the formation of PDGF-Rβ dimers, autophosphorylation 
and activation of PDGF-receptor signaling. Signaling through the PDGF-receptor results in diffe-
rentiation of RpE into a mesenchymal cell type characterized by decreased ZO-1 expression and in-
creased α-SMA expression and collagen production. The dashed line between factor Xa and PAR1 
indicates a weaker effect compared to thrombin.
81
Thrombin induces EmT by RpE
3
References
1. pastor JC. proliferative 
vitreoretinopathy: an overview. Surv 
Ophthalmol 1998;43:3-18.
2. pastor JC, de la Rua ER, martin 
f. proliferative vitreoretinopathy: risk 
factors and pathobiology. prog Retin Eye 
Res 2002;21:127-144.
3. D’Amico DJ. Clinical practice. 
primary retinal detachment. N Engl J med 
2008;359:2346-2354.
4. Casaroli-marano Rp, pagan R, 
Vilaro S. Epithelial-mesenchymal transition 
in proliferative vitreoretinopathy: 
intermediate filament protein expression 
in retinal pigment epithelial cells. Invest 
Ophthalmol Vis Sci 1999;40:2062-2072.
5. Kalluri R, Neilson Eg. Epithelial-
mesenchymal transition and its 
implications for fibrosis. J Clin Invest 
2003;112:1776-1784.
6. Kalluri R, Weinberg RA. The 
basics of epithelial-mesenchymal 
transition. J Clin Invest 2009;119:1420-
1428.
7. li H, Wang H, Wang f, gu Q, 
Xu X. Snail involves in the transforming 
growth factor beta1-mediated epithelial-
mesenchymal transition of retinal 
pigment epithelial cells. ploS One 
2011;6:e23322.
8. Saika S, Kono-Saika S, Ohnishi 
y, et al. Smad3 signaling is required for 
epithelial-mesenchymal transition of 
lens epithelium after injury. Am J pathol 
2004;164:651-663.
9. Connor TB, Jr., Roberts AB, 
Sporn MB, et al. Correlation of fibrosis 
and transforming growth factor-beta 
type 2 levels in the eye. J Clin Invest 
1989;83:1661-1666.
10. Robbins Sg, mixon RN, Wilson 
DJ, et al. platelet-derived growth factor 
ligands and receptors immunolocalized 
in proliferative retinal diseases. Invest 
Ophthalmol Vis Sci 1994;35:3649-3663.
11. Esser p, Heimann K, Bartz-
schmidt Ku, et al. Apoptosis in 
proliferative vitreoretinal disorders: 
possible involvement of Tgf-beta-
induced RpE cell apoptosis. Exp Eye Res 
1997;65:365-378.
12. umazume K, liu l, Scott pA, 
et al. Inhibition of pVR with a tyrosine 
kinase inhibitor, Dasatinib, in the swine. 
Invest Ophthalmol Vis Sci 2013.
13. Si y, Wang J, guan J, Han Q, Hui y. 
platelet-Derived growth factor Induced 
Alpha-Smooth muscle Actin Expression 
by Human Retinal pigment Epithelium 
Cell. J Ocul pharmacol Ther 2012.
14. Chan Cm, Chang HH, Wang VC, 
Huang CL, Hung CF. Inhibitory Effects 
of Resveratrol on pDgf-BB-Induced 
Retinal pigment Epithelial Cell migration 
via pDgfRbeta, pI3K/Akt and mApK 
pathways. ploS One 2013;8:e56819.
15. Velez g, Weingarden AR, lei 
H, Kazlauskas A, gao g. Su9518 Inhibits 
proliferative Vitreoretinopathy (pVR) 
in Fibroblast and Genetically Modified 
mueller Cell-Induced Rabbit models. 
Invest Ophthalmol Vis Sci 2013.
16. mercer pf, Chambers RC. 
Coagulation and coagulation signalling in 
fibrosis. Biochim Biophys Acta 2013.
17. Blanc-Brude Op, Chambers RC, 
leoni p, Dik WA, laurent gJ. factor Xa 
is a fibroblast mitogen via binding to 
effector-cell protease receptor-1 and 
autocrine release of pDgf. Am J physiol 
Cell physiol 2001;281:C681-689.
82
18. Krupiczojc mA, Scotton CJ, 
Chambers RC. Coagulation signalling 
following tissue injury: focus on the 
role of factor Xa. Int J Biochem Cell Biol 
2008;40:1228-1237.
19. Scotton CJ, Krupiczojc mA, 
Konigshoff M, et al. Increased local 
expression of coagulation factor X 
contributes to the fibrotic response in 
human and murine lung injury. J Clin 
Invest 2009;119:2550-2563.
20. yoshida A, Elner Sg, Bian 
Zm, Kunkel Sl, lukacs NW, Elner Vm. 
Thrombin regulates chemokine induction 
during human retinal pigment epithelial 
cell/monocyte interaction. Am J pathol 
2001;159:1171-1180.
21. Blanc-Brude Op, Archer f, leoni 
P, et al. Factor Xa stimulates fibroblast 
procollagen production, proliferation, 
and calcium signaling via pAR1 activation. 
Exp Cell Res 2005;304:16-27.
22. Vidaurri-Leal JS, Glaser BM. Effect 
of fibrin on morphologic characteristics 
of retinal pigment epithelial cells. Arch 
Ophthalmol 1984;102:1376-1379.
23. Schwartz D, de la Cruz ZC, 
green WR, michels Rg. proliferative 
vitreoretinopathy. ultrastructural study 
of 20 retroretinal membranes removed 
by vitreous surgery. Retina 1988;8:275-
281.
24. Nagasaki H, Shinagawa K, 
mochizuki m. Risk factors for proliferative 
vitreoretinopathy. prog Retin Eye Res 
1998;17:77-98.
25. Ricker lJ, Dieri RA, Beckers gJ, 
et al. High subretinal fluid procoagulant 
activity in rhegmatogenous retinal 
detachment. Invest Ophthalmol Vis Sci 
2010;51:5234-5239.
26. Bastiaans J, van meurs JC, van 
Holten-Neelen C, et al. factor Xa and 
thrombin stimulate proinflammatory 
and profibrotic mediator production by 
retinal pigment epithelial cells: a role in 
vitreoretinal disorders? graefes Arch Clin 
Exp Ophthalmol 2013;251:1723-1733.
27. Hollborn m, Kohen l, Werschnik 
C, Tietz l, Wiedemann p, Bringmann A. 
Activated Blood Coagulation factor X 
(fXa) Induces Angiogenic growth factor 
Expression in Human Retinal pigment 
Epithelial Cells. Invest Ophthalmol Vis Sci 
2012;53:5930-5939.
28. Hollborn M, Petto C, Steffen A, 
et al. Effects of thrombin on RPE cells are 
mediated by transactivation of growth 
factor receptors. Invest Ophthalmol Vis 
Sci 2009;50:4452-4459.
29. Scholz m, Vogel Ju, Hover g, 
et al. Thrombin stimulates Il-6 and Il-8 
expression in cytomegalovirus-infected 
human retinal pigment epithelial cells. Int 
J mol med 2004;13:327-331.
30. Bian Zm, Elner Sg, Elner Vm. 
Thrombin-induced VEgf expression in 
human retinal pigment epithelial cells. 
Invest Ophthalmol Vis Sci 2007;48:2738-
2746.
31. Ruiz-loredo Ay, lopez E, lopez-
Colome Am. Thrombin stimulates stress 
fiber assembly in RPE cells by PKC/CPI-17-
mediated mlCp inactivation. Exp Eye Res 
2012;96:13-23.
32. palma-Nicolas Jp, lopez-Colome 
Am. Thrombin induces slug-mediated 
E-cadherin transcriptional repression and 
the parallel up-regulation of N-cadherin by 
a transcription-independent mechanism 
in RpE cells. J Cell physiol 2013;228:581-
589.
Chapter 3
83
Thrombin induces EmT by RpE
3
33. Dik WA, Nadel B, przybylski gK, 
et al. Different chromosomal breakpoints 
impact the level of lmO2 expression in 
T-All. Blood 2007;110:388-392.
34. laurent gJ, Cockerill p, mcAnulty 
RJ, Hastings JR. A simplified method for 
quantitation of the relative amounts of 
type I and type III collagen in small tissue 
samples. Anal Biochem 1981;113:301-312.
35. van Steensel l, paridaens D, 
Schrijver B, et al. Imatinib mesylate 
and AmN107 inhibit pDgf-signaling in 
orbital fibroblasts: a potential treatment 
for graves’ ophthalmopathy. Invest 
Ophthalmol Vis Sci 2009;50:3091-3098.
36. Throckmorton DC, Brogden 
Ap, min B, Rasmussen H, Kashgarian m. 
pDgf and Tgf-beta mediate collagen 
production by mesangial cells exposed 
to advanced glycosylation end products. 
Kidney Int 1995;48:111-117.
37. yang f, Zhao p, She m, ye g, Han 
X. [The modulation of collagen synthesis 
and expressions of type I and III collagen 
mRNAs in aorta smooth muscle cell by 
pDgf and heparin]. Zhongguo yi Xue Ke 
Xue yuan Xue Bao 1999;21:13-18.
38. Andrae J, gallini R, Betsholtz C. 
Role of platelet-derived growth factors 
in physiology and medicine. genes Dev 
2008;22:1276-1312.
39. lee H, O’meara SJ, O’Brien 
C, Kane R. The role of gremlin, a 
Bmp antagonist, and epithelial-to-
mesenchymal transition in proliferative 
vitreoretinopathy. Invest Ophthalmol Vis 
Sci 2007;48:4291-4299.
40. friedlander m. fibrosis and 
diseases of the eye. J Clin Invest 
2007;117:576-586.
41. Esser p, Heimann K, Bartz-
Schmidt Ku, Walter p, Krott R, Weller m. 
plasminogen in proliferative vitreoretinal 
disorders. Br J Ophthalmol 1997;81:590-
594.
42. Duffield JS, Lupher M, Thannickal 
VJ, Wynn TA. Host responses in tissue 
repair and fibrosis. Annu Rev Pathol 
2013;8:241-276.
43. Watsky mA, Weber KT, Sun 
y, postlethwaite A. New insights 
into the mechanism of fibroblast to 
myofibroblast transformation and 
associated pathologies. Int Rev Cell mol 
Biol 2010;282:165-192.
44. Eyden B. The myofibroblast: 
phenotypic characterization as a 
prerequisite to understanding its 
functions in translational medicine. J Cell 
mol med 2008;12:22-37.
45. Ioachim E, Stefaniotou m, 
gorezis S, Tsanou E, psilas K, Agnantis 
NJ. Immunohistochemical study of 
extracellular matrix components 
in epiretinal membranes of 
vitreoproliferative retinopathy and 
proliferative diabetic retinopathy. Eur J 
Ophthalmol 2005;15:384-391.
46. Hattori N, Degen Jl, Sisson TH, 
et al. Bleomycin-induced pulmonary 
fibrosis in fibrinogen-null mice. J Clin 
Invest 2000;106:1341-1350.
47. Howell DC, goldsack NR, 
marshall Rp, et al. Direct thrombin 
inhibition reduces lung collagen, 
accumulation, and connective tissue 
growth factor mRNA levels in bleomycin-
induced pulmonary fibrosis. Am J Pathol 
2001;159:1383-1395.
48. parrales A, palma-Nicolas Jp, 
lopez E, lopez-Colome Am. Thrombin 
stimulates RpE cell proliferation by 
promoting c-fos-mediated cyclin D1 
expression. J Cell physiol 2010;222:302-
312.
49. Cui J, lei H, Samad A, et al. 
pDgf receptors are activated in human 
epiretinal membranes. Exp Eye Res 
2009;88:438-444.
84
50. lei H, Rheaume mA, 
Kazlauskas A. Recent developments 
in our understanding of how platelet-
derived growth factor (pDgf) and its 
receptors contribute to proliferative 
vitreoretinopathy. Exp Eye Res 
2010;90:376-381.
51. yoshida m, Tanihara H, 
yoshimura N. platelet-derived growth 
factor gene expression in cultured human 
retinal pigment epithelial cells. Biochem 
Biophys Res Commun 1992;189:66-71.
52. lei H, Rheaume mA, Velez g, 
mukai S, Kazlauskas A. Expression of 
pDgfRalpha is a determinant of the 
pVR potential of ARpE19 cells. Invest 
Ophthalmol Vis Sci 2011;52:5016-5021.
53. lei H, Velez g, Hovland p, Hirose 
T, gilbertson D, Kazlauskas A. growth 
factors outside the pDgf family drive 
experimental pVR. Invest Ophthalmol Vis 
Sci 2009;50:3394-3403.
54. Bringmann A, Iandiev I, 
pannicke T, et al. Cellular signaling and 
factors involved in muller cell gliosis: 
neuroprotective and detrimental effects. 
prog Retin Eye Res 2009;28:423-451.
55. Riewald m, Ruf W. mechanistic 
coupling of protease signaling and 
initiation of coagulation by tissue factor. 
proc Natl Acad Sci u S A 2001;98:7742-
7747.
56. Bhattacharjee g, Ahamed J, 
pawlinski R, et al. factor Xa binding to 
annexin 2 mediates signal transduction 
via protease-activated receptor 1. Circ 
Res 2008;102:457-464.
57. Schuepbach RA, Riewald m. 
Coagulation factor Xa cleaves protease-
activated receptor-1 and mediates 
signaling dependent on binding to the 
endothelial protein C receptor. J Thromb 
Haemost 2010;8:379-388.
58. van Steensel l, paridaens D, van 
Meurs M, et al. Orbit-infiltrating mast 
cells, monocytes, and macrophages 
produce pDgf isoforms that orchestrate 
orbital fibroblast activation in Graves’ 
ophthalmopathy. J Clin Endocrinol metab 
2012;97:E400-408.
Chapter 3
85
Thrombin induces EmT by RpE
3

Chapter 4
Monocyte-macrophage 
differentiation is induced in 
thrombin-stimulated monocyte-
ARPE-19 co-cultures
Jeroen Bastiaans, p. martin van Hagen,  Nicole m.A. Nagtzaam, Conny 
p.C.A. van Holten - Neelen, Jan C. van meurs, Herbert Hooijkaas and 
Willem A. Dik
Manuscript in preparation
88
Chapter 4
89
Thrombin induces macrophage differentiation
Abstract
Background: macrophages play an important role in proliferative vitreoretinopathy 
(pVR) and may therefore represent an attractive therapeutic target. macrophage 
differentiation is modulated by the local environment, but how this is controlled in PVR 
is largely unknown. Besides macrophages retinal pigment epithelial (RpE) cells are also 
important contributors to pVR development. Recently it was found that pVR is associated 
with increased intra-ocular thrombin activity. In this study we determined the effect of 
thrombin on RPE cells interacting with monocytes on macrophage differentiation. 
Methods: Human monocytes and the human RpE cell line ARpE-19 were cultured 
separately or in co-culture in the presence or absence of thrombin. macrophage 
differentiation was examined by immunocytochemistry for CD68. Experiments using 
neutralizing antibodies against integrin β2 (CD18) and ICAM-1 (CD54) were performed 
to study the contribution of these adhesion molecules. CXCl8, ICAm-1, Il-6, Il-10, pDgf-
BB, TGF-β1, TGF-β2 and VEgf-A levels were measured in culture supernatants with ElISA.
Results: Thrombin strongly enhanced monocyte-to-macrophage differentiation in 
monocyte-ARpE-19 co-cultures. This was abrogated by neutralizing antibodies against 
CD18 or CD54. Macrophage differentiation in the presence of ARPE-19 and thrombin was 
associated with significantly (P < 0.05) higher production of soluble ICAm-1, pDgf-BB and 
VEgf-A.
Conclusions: Thrombin supports monocyte-to-macrophage differentiation when co-
cultured with ARpE-19, which involves the adhesion molecules CD18 and CD54. This 
macrophage differentiation is associated with elevated secretion of the growth factors 
pDgf-BB and VEgf-A, suggestive for m2-maturation. Thrombin activity together with 
activated RpE and monocytes support the maturation of macrophages. This process 
may contribute to the development of pVR.
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Introduction
Proliferative vitreoretinopathy (PVR) is a fibrotic disorder of the retina that can develop 
after rhegmatogenous retinal detachment and is the most common failure of retinal 
detachment surgery 1. pVR development is characterized by the formation of subretinal, 
and/or epiretinal fibroproliferative membranes and intraretinal fibrosis, with excessive 
amounts of extracellular matrix (ECM) molecules and contractile myofibroblasts that 
cause the retina to detach 2, 3. pVR leads to visual impairment and can result in complete 
loss of vision if not treated in time. However, besides (repeated) surgery there is currently 
no satisfying medical treatment available for the treatment or prevention of pVR, likely 
because the pathobiology of pVR is still poorly understood.  
The fibroproliferative contractile membranes represent the final pathological end-stage 
of PVR and are formed through a complex interplay between different cell types, specific 
receptors and soluble molecules 4-10. Retinal pigment epithelial (RpE) cells are considered 
key players in the formation of these membranes, since they exhibit the capacity to 
de-differentiate into myofibroblasts (epithelial mesenchymal transition; EMT) that are 
potent producers of ECm molecules 1, 11.
In case of disturbed tissue homeostasis monocytes are recruited from the peripheral 
blood into tissue where they differentiate into macrophages 12. macrophages are 
specialized phagocytes that remove tissue debris and microbial components but they 
also respond to diverse environmental signals that drive further differentiation 13, 14. 
When macrophages adopt the alternatively activated m2-phenotype, a process driven 
by factors including granulocyte macrophage colony stimulating factor (gm-CSf), 
interleukin (IL)-4 and IL-13, they can hugely contribute to fibrosis 15, 16. m2-macrophages 
secrete pro-fibrotic growth factors including platelet-derived growth factor (PDGF), 
transforming growth factor (TGF)-β and vascular endothelial growth factor (VEGF) 17. 
These growth factors support proliferation of different cell types, including fibroblasts 
and epithelial cells, stimulate EmT and promote ECm molecule production as well as 
stabilization of already deposited ECm components 18-23.  PDGF, TGF-β and VEGF, are 
all elevated in vitreous of patients with established pVR 1-3, 24, 25. In addition, cytokines/
chemokines and adhesion molecules including chemokine (C-C motif) ligand (CCl)2, 
CCl3, CCl4, chemokine (C-X-C motif) ligand (CXCl)10 and intercellular adhesion molecule 
(ICAM)-1, that recruit monocytes and stimulate subsequent macrophage differentiation, 
are elevated in pVR vitreous 26-28. In line with this, monocytes and macrophages are 
abundantly present in pVR membranes and vitreous 1, 24, 26, 28-30. Therefore, macrophages 
are considered as important cellular source of growth factors that stimulate pro-fibrotic 
events, including EmT and ECm production by RpE cells, in pVR. macrophages may thus 
represent a cellular target to prevent pVR development. However, the mechanisms 
involved in macrophage differentiation in PVR are hardly examined so far. 
pVR is associated with increased intravitreal activity of the coagulation protease 
thrombin that stimulates the production of CCl2, CCl7 and gm-CSf by RpE cells, which 
are all chemoattractants for monocytes while GM-CSF also stimulates the differentiation 
of monocytes into macrophages 11, 31-34. In addition, it has been described that thrombin 
stimulates ICAm-1 expression by RpE cells and strengthens the physical interaction 
between RpE cells and monocytes when co-cultured 32, 33.
The data above suggest that thrombin activated RpE cells may facilitate retinal 
macrophage accumulation in pVR and may thus represent an attractive pharmacological 
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target to interfere with macrophage activity. In the current study we demonstrate for 
the first time that thrombin-activated monocyte-RPE co-cultures induce macrophage 
differentiation associated with increased production of the pro-fibrotic mediators 
PDGF-BB and VEGF-A and to a lesser extent TGF-β1 and TGF-β2. This suggests that under 
these conditions thrombin drives the generation of pro-fibrotic M2-type macrophages. 
Moreover this differentiation process likely depends on physical interaction between 
monocytes and RpE cells facilitated by adhesion molecules including ICAm-1 (CD54) and 
β2-integrin (CD18).  
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Materials and methods
Monocyte isolation
ficoll (ficoll-paqueTm plus, gE Healthcare Bio-Sciences AB, uppsala) density gradient 
separation was used to obtain peripheral blood mononuclear cells (PBMC) from buffy 
coat samples (Sanquin, Amsterdam, The Netherlands). monocytes were subsequently 
isolated from the pBmC by using CD14-beads (miltenyi Biotec gmbH, Bergisch gladbach, 
germany) and a automACS pro Seperator (miltenyi Biotec gmbH) according to the ma-
nufactures’ instructions. Isolated monocytes were cultured in RpmI1640 culture medium 
containing 10% heat-inactivated fetal calf serum (fCS) and 1% penicillin/streptomycin (all 
from BioWhittaker, Verviers, Belgium) for 24 hours.  
ARPE-19 culture
The human retinal pigment epithelial cell line ARpE-19 was obtained from ATCC (manas-
sas, VA, uS). ARpE-19 were cultured in RpE medium (DmEm/f-12 medium;  HyClone, lo-
gan, uT, uS), containing 10% fCS and penicillin/streptomycin (all from BioWhittaker). for 
experiments ARpE-19 cells between passage 23-27 were used. The cells were maintained 
under standard cell culture conditions at 37 oC in humidified air with 5% CO2.  
         
Immunocytochemical analysis   
ARpE-19 were seeded on cover slips (24x24 mm menzel-gläser; portsmouth, New Hamp-
shire, uS), which were placed inside the wells of 6-well plates (Nunc; Roskilde, Den-
mark), at a density of 5 x 105 cells/well in RpE medium containing 10% fCS and allowed 
to adhere overnight. Subsequently the medium was refreshed twice a week till the cells 
were grown 100% confluent. Prior to stimulation, both ARPE-19 and monocytes were se-
rum starved in RpmI1640 medium containing 1% fCS. monocytes, 5 x 105 cells/well, and 
a monolayer of ARpE-19 cells, separately or in co-culture were pre-incubated with fresh 
RpmI1640 medium with or without 7.5 u/ml of the thrombin inhibitor hirudin (Sigma 
Aldrich, St. louis, mO, uS) for 1 hour and subsequently stimulated with 5 u/ml thrombin 
(Calbiochem, la Jolla, CA, uS) in the presence or absence of 7.5 u/ml hirudin for an ad-
ditional 72 hours. Hereafter the culture medium and non-adherent cells were removed. 
Cells remaining on the glass slides were washed twice with pBS (pH 7.4) followed by 
fixation with 4% paraformaldehyde for 10 minutes where after the slides were again was-
hed twice with pBS followed by permeabilization with pBS containing 0.1% Triton X-100 
for 4 minutes. Slides were then washed twice with pBS containing 0.05% Tween20 and 
incubated with pBS containing 10% normal rabbit serum and 1% bovine serum albumin 
(BSA) for 10 minutes, followed by a single wash step in pBS containing 0.05% Tween20. 
Subsequently mouse anti-human CD68 (1/100; clone EBm11; Dako, Heverlee, Belgium) in 
pBS containing 1% BSA was applied for 1 hour. Thereafter, cells were washed twice with 
pBS containing 0.05% Tween20 and incubated for 30 minutes with rabbit anti-mouse Ig 
(1/400; Dako) in pBS containing 1% BSA and thereafter washed twice with pBS containing 
0.05% Tween20. Then streptavidin Poly-HRP conjugate (Thermo Fisher Scientific, Wal-
tham, mA, uS) in pBS containing 1% BSA was added for 1 hour followed by two washes 
with pBS and subsequent incubation with aminoethyl carbazole (AEC) solution for 10 
minutes. finally the cells on the slides were washed twice with pBS and stained with 
hematoxylin and eosin. All steps were performed at room temperature. After rinsing the 
cells with tap water the cells on the cover slip were covered with Kaiser’s glycerol/gela-
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tin (Boom BV; meppel, The Netherlands) and placed upside down on microscope slides 
(menzel). The slides were analyzed by microscopy and photographs were made using 
Axiocam (Zeiss, Sliedrecht, The Netherlands). 
Neutralization experiments
ARpE-19 were seeded on cover slips, which were placed inside the wells of 6-well plates, 
at a density of 5 x 105 cells/well in RpE medium containing 10% fCS and allowed to adhere 
overnight. Subsequently the medium was refreshed twice a week till the cells were grown 
100% confluent. Prior to stimulation, both ARPE-19 and monocytes were serum starved 
in RpmI1640 medium containing 1% fCS. monocytes, 5 x 105 cells/well and a monolayer 
of ARpE-19 cells in co-culture were pre-incubated with fresh RpmI1640 medium with or 
without 1 µg/ml mouse anti-human CD18 (clone mEm-148; Abcam, Cambridge, uK), 1µg/
ml mouse anti-human CD54 (clone p2A4; millipore, Billerica, mD, uS) or 1 µg/ml mouse-
Igg1 (isotype control, clone 11711; R&D systems) for 1 hour. Subsequently the cells were 
stimulated for 72 hours in RpmI1640 medium containing 1% fCS with or without 5 u/
ml thrombin and with or without 1 µg/ml mouse anti-human CD18, 1 µg/ml mouse anti-
human CD54 or 1 µg/ml mouse-Igg1. following the stimulation period of 72 hours culture 
supernatants were removed and cells on the glass slides were stained for CD68 positive 
cells as described above. 
Detection of cytokines, chemokines and growth factors 
ARpE-19 were seeded into 6-well plates at a density of 5 x 105 cells/well in RpE medium 
containing 10% fCS and allowed to adhere overnight. Subsequently the medium was 
refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, 
both ARpE-19 and monocytes were serum starved in RpmI1640 medium containing 1% 
fCS. monocytes, 5 x 105 cells/well, and a monolayer of ARpE-19 cells separately or in co-
culture were stimulated with 5 u/ml thrombin for 72 hours. following the stimulation 
period culture supernatants were collected and analyzed by ElISA for the m1 associated 
mediators CXCl8 and Il-6 (Invitrogen; paisley, uK) and the m2 associated mediators Il-
10, PDGF-BB, TGF-β1, TGF-β2 and VEgf-A (R&D Systems; Abingdon, uK) and ICAm-1 (R&D 
Systems) according manufacturer’s instructions. 
Statistical analysis
ElISA data were analyzed using the Kruskal-Wallis (one-way ANOVA) test followed by 
the mann-Whitney U test when applicable. A P value < 0.05 was considered significant.
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Results
The effect of thrombin on ARPE-19-mediated macrophage differentiation
monocytes, either stimulated with thrombin or unstimulated, did not adhere to the glass 
slides making further analysis into macrophage differentiation impossible. Co-culture of 
monocytes with ARpE-19 resulted in the generation of some CD68 positive macrophages 
(figure 1). Stimulation of the monocyte-ARpE-19 co-cultures with thrombin resulted in 
a morphological change of the ARPE-19 cells that became spindle-shaped fibroblast 
resembling cells (figure 1). This morphological change by ARpE-19 was also observed 
when ARpE-19 was stimulated with thrombin in the absence of monocytes and is in line 
with our previous observation that thrombin stimulates de-differentiation of RPE-cells 
into myofibroblasts 11. moreover, stimulation of the monocyte-ARpE-19 co-cultures with 
thrombin clearly enhanced the generation of CD68 positive macrophages (figure 1). 
monocytes used in these experiments were CD68 negative prior to stimulation as was 
measured by flow cytometry (data not shown).
To demonstrate that the effect truly depended on thrombin activity the experiments 
were repeated in the presence of the direct thrombin inhibitor hirudin. Hirudin clearly 
reduced the thrombin-induced generation of CD68 macrophages when monocytes were 
co-cultured with ARpE-19 (figure 1). 
The role of adhesion molecules on thrombin-induced ARPE-19-mediated macrophage 
differentiation
Addition of neutralizing antibodies against CD18 or CD54 to the thrombin-stimulated 
monocyte-ARpE-19 co-cultures inhibited the generation of CD68 expressing macrophages 
while the isotype control did not (figure 2).
Cytokine, chemokine and growth factor levels in culture supernatants 
Monocytes hardly produced any CXCL8, IL-6, ICAM-1, PDGF-BB, TGF-β1, TGF-β2 and VEgf-A 
and neither was this stimulated by thrombin (figure 3). ARpE-19 produced CXCl8, Il-6, 
ICAM-1, PDGF-BB, TGF-β1, TGF-β2 and VEgf-A under basal culture condition (figure 3). 
Thrombin significantly (P < 0.05) enhanced CXCL8, IL-6, ICAM-1, PDGF-BB, TGF-β1 and 
VEGF-A production by ARPE-19, while it had no statistically significant effect on TGF-β2 
production (Figure 3). Co-culture of monocytes with ARPE-19 resulted in significantly (P 
< 0.05) higher production of ICAm-1 and pDgf-BB compared to the levels produced by 
ARpE-19 alone (figure 3). Stimulation of the monocyte-ARpE-19 co-cultures with throm-
bin resulted in significantly (P < 0.05) higher production of ICAm-1, pDgf-BB and VEgf-A 
compared to unstimulated co-cultures (figure 3).
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figure 1:  monocytes and ARpE-19 cells were cultured on glass slides separately and in co-culture 
for 72 hours. The cells were stimulated with thrombin (5 u/ml) or remained unstimulated in the 
presence or absence of the direct thrombin inhibitor hirudin (7.5 u/ml). Non-adhered cells were 
washed away and adhered cells were stained with CD68 to identify macrophages. Representative 
example is depicted. 
unstimulated thrombin thrombin + hirudin
thrombin + αCD18 thrombin + αCD54 thrombin + isotype
figure 2: monocytes and ARpE-19 cells were co-cultured on glass slides for 72 hours. The cells 
were stimulated with thrombin (5 u/ml) or remained unstimulated in the presence or absence of 
the direct thrombin-inhibitor hirudin (7.5 u/ml) or neutralizing antibodies against CD18, CD54 or 
isotype control (each at 1 µg/ml). Non-adhered cells were washed away and adhered cells were 
stained with CD68 to identify macrophages. Representative example is depicted. 
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figure 3:  monocytes and ARpE-19 cells were cultured separately and in co-culture for 72 hours. 
The cells were stimulated with thrombin (5 u/ml) or remained unstimulated. Culture supernatants 
were analyzed for CXCL8, IL-6, IL-10, ICAM-1, PDGF-BB, TGF-β1, TGF-β2 and VEgf-A by ElISA. Data 
are presented as the mean value from five independent experiments ± SEM. Statistical analysis 
was performed with the Kruskal-Wallis (one-way ANOVA) test followed by the mann-Whitney U 
test when applicable. A P value < 0.05 was considered significant. *P < 0.05.
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figure 4:  Schematic overview of proposed model: Activation of RpE by thrombin results in 
increased production of cytokines, chemokines and growth factors. The produced cytokines 
induce ICAm-1expression by RpE and produced chemokines recruit monocytes. The presence of 
gm-CSf and cell-cell contact between monocytes and RpE via their adhesion molecules, including 
at least CD18 and ICAM-1, induce M2-macrophage differentiation. Growth factors produced by 
both thrombin-activated RPE and newly formed M2-macrophages induce fibrotic processes such 
as proliferation, migration, EmT and ECm production by at least the RpE cells. All these processes 
combined result in the formation of fibroproliferative membranes which can cause the retina to 
detach.
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Discussion
macrophages are important contributors to pVR via the secretion of growth factors that 
stimulate fibrosis. This would make them interesting cellular targets for therapy, if such 
agents were available. However, the mechanism of macrophage differentiation in PVR 
is so far hardly understood. Recently, we described that pVR development is associated 
with increased intraocular thrombin activity 31. Here we demonstrate that thrombin 
strongly enhances macrophage formation from monocytes when co-cultured with the 
human RPE cell line ARPE-19. Neutralizing antibodies against the adhesion molecules β2-
integrin (CD18) or ICAM-1 (CD54) abrogate this macrophage differentiation. Moreover, 
macrophage differentiation in this thrombin-monocyte-ARPE-19 co-culture model is 
associated with high production of the pro-fibrotic growth factors PDGF-BB and VEGF-A. 
In previous studies Osusky et al examined interactions between human monocytes 
and RpE cells. They demonstrated that co-culture of human monocytes with RpE cells 
resulted in increased proliferation of RPE. This effect was greatly reduced when direct 
cell contact was prevented when monocytes and RpE were separated by a membrane in 
a transwell culture system 35. In other studies this group demonstrated that monocyte-
RPE co-culture resulted in monocyte-macrophage differentiation, which involved the 
adhesion molecule CD11c as well as TGF-β activity 36, 37. In line with these findings we 
observed that co-culture of monocytes with ARpE-19 was associated with elevated 
secretion of pDgf-BB, a potent mitogen for RpE cells 19, 38. In our study thrombin further 
enhanced the pDgf-BB production in the monocyte-ARpE-19 cultures, suggesting that 
this might further enhance the proliferative activity of RpE cells in pVR. Comparable to 
Osusky et al, we observed macrophage differentiation when peripheral blood derived 
monocytes where co-cultured with ARPE-19. This macrophage differentiation was 
drastically enhanced when thrombin was present in the monocyte-ARpE-19 co-cultures 
and was associated with a significantly higher level of soluble ICAM-1. 
ICAm-1 interacts with other adhesion molecules, including lymphocyte function-
associated antigen-1 (lfA-1: CD11a/CD18), macrophage adhesion ligand-1 (mAC-1: CD11b/
CD18) and the integrin p150,95 (CD11c/CD18; type 4 complement receptor), which are 
expressed by myeloid cells and are required for adhesion and chemotaxis 39.  Here we 
found that neutralizing antibodies against CD18 or ICAm-1 abrogated the monocyte-
to-macrophage differentiation when co-cultured with ARPE-19 and thrombin. ICAM-1 
is absent from resting leukocytes but moderately expressed on activated leukocytes, 
including monocytes/macrophages. moreover, ICAm-1 is expressed on epithelia, 
including RPE, which is enhanced upon activation with inflammatory stimuli 40. CD18 is 
expressed at high level by especially leukocytes although human RpE cells might express 
CD18 as well 41. Although we did not examine CD18 and CD54 expression levels under the 
culture conditions studied we expect that ICAm-1 was mostly expressed by ARpE-19 and 
CD18 by the monocyte/macrophages. Nevertheless the data so far suggest that physical 
interaction between monocytes and ARpE-19, mediated by at least CD18 and ICAm-1, 
is involved in the enhanced monocyte-to-macrophage differentiation when thrombin is 
present (figure 4). We can however not exclude that soluble factors, including soluble 
ICAm-1 but also gm-CSf that are induced in RpE by thrombin, contributed as well 32. 
Experiments using transwell culture systems will provide more insight into this process 
(work in progress).
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macrophages can adopt an m1 or m2-phenotype that can be distinguished by expression 
of specific surface molecules and signature cytokines and growth factors 15, 17, 42. m1 
macrophages are pro-inflammatory via secretion of for instance tumor necrosis factor 
(TNF)-α and IL-6 43, 44. M2-macrophages are anti-inflammatory and contribute to healing/
tissue remodeling responses through secretion of high levels of mediators like Il-10, 
TGF-β, PDGF and VEGF 42. In this study pDgf-BB and VEgf-A levels were highly elevated in 
the thrombin-monocyte-ARpE-19 co-culture supernatants (figure 3). moreover, there was 
a trend toward higher levels of TGF-β1, TGF-β2 in thrombin-monocyte-ARpE-19 co-culture 
supernatants compared to thrombin-stimulated ARpE-19 monoculture supernatants 
(figure 3). We did so far not examine expression of m1/m2 related surface molecules 
(e.g. CD163 for m1 and CD206 for m2 45) but our results demonstrate that monocytes 
co-cultured with ARPE-19 in the presence of thrombin differentiated into macrophages, 
which was associated with enhanced production of m2-related growth factors (esp. 
pDgf-BB and VEgf-A) and not m1-related cytokines (CXCl8 and Il-6). A more extensive 
analysis of both cellular and soluble markers (e.g. interleukin-1 receptor antagonist, 
pentraxin-related protein, TNF-α) might generate better insight into the subtype of 
macrophage generated (work in progress) 43, 44. However, so far we assume that the 
increased levels of pDgf-BB and VEgf-A from the thrombin-stimulated co-cultures are 
derived from M2 differentiated macrophages. It can however not be excluded that 
ARpE-19 contributed to the elevated levels as well.  
Based on our current findings and our previous observation that PVR is associated with 
increased intraocular thrombin activity we propose the model depicted in figure 4 where 
thrombin facilitates the interaction between monocytes and RpE cells and subsequent 
differentiation of pro-fibrotic M2-macrophages 31. These findings indicate that thrombin 
inhibition may reduce the development of pro-fibrotic M2-macrophages in those patients 
at risk for pVR.
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Abstract
Purpose: To determine the role of thrombin in the development of proliferative 
vitreoretinopathy. 
Methods: Vitreous was collected from patients undergoing a vitrectomy (macular holes 
and puckers n = 11 (controls), retinal detachment without PVR development following 
vitrectomy n = 15 (RRD1), retinal detachment with PVR development within 6 months 
after vitrectomy n = 11 (RRD2), and established PVR  n = 14 (PVR)). Thrombin activity 
in vitreous was determined using a thrombin-specific chromogenic substrate. ARPE-19 
cells were stimulated with 8 times diluted vitreous samples in the presence and absence 
of hirudin. The  samples were analyzed at t = 0 and t = 24 hours for the presence of 27 
cytokines/chemokines and growth factors using a multiplex approach. In comparable 
studies, ARpE-19 cells were stimulated for 2 hours and mRNA expression levels for CCL2, 
CXCL8, GMCSF, IL6 and PDGFB were determined by RQ-pCR.  
Results: Thrombin activity was significantly (P < 0.05) higher in vitreous of the pVR group 
compared to the other groups. pVR vitreous stimulated the production CCl2, CXCl8, gm-
CSF, IL-6 and PDGF-BB by ARPE-19 to significantly (P < 0.05) higher levels that vitreous 
from the RRD1 and RRD2 groups. These effects of PVR vitreous were significantly (P < 
0.05) reduced by hirudin. These data were confirmed by mRNA studies.
Conclusion: Thrombin activity is increased in vitreous of patients with established pVR 
and is involved in the activation of pro-inflammatory and pro-fibrotic pathways in RPE 
cells. Inhibition of thrombin activity may therefore represent a potential treatment 
option for proliferative vitreoretinopathy.  
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Introduction
Proliferative vitreoretinopathy (PVR) is an inflammatory fibrotic disorder which can 
develop after rhegmatogenous retinal detachment, and is the most common failure 
of retinal detachment repair. pVR development is characterized by the formation of 
subretinal, intraretinal and/or epiretinal fibroproliferative membranes that cause the 
retina to detach due to the contractile properties of myofibroblasts that are abundantly 
present in these membranes 1, 2. Retinal pigment epithelial (RpE) cells contribute to the 
formation of these fibroproliferative membranes through the secretion of cytokines and 
growth factors, proliferation, and de-differentiation into extracellular matrix producing 
myofibroblasts 1, 3, 4. However, our current knowledge of the underlying pathobiological 
processes in pVR is still limited, which may explain why no clear improvement in medical 
therapy has been achieved during the last decades.  pVR development is associated with 
blood-retinal barrier breakdown and activation of the coagulation system, as evidenced 
by fibrin deposition in retina and vitreous from PVR patients 5-7. Thrombin is the terminal 
coagulation enzyme that converts soluble fibrinogen into the insoluble fibrin clot, and 
subretinal fluids from retinal detachment patients have been described to contain 
high capacity to generate thrombin activity 6, 8. Besides its central role in coagulation, 
thrombin stimulates many cellular processes involved in inflammation, wound repair 
and fibrosis in a variety of cell types, including RPE cells, by activating the high affinity 
thrombin receptor:  protease-activated receptor (pAR)1 5, 9-13. Recently we demonstrated 
that thrombin stimulates human RpE cells to produce a wide variety of cytokines, 
chemokines and growth factors, amongst which chemokine (C-C motif) ligand (CCl)7, 
chemokine (C-X-C motif) ligand (CXCl)8, granulocyte-macrophage colony-stimulating 
factor (gm-CSf), interleukin (Il)-6, platelet-derived growth factor (pDgf)-AA and pDgf-
BB are associated with pVR development 9, 10, 14-17. Although these data suggest that 
thrombin can contribute to pVR development, no data are present on thrombin activity 
in vitreous samples and its contribution to RpE cell activation in pVR.
Here we examined intravitreal thrombin activity in PVR. This study is the first to 
demonstrate that vitreous from pVR patients contains increased thrombin activity which 
contributes to vitreous-induced  production of cytokines/chemokines and growth factors 
by RpE cells. Our data indicate that elevated intravitreal thrombin activity contributes 
to PVR development, at least by inducing pro-inflammatory and pro-fibrotic responses 
in RpE  cells. Intravitreal thrombin activity may represent a novel biomarker for pVR 
development, and thrombin inhibition may be considered as therapeutic option in the 
treatment of pVR.    
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Methods
Vitreous fluids
Vitreous samples varying from 0.6 - 1.2 ml from the following groups of patients that 
underwent a standard three-port vitrectomy were used for this study: 1) macular holes 
n = 3 and idiopathic macular puckers n = 8, which served as controls, 2) rhegmatogenous 
retinal detachment without PVR development after vitrectomy (RRD1, n = 15), 3) rheg-
matogenous retinal detachment with pVR development within 6 months following vit-
rectomy (RRD2,  n = 11), and 4) established PVR (PVR,  n = 14). The vitreous samples were 
collected from 2010-2013, centrifuged at 1500 Rpm and stored at -20 oC for a maximum 
of 7 days before long term storage at -80 oC. All subjects gave their consent for the use 
of rest material for research; storage and use of the vitreous for further studies was ac-
cording to the guidelines of the medical Ethics Committee of the Erasmus mC, university 
medical Center Rotterdam. patient characteristics are given in table 1.
Group Description Sex, 
Male/
Female
Age, y
Controls macular holes and macular puckers 6/5 74.73 ± 6.07
RRD1 Rhegmatogenous retinal detachment (no pVR 
development; 6 months after vitrectomy)
10/4 57.33 ± 6.89
RRD2 Rhegmatogenous retinal detachment (with pVR 
development; 6 months after vitrectomy)
11/4 64.64 ± 19.82
pVR Established pVR 6/5 59.36 ± 11.24
Table 1: patients and Controls
Cell cultures
The human retinal pigment epithelial cell line ARpE-19 was obtained from ATCC (manas-
sas, VA, uS). ARpE-19 cells were cultured in RpE medium (DmEm/HAm’s f-12 1:1 medium 
(HyClone, logan, uT, uS), containing 10% heat inactivated fetal calf serum (fCS) and pe-
nicillin/streptomycin (all from BioWhittaker, Verviers, Belgium)) and between passage 
23-30 when used for experiments. The cells were maintained under standard cell culture 
conditions at 37 oC in humidified air with 5% CO2.  
Thrombin activity measurement in vitreous fluids
Thrombin activity in vitreous was determined by using a thrombin-specific substrate as 
we and others did previously for bronchoalveolar lavage fluid 18, 19. In short, 25 µl vitreous 
fluid was diluted in a 96-well microtiter plate with 25 µl Tris-buffered saline (TBS pH 8.3) 
or TBS containing 0.1 U/ml of the specific thrombin inhibitor hirudin (Sigma, St Louis, MO, 
uS). A thrombin (Calbiochem, la Jolla, CA, uS) standard curve ranging from 50 - 0.78 
milli units per ml (mu/ml) was prepared in TBS or TBS containing 0.1 u/ml hirudin. All 
solutions were incubated for 30 minutes at 37 oC to allow formation of thrombin-hirudin 
complexes. Thereafter, 50 µl of a 1 mM solution of the thrombin specific substrate Tos-
gly-pro-Arg-pNA (Sigma), dissolved in 1.5 mm HCl, was added to the (diluted) samples 
and incubated at 37 oC. The optical density (OD) was measured at 405 nm after 8 hours. 
Thrombin activity in vitreous fluid was quantified based on the difference in OD between 
vitreous fluid with and without hirudin and the reference curve and expressed as mU/ml. 
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Determining the effect of different vitreous dilutions on IL6 and PDGFB mRNA expres-
sion by ARPE-19
ARpE-19 cells were seeded in 12-wells plates at a density of 3 x 105 cells/well in RpE medi-
um containing 10% fCS and allowed to adhere overnight. Subsequently the medium was 
refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, the 
cells were serum starved in RpE medium containing 1% fCS for 24 hours followed by an 
additional 24 hours in serum free RpE medium. Hereafter, cells were stimulated for 1, 2 
or 4  hours with vitreous of 4 pVR patients diluted 1/4 and 1/8 in serum free RpE medium. 
RNA was isolated using a genEluteTm mammalian Total RNA miniprep Kit (Sigma) and 
reverse transcribed into cDNA 10. Transcript levels of IL6 and PDGFB mRNA were deter-
mined by real-time quantitative (RQ)-pCR (7700 pCR system; Applied Biosystems [ABI], 
foster City, CA, uS). Expression levels of the analyzed gene transcripts were normalized 
to the control gene ABL (Abelson) 10. primer and probe combinations used are listed in 
table 2. 
Measurement of vitreous-induced cytokine, chemokine and growth factor secretion 
by ARPE-19
ARpE-19 cells were seeded in 12-wells plates at a density of 3 x 105 cells/well in RpE medi-
um containing 10% fCS and allowed to adhere overnight. Subsequently the medium was 
refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, 
the cells were serum starved in RpE medium containing 1% fCS for 24 hours followed 
by an additional 24 hours in serum free RpE medium without fCS. Hereafter cells were 
pre-incubated with fresh serum free RpE medium with or without 7.5 u/ml hirudin for 60 
minutes. Subsequently the cells were stimulated for 24 hours with serum free medium 
containing 1/8 diluted vitreous (average thrombin concentration per sample for RRD1: 
0,699 ± 0,14 mu/ml,  RRD2: 0,917 ± 0,38 mu/ml and pVR; 5,678 ± 1,88  mu/ml) or 5 u/ml 
thrombin with or without 7.5 u/ml hirudin. following the  stimulation period of 24 hours 
(T24) culture supernatants were harvested for cytokine, chemokine and growth factor 
analysis. In addition, an aliquot of 125 µl of the prepared 1/8  diluted vitreous samples (t 
= 0 hours; T0) was stored at -20 oC for determination of basal cytokine, chemokine and 
Gene Sequence Forward Primer, 5’–3’ Sequence Reverse Primer, 5’–3’ Sequence Probe, 5’–3’
ABL TggAgATAACATCTAAgCATAACTAAAggT gATgTAgTTgCTTgggACCCA fAm-CCATTTTTggTTTgggCTTCACACCATT-TAmRA
CXCL8 ggCCgTggCTCTCTTgg gggTggAAAggTTTggAgTATgT fAm-TgTgTgAAggTgCAgTTTTgCCAAggA-TAmRA
GMCSF CCgCCTggAgCTgTACAA AggggATgACAAgCAgAAAgTC fAm-TTgCACAggAAgTTTCCggggTTg-TAmRA
IL6 TAgCCgCCCCACACAgA gTgCCTCTTTgCTgCTTTCAC fAm-AgCCACTCACCTCTTCAgAACgAATTgACA-TAmRA
PDGFB TCCCgAggAgCTTTATgAgATg CgggTCATgTTCAggTCCAAC fAm-AgTgACCACTCgATCCgCTCCTTTg-TAmRA
Table 2: primer and probe Sequences
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growth factor levels.  T0 samples and T24 culture supernatants were analyzed with a Bio-
plex pro™ Human Cytokine, Chemokine, and growth factor Assay (Bio-Rad, Hercules, 
CA, uS) allowing simultaneous detection of the following cytokines, chemokines and 
growth factors: IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12 (p70), 
IL-13, IL-15, IL-17, FGFb, Eotaxin, G-CSF, GM-CSF, IFNγ, IP-10/CXCL10, MCP-1/CCL2, MIP-1α/
CCL3, MIP-1β/CCL4, PDGF-BB, RANTES, TNF-α, VEGF-A (see supplemental table 1 for the 
detection limits). The assay was performed according manufacturer’s instructions.
Measurement of PVR vitreous-induced cytokine, chemokine and growth factor mRNA 
expression levels in ARPE-19
ARpE-19 cells were seeded in 12-wells plates at a density of 3 x 105 cells/well in RpE medi-
um containing 10% fCS and allowed to adhere overnight. Subsequently the medium was 
refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, the 
cells were serum starved in RpE medium containing 1% fCS for 24 hours followed by an 
additional 24 hours in serum free RpE medium. Hereafter, cells were pre-incubated with 
serum free RpE medium with or without 7.5 u/ml hirudin for 60 minutes and subsequent-
ly stimulated for 2 hours with serum free medium containing 1/8 diluted pVR vitreous 
(average thrombin concentration per sample; 4,211 ± 0,60 mu/ml) with or without 7.5 
u/ml hirudin. RNA was isolated and reverse transcribed into cDNA 10. Transcript levels of 
CCL2, CXCL8, GMCSF, IL6 and PDGFB were determined by RQ-pCR. Expression levels of the 
analyzed gene transcripts were normalized to the control gene ABL 10. CCL2 transcript 
levels were determined using a commercially available Taqman gene Expression assay 
(Applied Biosystems). Other primer and probe combinations used are listed in table 2.
Statistical analysis
messenger RNA and protein data were analyzed using the Kruskal-Wallis (One-way ANO-
VA) test followed by the mann-Whitney u test when applicable. A P-value < 0.05 was 
considered significant. 
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ABL TggAgATAACATCTAAgCATAACTAAAggT gATgTAgTTgCTTgggACCCA fAm-CCATTTTTggTTTgggCTTCACACCATT-TAmRA
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Results
Thrombin activity in vitreous
Thrombin activity was hardly present in the vitreous of patients from the control group 
(2.48  ±1.25 mu/ml, mean value ± standard error of the mean (SEm), figure 1). Vitreous 
samples from patients with rhegmatogenous retinal detachment without pVR develop-
ment in a later stage (RRD1) displayed slightly, but not significantly, higher thrombin 
activity (9.93 ± 1.86 mu/ml) than the control group. Thrombin activity in vitreous sam-
ples of patients with rhegmatogenous retinal detachment that did develop pVR within 
6 months after vitrectomy (RRD2) showed a clear trend towards increased thrombin 
activity (18.93 ± 10.61 mu/ml) compared to the control and RRD1 group, but this was 
not statistically significant. Thrombin activity (39.30 ± 14.04 mU/ml) was significantly (P 
< 0.05) elevated in the vitreous of patients with established pVR compared to all other 
groups (Figure 1). There were no statistical differences between the gender or age of the 
patients in the different groups (Table 1).
*
*
**
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250
200
150
100
50
0
Figure 1
figure 1: Thrombin activity in vitreous 
samples (controls: macular holes n= 3 and 
macular puckers n = 8, rhegmatogenous 
retinal detachment with no pVR 
development after vitrectomy (RRD1) n = 
15, rhegmatogenous retinal detachment 
with pVR development after vitrectomy 
(RRD2) n = 11 and established PVR (PVR) n 
= 14) was determined with the thrombin-
specific chromogenic substrate Tos-Gly-
pro-Arg-pNA in the absence and presence 
of the thrombin-specific inhibitor hirudin. 
Statistical analysis was performed by 
using a Kruskal-Wallis (One-way ANOVA) 
test followed by the mann-Whitney u 
test. P < 0.05 was considered significant. 
*P < 0.05 and **P < 0.01.
The effect of different vitreous dilutions on IL6 and PDGFB mRNA expression by ARPE-
19  
Vitreous enhanced IL6 mRNA expression by ARpE-19 cells after 1 and 2 hours of stimula-
tion, which returned to baseline level again after 4 hours of stimulation (figure 2). PD-
GFB mRNA expression level by ARpE-19 was also enhanced by vitreous stimulation with 
equal levels of induction after 1, 2 and 4 hours of stimulation (Figure 2). No differences 
between the 1/4 and 1/8 vitreous dilution were seen for either IL6 mRNA or PDGFB mRNA 
induction in ARpE-19 (figure 2). Based on these data further studies were undertaken 
with vitreous dilutions of 1/8. 
The effects of vitreous on cytokine, chemokine  and growth factor production  by 
ARPE-19
Stimulation of ARpE-19 cells with RRD1, RRD2 and pVR vitreous samples for 24 hours 
significantly (P < 0.05) stimulated CCl2, CXCl8, Il-6, Il-12 (p70) and VEgf-A production 
by ARpE-19 cells (figure 3). pVR vitreous stimulated CCl2, CXCl8 and Il-6 production by 
ARPE-19 to significantly (P < 0.05) higher levels than RRD1 and RRD2 vitreous samples, 
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while no differences were observed between the groups for vitreous-induced IL-12(p70) 
and VEgf-A production by ARpE-19. pVR vitreous stimulated g-CSf and Il-17A production 
by ARPE-19, albeit not to a statistically significant level. PDGF-BB production by ARPE-
19 was significantly (P < 0.05) enhanced by pVR vitreous samples, but not by RRD1 and 
RRD2 vitreous samples (Figure 3). CCL4 levels were significantly higher (P < 0.05) in the 
T0 samples from RRD2 and pVR patients compared to T0 samples from RRD1 patients 
while CXCL10 was significantly (P < 0.05) higher in the T0 samples from pVR patients 
compared to T0 samples from RRD1 and RRD2 patients (figure 3). CCl4 and CXCl10 le-
vels did not increase after stimulating the ARpE-19 cells for 24 hours with vitreous from 
either the RRD1, RRD2 or PVR groups (Figure 3). In all groups basic fibroblast growth 
factor (FGFb) levels significantly (P < 0.05) declined after 24 hours of ARpE-19 stimulation 
when compared to the levels detected in the T0 samples (figure 3). After 24 hours of 
ARPE-19 stimulation GM-CSF levels declined significantly (P < 0.05) in the RRD1 and the 
RRD2 groups but not in the PVR group, with GM-CSF levels being significantly (P < 0.05) 
higher in the pVR group compared to RRD1 and RRD2 samples at T24. All other factors 
measured by the used multiplex assay were not detected. for a total summary see sup-
plemental table 1.
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figure 2: ARpE-19 cells were stimulated 
for 1, 2 and 4 hours with vitreous of 
patients with established pVR (4x and 
8x diluted) and IL6 (top panel) and 
PDGFB (bottom panel) mRNA expression 
levels were determined by RQ-pCR and 
normalized against the control gene ABL. 
Data are presented as the mean value 
from 4 independent experiments ± SEm. 
US = unstimulated.
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The effect of thrombin inhibition on PVR vitreous-induced cytokine, chemokine and 
growth factor production by ARPE-19
Stimulation of ARPE-19 cells with PVR vitreous samples for 24 hours significantly (P < 
0.05) stimulated CCl2, CXCl8, gm-CSf, Il-6 and pDgf-BB production by ARpE-19 cells 
compared to the RRD1 and RRD2 vitreous samples (figure 3 and supplemental table 1). 
Thrombin (5 U/ml), used as positive control, also significantly (P < 0.05) stimulated CCl2, 
CXCl8, gm-CSf, Il-6 and pDgf-BB production by ARpE-19, which was completely abolis-
hed by the direct thrombin inhibitor hirudin (P < 0.05) (figure 4 and supplemental table 
1). The stimulatory effect of RRD1 and RRD2 vitreous on the production of these factors 
by ARPE-19 was not affected by hirudin (Figure 4 and supplemental table 1). Hirudin did 
significantly (P < 0.05) reduce the capacity of pVR vitreous to stimulate CCl2, CXCl8, 
gm-CSf, Il-6 and pDgf-BB production by ARpE-19 after 24 hours of stimulation (figures 
4 and supplemental table 1). This inhibition was not complete and reached the levels 
induced by the RRD1 and RRD2 vitreous samples (Supplemental table 1). Thrombin (5 u/
ml) significantly (P < 0.05) stimulated CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expres-
sion by ARPE-19 after 2 hours of stimulation, which was significantly (P < 0.05) reduced 
by hirudin (figure 5). pVR vitreous samples also enhanced CCL2, CXCL8, GMCSF, IL6 and 
PDGFB mRNA expression levels by ARpE-19 after 2 hours of stimulation, which was signi-
figure 3:  ARpE-19 cells were stimulated for 24 hours with 8x diluted vitreous from the RRD1, RRD2, 
pVR patient groups.  Culture supernatants were analyzed by a Bio-plex pro™ Human Cytokine, 
Chemokine, and growth factor Assay; allowing the detection of 27 cytokines, chemokines and 
growth factors simultaneously. Data are presented as the mean value from 4 individual vitreous 
samples per group ± SEm. Statistical analysis was performed by using a Kruskal-Wallis (One-way 
ANOVA) test followed by the mann-Whitney u test. P < 0.05 was considered significant. *P < 
0.05.
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ficant (P < 0.05) for CXCL8, IL6 and PDGFB mRNA (figure 5). Addition of hirudin reduced 
the capacity of the pVR vitreous samples to stimulate CCL2, CXCL8, GMCSF, IL6 and PDGFB 
mRNA production by ARPE-19, which was significant (P < 0.05) for CXCL8, IL6 and PDGFB. 
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figure 4: ARpE-19 cells were stimulated for 24 hours with 8x diluted vitreous from the RRD1, RRD2, 
PVR patient groups or thrombin (5 U/ml) in the absence or presence of the thrombin-specific 
inhibitor hirudin (7,5 u/ml). Culture supernatants were analyzed by a Bio-plex pro™ Human Cytokine, 
Chemokine, and growth factor Assay; allowing the detection of 27 cytokines, chemokines and 
growth factors simultaneously. Factors that showed significant differences between PVR, RRD1 
and RRD2 after 24 hours of stimulation (figure 3) are shown. Data are presented as the mean value 
from 4 individual samples per group ± SEm. Statistical analysis was performed by using a Kruskal-
Wallis (One-way ANOVA) test followed by the mann-Whitney u test. P < 0.05 was considered 
significant. *P < 0.05. 
figure 5: ARpE-19 cells were stimulated for 2 hours with 8x diluted vitreous from pVR patients ( 
n = 7) or thrombin (5 U/ml) in the absence or presence of the thrombin-specific inhibitor hirudin 
(7,5 u/ml). CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expression levels were determined by RQ-
pCR and normalized against the control gene ABL. Data are presented as the mean value ± SEm. 
Statistical analysis was performed with the Kruskal-Wallis (one-way ANOVA) test followed by the 
mann-Whitney u test when applicable. P < 0.05 was considered significant. *P < 0.05 and **P < 
0.01. US = unstimulated.
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Discussion 
Breakdown of the blood-retinal barrier is associated with pVR and a role for direct RpE 
activating effects of thrombin have been proposed to contribute to the pathobiology of 
PVR. Our study is the first to demonstrate increased thrombin activity in vitreous from 
patients with established PVR and that this stimulates RPE cells to produce pro-inflam-
matory cytokines and chemokines such as CCl2, CXCl8, gm-CSf and Il-6, as well as the 
pro-fibrotic mediator PDGF-BB.
In this study we measured thrombin activity in vitreous from patients with macular hole 
development, idiopathic macular pucker formation, rhegmatogenous retinal detach-
ment without pVR development after vitrectomy, rhegmatogenous retinal detachment 
with later pVR development after vitrectomy and established pVR. In macular hole and 
macular pucker patients the blood retinal barrier is intact and we detected no-to-low 
thrombin activity in these vitreous samples, with levels comparable to that reported in 
two recently published studies 20, 21. Compared to this, thrombin activity was significantly 
elevated in vitreous from patients with established pVR, while a trend towards incre-
ased thrombin activity was seen in vitreous from patients that developed pVR within six 
months following vitrectomy. Our study therefore supports that pVR development is a 
gradual process in which later stages of disease are associated with increased intravit-
real thrombin activity. Whether this increase is cause or consequence of disease progres-
sion is so far unclear. Nevertheless, measurement of intraocular thrombin activity might 
represent a new biomarker for pVR development that warrants further studies.
Inflammation is an important component of PVR pathogenesis and RPE cells contribute 
to ocular inflammation via the production of pro-inflammatory mediators. Thrombin has 
been described as a potent inducer of cytokine/chemokine and growth factor producti-
on by RpE cells via activation of pAR1 10, 12. Here we found that vitreous from the RRD1, 
RRD2 and PVR groups significantly stimulated the production of CCL2, CXCL8 (IL-8), IL-6, 
Il-12 (p70) and VEgf-A by RpE-cells. Vitreous of patients with established pVR stimula-
ted the production of CCL2, CXCL8, and IL-6 by RPE cells to significantly higher levels 
than vitreous from the RRD1 and RRD2 groups. Thrombin inhibition only inhibited the 
capacity of pVR vitreous to induce CCl2, CXCl8, and Il-6 production by ARpE-19, but 
although significant this was not complete and reached the levels induced by the RRD1 
and RRD2 vitreous samples (Supplemental table 1). Thus in established pVR, intravitreal 
thrombin activity is a major, but not the sole, factor that stimulates production of the 
pro-inflammatory mediators CCL2, CXCL8 and IL-6 by RPE, while in RRD patients wit-
hout pVR (RRD1) development or pVR development later on (RRD2) the induction of 
these factors appears to be largely independent of intravitreal thrombin activity. The 
vitreous-induced production of VEgf-A and Il-12 (p70) was equal between the three 
groups and not reduced by thrombin inhibition (Supplemental table 1), suggesting no 
or a limited role for intravitreal thrombin in inducing the production of these factors 
by ARpE-19. Thrombin (5 u/ml) did however induce Il-12 (p70) and VEgf-A by ARpE-19 
(Supplemental table 1), while others demonstrated a dose-dependent effect of thrombin 
on VEgf-A production 12. In our experiments we used diluted vitreous (1/8), which may 
have obscured effects of intravitreal thrombin activity on the production of factors such 
as Il-12 (p70), VEgf-A as well as others by the ARpE-19 cells. Incubation of the ARpE-19 
cells with vitreous from RRD1 and RRD2 patients resulted in a decline of gm-CSf levels 
in the culture media. This might be related to binding of gm-CSf to its receptor, which 
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is ubiquitous expressed by epithelial cells 22. This decline in gm-CSf was not observed 
when pVR vitreous was added to the ARpE-19 cells. moreover thrombin did stimulate 
gm-CSf secretion by ARpE-19 (Supplemental table 1), while pVR vitreous enhanced gm-
CSf mRNA levels in RpE cells, as did thrombin alone, which was blocked by hirudin. This 
indicates that intravitreal thrombin activity present in pVR vitreous stimulates gm-CSf 
production by RpE cells. Our data therefore clearly implicate that intravitreal thrombin 
activity is involved in driving the production of CCl2, CXCl8, gm-CSf and Il-6 by RpE in 
pVR. CCl2, CXCl8, gm-CSf and Il-6 are potent activators and chemoattractants for im-
mune cells such as monocytes, macrophages, neutrophils and B-lymphocytes which are 
present in PVR membranes and vitreous, while GM-CSF also stimulates differentiation of 
monocytes into macrophages 10, 23-26. 
Retinal fibrotic contractile membranes represent the final stage of PVR, but their for-
mation requires a complex process of proliferation, migration, de-differentiation and 
extracellular matrix deposition by different cell types, amongst which RPE, that is dri-
ven by pro-fibrotic mediators 1. Basic fibroblast growth factor (FGFb) is a pro-fibrotic 
factor proposed to contribute to pVR 27. We found a reduction of fgfb after vitreous 
incubation with ARpE-19 while thrombin alone did not induce fgfb production by ARpE-
19 (Supplemental table 1) 10. This suggests that the reduction in fgfb might be due to 
binding to its receptor which is expressed by RpE and illustrates that thrombin does not 
stimulate FGFb production by RPE cells. PDGF is considered an important pro-fibrotic 
mediator in PVR that induces proliferation and de-differentiation of RPE cells into con-
tractile myofibroblasts that are abundantly present in PVR membranes and represent 
the main cellular subset responsible for excessive collagen production in fibrosis 4, 27-30. 
Recently, we demonstrated that thrombin induces de-differentiation of RPE cells into 
collagen producing myofibroblasts via autocrine release of PDGF-BB 9. Here we found 
that vitreous from pVR patients strongly stimulated the production of pDgf-BB by ARpE-
19 in a thrombin dependent manner. Consequently elevated intravitreal thrombin activi-
ty can activate pro-fibrotic processes in PVR, at least via autocrine PDGF-BB release and 
signaling in RpE cells. 
Vitreous samples did not stimulate production of the chemokines CCl4 and CXCl10 by 
ARpE-19 cells. CCl4 and CXCl10 were, however, present at higher levels in the prepared 
1/8 diluted vitreous samples (T0, figure 3 and supplemental table 1) from the patients 
that later on developed pVR (RRD2) or had established pVR at the time of vitrectomy. 
Vitreous from established pVR contained higher levels of CXCl10 than RRD2 vitreous, 
implicating that CXCl10 has a more profound role in later stages of disease. These obser-
vations are in line with previous reports and support a role for these chemokines in the 
inflammatory response in PVR and suggest that CCL4 and CXCL10 may represent ocular 
biomarkers for pVR development 31-33. 
polarity is an important determinant for RpE function in the maintenance of ocular ho-
meostasis 34. for our studies we used non-polarized ARpE-19 monolayers. It has howe-
ver been described that polarized RPE can react differently under inflammatory con-
ditions than non-polarized cells with regard to pigment epithelial derived factor and 
VEgf production, which is related to opposing activity levels of the nuclear factor kap-
pa-light-chain-enhancer of activated B cells (NF-κB) and c-Jun N-terminal kinase (JNK) 
pathway 34, 35. previously we demonstrated that thrombin-induced cytokine/chemokine/
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growth factor production by ARpE-19 and primary RpE was mediated via pAR1-induced 
NF-κB signaling, while others demonstrated that thrombin activates multiple signaling 
pathways post-PAR1, including NF-κB and JNK 10, 11. Therefore we cannot exclude the 
possibility that polarized ARPE-19 cells would have responded differently with regard to 
vitreous-induced cytokine/chemokine/growth factor production compared to non-pola-
rized ARPE-19 cells, for instance for VEGF production. However, RPE dedifferentiation 
and loss of polarity is part of pVR development and progression 36.  
In conclusion, this study demonstrates that pVR development is associated with an 
increase in intravitreal thrombin activity, especially during the later stage of pVR, and 
supports a role for intravitreal thrombin activity in stimulating inflammatory and fibrotic 
pathways in RPE. We propose a comparable role for  thrombin in other inflammatory 
proliferative vitreoretinal disorders with blood retinal barrier breakdown, such as exu-
dative age-related macular degeneration, proliferative diabetic retinopathy and retinal 
vein occlusion, of which the latter was recently found to be associated with increased 
intravitreal thrombin activity 22. Inhibition of thrombin activity may therefore represent a 
potential treatment option for proliferative vitreoretinal diseases as pVR. 
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All cytokines/chemokines and growth factors detectable with the Bio-Plex Pro™ Human Cytokine, Chemokine and Growth Factor    Assay are given in the first column. The detected concentration of these factors in culture supernatants from ARPE-19 cells in unstimu-
lated situation (PBS) or after stimulation with vitreous or thrombin (5 U/ml) both in the presence and absence of hirudin is indicated   in the second till twentieth column, at t = 0 hours (T0) and t = 24 hours (T24). 
pBS PBS + hirudin RRD1 RRD1 + hirudin RRD2 RRD2 + hirudin pVR PVR + hirudin thrombin thrombin + hirudin llOQ ulOQ
T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24
IL-1β not 
detectable
3.2 3261
IL-1rα not 
detectable
81.1 70487
Il-2 not 
detectable
2.1 17772
Il-4 not 
detectable
2.2 3467
Il-5 not 
detectable
3.1 7380
Il-6 1.21 
± 0.14
40.57 ± 
12.22
1.99 ± 
0.36
67.07 ± 
3.62
15.18 ± 
8.67
229.67 ± 
75.92
20.28 ± 
13.38
158.43 ± 
63.43
21.80 ± 
6.13
275.73 
± 102.27
24.34
± 7.30
357.87 
± 151.82
57.75 
± 7.9
2267.63 ± 
1208.89
59.22 ± 
9.19
368.69 ± 
138.98
36.47 ± 
14.98
7830.13 ± 
3580.09
2.77 ± 
1.00
105.84 ± 
18.72
2.3 18880
Il-7 not 
detectable
3.1 6001
Il-8/CXCl8 9.30 
± 1.34
277.82 ± 
88.37
9.33 ± 1.34 475.38 ± 
59.96
8.53 ± 
0.32
1783.76 ± 
390.58
9.97 ± 
1.20
1269.07 ± 
263.88
12.52 ± 
1.69
 .63 
± 650.69
14.18 
± 2.25
3235.38 ± 
903.7
271.32
±250.33
17493.14± 
9475.47
19.02 ± 
2.57
2058.82 ± 
532.18
802.13 ±  
292.78
29362.23 ± 
3207.66
8.95 ± 2.1 700.67 ± 
137.69
1.9 26403
Il-9 11.97 
± 1.58
5.01 ± 
0.63
13.23 ± 2.11 4.57 ± 
0.59
10.02 ± 
0.51
6.09 ± 
1.30
11.98 ± 
1.80
5.67 ± 
0.90
11.55 ± 
1.16
7.82 
± 2.07
13.96 
± 1.11
9.12 
± 2.01
10.43 
± 0.64
12.16 
± 3.81
15.00 ± 
2.84
2.63 ± 
0.85
13.76 ± 
1.26
16.69 ± 
1.22
15.47 ± 
4.26
5.18 ± 
1.23
2.1 7989
Il-10 not 
detectable
2.2 8840
Il-12 (p70) 16.15 
±  4.07
112.52 ± 
12.46
27.61 ± 
5.29
123.47 ± 
5.05
21.30 ± 
1.57
144.77 ± 
6.50
24.10 ± 
3.25
153.90 ± 
11.00
23.28 ± 
4.68
144.17 
± 19.72
25.24 ± 
4.69
164.03 ± 
16.24
22.02 ± 5.85 171.62 ± 
37.97
26.43 ± 
3.07
122.75 ±  
3.59
38.33 ± 
4.99
205.73 ± 
4.27
32.73 ± 
5.32
113.22 ± 
7.10
3.3 13099
Il-13 0.61 
± 0.09
1.18 ± 
0.19
0.82 ± 
0.23
1.31 ± 
0.08
1.68 ± 
0.40
2.21 ± 
0.24
1.84 ± 
0.48
1.86 ± 
0.15
2.88 ± 
0.75
2.58 
± 0.70
3.07 ± 0.71 2.99 ± 
0.73
4.67 ± 1.37 3.98 ± 
1.10
3.72 ± 
0.89
2.5 ± 0.47 0.55 ± 
0.19
2.7 ± 0.10 0.92 ± 
0.34
1.31 ± 
0.19
3.7 3137
Il-15 not 
detectable
2.1 2799
Il-17 52.73 
± 6.59
42.71 ± 
11.83
63.69 ± 
9.07
49.65 ± 
3.92
42.42 ± 
1.23
48.02 ± 
1.29
50.65 ± 
4.58
49.56 ± 
4.22
40.70 ± 
5.08
51.24 
± 10.25
46.56 ± 
4.90
60.64 ± 
9.67
34.43 ± 2.74 126.88 ± 
62.93
47.92 ± 
8.92
46.67 ± 
3.02
52.23 ± 
11.13
117.12 ± 
9.30
67.27 ± 
16.48
48.91 ± 
7.97
4.9 12235
fgfb 473.37 
± 162.29
93.92 ± 
33.97
623.21 ± 
57.99
115.88 ± 
9.16
590.20 ± 
77.10
86.81 ±  
34.26
607.90 ± 
61.22
43.17 ± 
7.18
642.52 ± 
77.50
93.40 
± 38.61
715.43 ± 
51.94
119.78 ± 
46.26
692.40 ± 
96.83
143.19 ± 
23.37
697.10 ± 
76.55
55.77 ± 
11.55
692.23 ± 
183.86
405.80 ± 
139.88
712.71 ± 
157.80
91.51 ± 
29.71
40.9 5824
Eotaxin not 
detectable
27.2 7581
g-CSf 29.88 
± 9.50
21.72 ± 
6.33
37.60 ± 
4.95
25.67 ± 
1.66
31.52 ± 
1.30
25.69 ± 
1.15
42.05 ± 
3.81
25.14 ± 
0.99
35.79 ± 
2.17
25.70 
± 5.07
39.43 ± 
3.26
29.15 ± 
4.10
43.49 ±  
4.01
87.50 ± 
43.57
58.67 ± 
10.93
31.96 ± 
2.84
23.99 ± 
5.15
77.48 ± 
6.65
37.59 ± 
8.32
25.73 ± 
2.92
2.4 11565
gm-CSf 148.44 
± 24.54
43.96 ± 
11.88
140.49 ± 
10.44
59.19 ± 
10.70
112.43 ± 
3.84
39.27 ± 
7.40
125.44 ± 
8.12
37.63 ± 
9.00
113.22 ± 
7.91
38.19 
± 7.24
124.98 ± 
6.84
45.88 ± 
8.17
115.49 ± 
3.86
135.15 ± 
66.11
131.00 ± 
13.90
36.21 ± 
4.52
146.68 ± 
12.62
307.12 ± 
53.74
158.14 ± 
22.51
41.75 ± 
10.27
63.3 6039
IFNγ 6.49 
± 0.65
16.79 ± 
3.72
9.88 ± 
1.92
20.46 ± 
1.00
6.87 ± 
0.41
23.17 ± 
1.26
8.67 ± 
1.48
23.03 ± 
1.97
6.80 ± 
1.51
25.06 
± 3.73
8.15 ± 0.71 27.17 ± 
3.93
7.60 ±  1.34 44.36 ± 
17.51
9.24 ± 
1.90
20.81 ±  
1.43
9.30 ± 
2.91
50.48 ± 
3.73
10.75 ± 
2.65
20.24 ± 
3.02
92.6 52719
Ip-10/CXCl10 2.52 
± 0.28
4.60 ± 
1.32
4.08 ± 
1.06
5.08 ± 
0.42
23.58 ± 
5.04
28.81 ± 
4.89
26.97 ± 
5.53
27.64 ± 
5.31
58.10 ± 
9.97
62.91 
± 13.57
78.88 ± 
16.26
66.74 ± 
13.76
172.51 ± 
33.14
154.78 ± 
40.32
212.64 ± 
56.58
150.89 ± 
24.43
4.83 ± 
0.56
13.07 ± 
0.78
4.13 ± 
1.70
4.93 ± 
1.60
18.8 26867
mCp-1/CCl2 107.23 
± 30.23
1618.93 ± 
186.16
192.47 ± 
26.89
2148.21 ± 
240.98
275.88 
±8.18
1633.06 ± 
352.4    5
287.53 ±  
16.29
1474.68 ± 
419.83
427.66 ± 
40.76
1316.33 
± 256.85
429.90 ± 
39.60
1216.11 ± 
324.46
560.76 ± 
67.02
3365.65 ± 
729.62
445.41 ± 
38.13
1957.86  
±117.37
443.19 ± 
112.32
7468.30 ± 
3529.43
212.52 ± 
22.93
1936.54 ± 
123.48
2.1 1820
MIP-1α/CCL3 not 
detectable
1.4 836
MIP-1β/CCL4 1.92 ± 1.21 1.42 ± 
0.42
2.60 ± 
0.77
2.03 ± 
0.13
4.45 ± 
0.56
3.78 ± 
0.37
5.50 ± 
0.76
3.57 ± 
0.52
9.47 ± 
0.82
7.21 
± 1.74
10.86 ± 
0.77
7.92 ± 
1.76
8.87 ± 1.44 8.59 ± 
2.69
10.05 ± 
2.73
4.88 ± 
0.65
3.05 ± 
0.79
6.52 ± 
0.45
3.51 ± 
1.09
2.94 ± 
0.32
2.0 1726
pDgf-BB 3.32 ±0.22 3.15 ±1.64 3.40 ±1.48 2.95 
±1.00
5.40 ± 
0.75
2.71 ± 
0.39
5.58 ± 1.21 1.40 ± 
0.70
5.79 ± 
1.00
3.92 
± 1.91
6.51 ± 1.12 4.65 ± 
1.97
4.39 ± 1.16 553.92 ± 
260.17
6.78 ± 
1.54
3.22 ± 
1.59
7.43 
±1.47
853.28 
±80.73
6.38 
±2.59
5.03 
±0.46
7.0 51933
RANTES not detec-
table
2.2 8617
TNF-α not detec-
table
5.8 95484
VEgf-A 122.19 ± 
21.34
1840.05 ± 
276.47
186.26 ± 
25.49
2274.15 ± 
51.80
140.69 ± 
4.77
2627.33 ± 
271.35
151.74 ± 
12.02
2554.81 ± 
311.97
148.32 ± 
23.33
2386.72 
± 188.63
156.29 ± 
19.41
2442.43 ± 
159.90
200.88 ± 
50.69
3366.20 ± 
712.86
177.16 ± 
12.21
2611.92 ± 
66.76
350.07 ± 
50.71
4989.78 ± 
254.25
230.76 ± 
27.41
2333.01 ± 
125.82
5.5 56237
Supplemental table 1 : Bio-plex pro™ Human Cytokine, Chemokine, and growth factor Assay analysis
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All cytokines/chemokines and growth factors detectable with the Bio-Plex Pro™ Human Cytokine, Chemokine and Growth Factor    Assay are given in the first column. The detected concentration of these factors in culture supernatants from ARPE-19 cells in unstimu-
lated situation (PBS) or after stimulation with vitreous or thrombin (5 U/ml) both in the presence and absence of hirudin is indicated   in the second till twentieth column, at t = 0 hours (T0) and t = 24 hours (T24). 
pBS PBS + hirudin RRD1 RRD1 + hirudin RRD2 RRD2 + hirudin pVR PVR + hirudin thrombin thrombin + hirudin llOQ ulOQ
T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24 T0 T24
IL-1β not 
detectable
3.2 3261
IL-1rα not 
detectable
81.1 70487
Il-2 not 
detectable
2.1 17772
Il-4 not 
detectable
2.2 3467
Il-5 not 
detectable
3.1 7380
Il-6 1.21 
± 0.14
40.57 ± 
12.22
1.99 ± 
0.36
67.07 ± 
3.62
15.18 ± 
8.67
229.67 ± 
75.92
20.28 ± 
13.38
158.43 ± 
63.43
21.80 ± 
6.13
275.73 
± 102.27
24.34
± 7.30
357.87 
± 151.82
57.75 
± 7.9
2267.63 ± 
1208.89
59.22 ± 
9.19
368.69 ± 
138.98
36.47 ± 
14.98
7830.13 ± 
3580.09
2.77 ± 
1.00
105.84 ± 
18.72
2.3 18880
Il-7 not 
detectable
3.1 6001
Il-8/CXCl8 9.30 
± 1.34
277.82 ± 
88.37
9.33 ± 1.34 475.38 ± 
59.96
8.53 ± 
0.32
1783.76 ± 
390.58
9.97 ± 
1.20
1269.07 ± 
263.88
12.52 ± 
1.69
 .63 
± 650.69
14.18 
± 2.25
3235.38 ± 
903.7
271.32
±250.33
17493.14± 
9475.47
19.02 ± 
2.57
2058.82 ± 
532.18
802.13 ±  
292.78
29362.23 ± 
3207.66
8.95 ± 2.1 700.67 ± 
137.69
1.9 26403
Il-9 11.97 
± 1.58
5.01 ± 
0.63
13.23 ± 2.11 4.57 ± 
0.59
10.02 ± 
0.51
6.09 ± 
1.30
11.98 ± 
1.80
5.67 ± 
0.90
11.55 ± 
1.16
7.82 
± 2.07
13.96 
± 1.11
9.12 
± 2.01
10.43 
± 0.64
12.16 
± 3.81
15.00 ± 
2.84
2.63 ± 
0.85
13.76 ± 
1.26
16.69 ± 
1.22
15.47 ± 
4.26
5.18 ± 
1.23
2.1 7989
Il-10 not 
detectable
2.2 8840
Il-12 (p70) 16.15 
±  4.07
112.52 ± 
12.46
27.61 ± 
5.29
123.47 ± 
5.05
21.30 ± 
1.57
144.77 ± 
6.50
24.10 ± 
3.25
153.90 ± 
11.00
23.28 ± 
4.68
144.17 
± 19.72
25.24 ± 
4.69
164.03 ± 
16.24
22.02 ± 5.85 171.62 ± 
37.97
26.43 ± 
3.07
122.75 ±  
3.59
38.33 ± 
4.99
205.73 ± 
4.27
32.73 ± 
5.32
113.22 ± 
7.10
3.3 13099
Il-13 0.61 
± 0.09
1.18 ± 
0.19
0.82 ± 
0.23
1.31 ± 
0.08
1.68 ± 
0.40
2.21 ± 
0.24
1.84 ± 
0.48
1.86 ± 
0.15
2.88 ± 
0.75
2.58 
± 0.70
3.07 ± 0.71 2.99 ± 
0.73
4.67 ± 1.37 3.98 ± 
1.10
3.72 ± 
0.89
2.5 ± 0.47 0.55 ± 
0.19
2.7 ± 0.10 0.92 ± 
0.34
1.31 ± 
0.19
3.7 3137
Il-15 not 
detectable
2.1 2799
Il-17 52.73 
± 6.59
42.71 ± 
11.83
63.69 ± 
9.07
49.65 ± 
3.92
42.42 ± 
1.23
48.02 ± 
1.29
50.65 ± 
4.58
49.56 ± 
4.22
40.70 ± 
5.08
51.24 
± 10.25
46.56 ± 
4.90
60.64 ± 
9.67
34.43 ± 2.74 126.88 ± 
62.93
47.92 ± 
8.92
46.67 ± 
3.02
52.23 ± 
11.13
117.12 ± 
9.30
67.27 ± 
16.48
48.91 ± 
7.97
4.9 12235
fgfb 473.37 
± 162.29
93.92 ± 
33.97
623.21 ± 
57.99
115.88 ± 
9.16
590.20 ± 
77.10
86.81 ±  
34.26
607.90 ± 
61.22
43.17 ± 
7.18
642.52 ± 
77.50
93.40 
± 38.61
715.43 ± 
51.94
119.78 ± 
46.26
692.40 ± 
96.83
143.19 ± 
23.37
697.10 ± 
76.55
55.77 ± 
11.55
692.23 ± 
183.86
405.80 ± 
139.88
712.71 ± 
157.80
91.51 ± 
29.71
40.9 5824
Eotaxin not 
detectable
27.2 7581
g-CSf 29.88 
± 9.50
21.72 ± 
6.33
37.60 ± 
4.95
25.67 ± 
1.66
31.52 ± 
1.30
25.69 ± 
1.15
42.05 ± 
3.81
25.14 ± 
0.99
35.79 ± 
2.17
25.70 
± 5.07
39.43 ± 
3.26
29.15 ± 
4.10
43.49 ±  
4.01
87.50 ± 
43.57
58.67 ± 
10.93
31.96 ± 
2.84
23.99 ± 
5.15
77.48 ± 
6.65
37.59 ± 
8.32
25.73 ± 
2.92
2.4 11565
gm-CSf 148.44 
± 24.54
43.96 ± 
11.88
140.49 ± 
10.44
59.19 ± 
10.70
112.43 ± 
3.84
39.27 ± 
7.40
125.44 ± 
8.12
37.63 ± 
9.00
113.22 ± 
7.91
38.19 
± 7.24
124.98 ± 
6.84
45.88 ± 
8.17
115.49 ± 
3.86
135.15 ± 
66.11
131.00 ± 
13.90
36.21 ± 
4.52
146.68 ± 
12.62
307.12 ± 
53.74
158.14 ± 
22.51
41.75 ± 
10.27
63.3 6039
IFNγ 6.49 
± 0.65
16.79 ± 
3.72
9.88 ± 
1.92
20.46 ± 
1.00
6.87 ± 
0.41
23.17 ± 
1.26
8.67 ± 
1.48
23.03 ± 
1.97
6.80 ± 
1.51
25.06 
± 3.73
8.15 ± 0.71 27.17 ± 
3.93
7.60 ±  1.34 44.36 ± 
17.51
9.24 ± 
1.90
20.81 ±  
1.43
9.30 ± 
2.91
50.48 ± 
3.73
10.75 ± 
2.65
20.24 ± 
3.02
92.6 52719
Ip-10/CXCl10 2.52 
± 0.28
4.60 ± 
1.32
4.08 ± 
1.06
5.08 ± 
0.42
23.58 ± 
5.04
28.81 ± 
4.89
26.97 ± 
5.53
27.64 ± 
5.31
58.10 ± 
9.97
62.91 
± 13.57
78.88 ± 
16.26
66.74 ± 
13.76
172.51 ± 
33.14
154.78 ± 
40.32
212.64 ± 
56.58
150.89 ± 
24.43
4.83 ± 
0.56
13.07 ± 
0.78
4.13 ± 
1.70
4.93 ± 
1.60
18.8 26867
mCp-1/CCl2 107.23 
± 30.23
1618.93 ± 
186.16
192.47 ± 
26.89
2148.21 ± 
240.98
275.88 
±8.18
1633.06 ± 
352.4    5
287.53 ±  
16.29
1474.68 ± 
419.83
427.66 ± 
40.76
1316.33 
± 256.85
429.90 ± 
39.60
1216.11 ± 
324.46
560.76 ± 
67.02
3365.65 ± 
729.62
445.41 ± 
38.13
1957.86  
±117.37
443.19 ± 
112.32
7468.30 ± 
3529.43
212.52 ± 
22.93
1936.54 ± 
123.48
2.1 1820
MIP-1α/CCL3 not 
detectable
1.4 836
MIP-1β/CCL4 1.92 ± 1.21 1.42 ± 
0.42
2.60 ± 
0.77
2.03 ± 
0.13
4.45 ± 
0.56
3.78 ± 
0.37
5.50 ± 
0.76
3.57 ± 
0.52
9.47 ± 
0.82
7.21 
± 1.74
10.86 ± 
0.77
7.92 ± 
1.76
8.87 ± 1.44 8.59 ± 
2.69
10.05 ± 
2.73
4.88 ± 
0.65
3.05 ± 
0.79
6.52 ± 
0.45
3.51 ± 
1.09
2.94 ± 
0.32
2.0 1726
pDgf-BB 3.32 ±0.22 3.15 ±1.64 3.40 ±1.48 2.95 
±1.00
5.40 ± 
0.75
2.71 ± 
0.39
5.58 ± 1.21 1.40 ± 
0.70
5.79 ± 
1.00
3.92 
± 1.91
6.51 ± 1.12 4.65 ± 
1.97
4.39 ± 1.16 553.92 ± 
260.17
6.78 ± 
1.54
3.22 ± 
1.59
7.43 
±1.47
853.28 
±80.73
6.38 
±2.59
5.03 
±0.46
7.0 51933
RANTES not detec-
table
2.2 8617
TNF-α not detec-
table
5.8 95484
VEgf-A 122.19 ± 
21.34
1840.05 ± 
276.47
186.26 ± 
25.49
2274.15 ± 
51.80
140.69 ± 
4.77
2627.33 ± 
271.35
151.74 ± 
12.02
2554.81 ± 
311.97
148.32 ± 
23.33
2386.72 
± 188.63
156.29 ± 
19.41
2442.43 ± 
159.90
200.88 ± 
50.69
3366.20 ± 
712.86
177.16 ± 
12.21
2611.92 ± 
66.76
350.07 ± 
50.71
4989.78 ± 
254.25
230.76 ± 
27.41
2333.01 ± 
125.82
5.5 56237
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Abstract
Purpose: Proliferative vitreoretinopathy (PVR) is a vitreoretinal inflammatory fibrotic 
disorder characterized by the formation of fibroproliferative membranes. Retinal 
pigment epithelial (RPE) cells contribute to vitreoretinal inflammation and fibrosis 
in pVR. Vitreous of pVR patients contains increased thrombin activity which induces 
proinflammatory and profibrotic programs in RPE cells. Inhibition of intravitreal thrombin 
activity should therefore be considered as treatment option for pVR. In this study we 
examined the capacity of the clinically available direct thrombin-inhibitor dabigatran and 
the clinically available anti-inflammatory agent dexamethasone to inhibit thrombin- and 
PVR vitreous-induced expression of inflammatory/fibrotic mediators by ARPE-19 cells. 
Methods: ARpE-19 and Hfl-1 cells were cultured with thrombin in the presence or 
absence of dabigatran (range: 10-5 - 10-7 m), dexamethasone (range: 10-7 - 10-9 m) or the 
NF-κB inhibitor SC-514 (10-4 m). moreover, ARpE-19 cells were cultured with vitreous 
lacking thrombin activity and vitreous from patients with pVR with elevated thrombin 
activity in the presence and absence of dabigatran (10-5 m). CCL2, CXCL8, GMCSF, IL6 and 
PDGFB mRNA expression levels were determined by RQ-pCR.
Results: Thrombin and pVR vitreous induced CCL2, CXCL8, GMCSF, IL6 and PDGFB expression 
by ARpE-19 cells, which was inhibited by dabigatran. Vitreous without thrombin activity 
had no effect on CCL2, CXCL8, GMCSF, IL6 and PDGFB expression levels by ARpE-19 cells. 
Dexamethasone did not inhibit the effect of thrombin on ARPE-19 cells. 
Conclusions: Our findings indicate that dabigatran is capable to inhibit RPE activation due 
to increased intravitreal thrombin activity associated with pVR. 
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Introduction
Thrombin is a key serine protease of blood coagulation that converts soluble fibrinogen 
into insoluble fibrin 1. In addition to its role in coagulation, thrombin induces cellular 
responses that have important roles in inflammation and tissue repair, but also contribute 
to the development of fibrosis 2-4. Thrombin for instance stimulates the production of 
inflammatory mediators by several cell types, promotes chemotaxis of inflammatory 
cells, stimulates the proliferation of fibroblasts and smooth muscle cells, and induces 
myofibroblast differentiation and the production extracellular matrix (ECM) components 
such as collagen 5. These cellular responses to thrombin are mostly mediated via the g 
protein-coupled receptor protease-activated receptor (pAR)-1 6.    
proliferative vitreoretinopathy (pVR) is a complication of retinal detachment caused by a 
retinal tear (rhegmatogenous retinal detachment (RRD)) or trauma that is characterized 
by inflammation and the formation of subretinal, intraretinal, and/or epiretinal 
fibrotic membranes 7, 8. Retinal pigment epithelial (RpE) cells dispersed during retinal 
detachment, are important contributors to pVR pathogenesis as they produce cytokines 
and chemokines that recruit and activate immune cells 7. Moreover, dedifferentiation of 
these dispersed RPE cells into collagen producing myofibroblasts is a key event in the 
development of the contractile fibrotic membranes 8. Although these pathobiological 
processes are well recognized to contribute to pVR, medical treatment options are so far 
limited and treatment mostly still depends on (recurrent) surgical intervention 8.
Activation of the coagulation cascade, as evidenced by intraocular fibrin deposition and 
increased intravitreal thrombin activity, occurs in pVR 9-11. moreover, we demonstrated 
that this increased intravitreal thrombin activity stimulates RpE cells to produce pro-
inflammatory mediators (CCL2, CXCL8, GM-CSF, IL-6) that are involved in immune cell 
activation, recruitment and differentiation as well as the pro-fibrotic mediator platelet-
derived growth factor (PDGF)-BB that subsequently induces dedifferentiation of RPE 
cells into collagen producing myofibroblasts 9, 12. All together this data points at an 
important role for thrombin in stimulating pro-inflammatory and pro-fibrotic responses 
by RpE in pVR. Thrombin may therefore represent an attractive treatment target for this 
disease.  
Dabigatran-etexilate is a small molecule oral pro-drug that is hydrolyzed to its active 
compound dabigatran. Dabigatran is a selective, competitive and reversible direct 
thrombin inhibitor (DTI) that binds to the active site of the thrombin molecule, thereby 
blocking the interaction between thrombin and its substrates 13. Dabigatran prevents 
thrombin-induced cleavage of fibrinogen’s fibrinopeptides at particular Arg-Gly bonds 
thereby precluding fibrin formation, but also inhibits thrombin induced cleavage of PAR-
1 at the peptide bond between residues Arg-41 and Ser-42 14, 15. 
The present study was undertaken to investigate whether dabigatran inhibits thrombin-
induced cytokine and growth factor production by RpE cells and to compare this with 
the effect established by the glucocorticoid dexamethasone, which was already used 
in clinical studies to modulate PVR. In addition, the efficacy of dabigatran to inhibit 
thrombin activity in vitreous of patients with established pVR was examined. We 
show that dabigatran inhibits thrombin-induced CCl2, CXCl8, gm-CSf, Il-6 and pDgf-
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BB production by ARpE-19 cells, while dexamethasone did not. moreover, dabigatran 
inhibited the capacity of pVR vitreous to induce CCl2, CXCl8, gm-CSf, Il-6 and pDgf-BB 
production by ARpE-19 cells. Therefore dabigatran may be considered as drug to treat 
PVR with the potential to reduce thrombin-induced proinflammatory and profibrotic 
mediator production by RpE.   
6
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Materials and Methods
Vitreous fluids
Vitreous samples without thrombin activity (rhegmatogenous retinal detachment 
(RDD) without PVR development after vitrectomy (n = 5)) and with thrombin activity 
(established PVR (n = 5): mean intravitreal thrombin activity = 56,19 ± 83,62 mU/ml) were 
selected from our previous study 9. All subjects gave their consent for the use of rest 
material for research; storage and use of the vitreous for further studies were according 
to the guidelines of the medical Ethics Committee of the Erasmus mC, university medical 
Center, Rotterdam and were performed in accordance with guidelines established by 
the Declaration of Helsinki.
Cell cultures
The human retinal pigment epithelial cell line ARPE-19 and the human fetal lung fibroblast 
cell line Hfl-1 were obtained from American Type Culture Collection (ATCC; manassas, 
VA, US). ARPE-19 cells were cultured in RPE medium (Dulbecco’s modified Eagle’s 
medium (DmEm)/f-12 (HyClone, logan, uT, uS), containing 10% heat inactivated fetal 
calf serum (fCS) and penicillin/streptomycin (all from BioWhittaker, Verviers, Belgium)) 
and between passage 23-30 when used for experiments. Hfl-1 cells were cultured in 
DmEm (BioWhittaker) containing 10% heat inactivated fCS and penicillin/streptomycin 
and between passage 14-18 when used for experiments. The cell lines were analyzed 
by short tandem repeat (STR) analysis (DSmZ, Braunschweig, germany) for cell line 
authentication and were mycoplasma free. The cells lines were maintained under 
standard cell culture conditions at 37 oC in humidified air with 5% CO2.  
Determining the efficacy of dabigatran and dexamethasone to inhibit thrombin-induced 
cytokine and growth factor mRNA expression by ARPE-19 and HFL-1
ARpE-19 cells were seeded in 12-wells plates at a density of 3 x 105 cells/well in RpE 
medium containing 10% fCS and allowed to adhere overnight. Subsequently the medium 
was refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, 
the cells were serum starved in RpE medium containing 1% fCS for 24 hours followed by 
an additional 24 hours in serum free RpE medium. Hereafter cells were pre-incubated 
with fresh serum free RpE medium with or without active dabigatran (BIBR 953 range: 
10-5 - 10-7 m: kindly provided by Boehringer Ingelheim pharma gmbH & Co. Kg (Ingelheim 
am Rein, germany) or dexamethasone (range: 10-7 - 10-9 m; Centrafarm B.V., Etten-leur, 
The Netherlands) for 60 minutes. Subsequently thrombin (Calbiochem, la Jolla, CA) was 
added to a final concentration of 5 U/ml (concentration based on previous studies 9, 12, 16) 
or cells remained unstimulated for a period of 2 hours. Hereafter cells were harvested for 
RNA isolation. Experiments were also performed with the human fetal lung fibroblast 
cell line Hfl-1, which was seeded in 12-wells plates at a density of 2 x 105 cells/well in 
DmEm containing 10% fCS and allowed to adhere overnight. prior to stimulation, the cells 
were serum starved in DmEm containing 1% fCS for 24 hours followed by an additional 
24 hours in serum free DmEm. The dabigatran and dexamethasone concentrations 
used were nontoxic to ARpE-19 and Hfl-1 cells as determined by lactate dehydrogenase 
(lDH) release (Roche, mannheim, germany) and microscopic appearance of the cells. In 
addition, inhibition experiments were  performed with the NF-κB inhibitor SC-514 (10-4 m; 
Calbiochem, concentration based on previous studies 16, 17).  
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Determining the efficacy of dabigatran to inhibit PVR vitreous-induced cytokine, 
chemokine and growth factor mRNA expression levels in ARPE-19
ARpE-19 cells were seeded in 12-wells plates at a density of 3 x 105 cells/well in RpE 
medium containing 10% fCS and allowed to adhere overnight. Subsequently the medium 
was refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, 
the cells were serum starved in RpE medium containing 1% fCS for 24 hours followed by 
an additional 24 hours in serum free RpE medium. Hereafter, cells were pre-incubated 
with serum free RpE medium with or without dabigatran (10-5 m) for 60 minutes and 
subsequently stimulated for 2 hours with serum free medium containing 1/8 diluted 
vitreous (dilution based on previous study 9) with or without dabigatran (10-5 m). 
Hereafter cells were harvested for RNA isolation. 
RNA isolation and real-time quantitative PCR
RNA was isolated using a genEluteTm mammalian Total RNA miniprep Kit (Sigma-
Aldrich, St. louis, mO) and reverse transcribed into cDNA 9. Transcript levels of CCL2, 
CXCL8, GMCSF, IL6 and PDGFB mRNA were determined by real-time quantitative (RQ)-
pCR (7700 pCR system; Applied Biosystems [ABI], foster City, CA, uS) using primer 
and probe combinations as previously described 9. In addition the expression level of 
the glucocorticoid receptor gene NR3C1 was determined in unstimulated cells using a 
commercially available Taqman gene Expression assay (Applied Biosystems). Expression 
levels of the analyzed gene transcripts were normalized to the control gene ABL 
(Abelson) 9. 
Statistical analysis
messenger RNA data were analyzed using the Kruskal-Wallis (One-way ANOVA) test 
followed by the mann-Whitney u test when applicable. A P-value < 0.05 was considered 
significant. 
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Results
Effect of dabigatran and dexamethasone on thrombin-induced cytokine, chemokine 
and growth factor mRNA expression by ARPE-19
In line with our previous observations, thrombin significantly (P < 0.05) induced CCL2, 
CXCL8, GMCSF, IL6 and PDGFB mRNA expression levels in ARpE-19 (figure 1) 9, 12, 16. This 
stimulatory effect of thrombin was dose-dependently inhibited by dabigatran for all 
genes, being significant (P < 0.05) at a concentration of 10-5 m (figure 1A). In contrast, 
dexamethasone at the tested concentrations did not inhibit the thrombin-induced 
increase in CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA levels in ARpE-19 (figure 1B). 
Dabigatran and dexamethasone alone had no effect on CCL2, CXCL8, GMCSF, IL6 and 
PDGFB mRNA expression levels (figure 1).   
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figure 1: ARpE-19 cells were stimulated for 2 hours with thrombin (5 u/ml) or remained unstimulated 
in the absence or presence of (A) dabigatran (range: 10-5 - 10-7 m) or (B) dexamethasone (range: 
10-7 - 10-9 m). CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expression levels were determined by RQ-
pCR and normalized against the control gene ABL. Data are presented as the mean value from 4 
independent experiments ± SEm. Statistical analysis was performed with the Kruskal-Wallis (One-
way ANOVA) test followed by the mann-Whitney u test when applicable. P < 0.05 was considered 
significant. * = P < 0.05 and ** = P < 0.01.
Effects of dabigatran and dexamethasone on thrombin-induced  cytokine, chemokine 
and growth factor mRNA expression by ARPE-19 and HFL-1
In order to determine whether the inability of dexamethasone to inhibit the thrombin-
induced increase in CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA levels was confined to 
ARPE-19 we also examined the response of  the human fetal lung fibroblast cell line HFL-
1. Because we previously found that thrombin-induced cytokine/chemokine and growth 
factor production by RPE cells involves activation of the NF-κB pathway, which is also a 
target for the glucocorticoid/glucocorticoid receptor complex, we used the specific NF-
κB inhibitor SC-514 as control in these experiments 16, 18. Thrombin stimulation enhanced 
CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expression levels both in ARpE-19 and Hfl-
1 and this effect was significantly inhibited (P < 0.05) up to basal expression levels by 
dabigatran in both cell lines (Figure 2). Dexamethasone did not inhibit the effects of 
thrombin in ARpE-19 but did inhibit (P < 0.05) the thrombin-induced increase in CCL2, 
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figure 2: ARpE-19 and Hfl-1 cells were stimulated for 2 hours with thrombin (5 u/ml) or remained 
unstimulated in the absence or presence of dabigatran (dabi, 10-5 m) dexamethasone (dex, 10-7 m) 
or SC-514 (10-4 m). CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expression levels were determined 
by RQ-pCR and normalized against the control gene ABL. Data are presented as the mean value 
from 4-5 independent experiments ± SEm. Statistical analysis was performed with the Kruskal-
Wallis (One-way ANOVA) test followed by the mann-Whitney u test when applicable. P < 0.05 was 
considered significant. * = P < 0.05 and ** = P  0.01.
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figure 3: NR3C1 mRNA expression levels were determined in unstimulated 
ARpE-19 and Hfl-1cells by RQ-pCR and normalized against the control 
gene ABL. Data are presented as the mean value from 6 independent 
measurements ± SEm. Statistical analysis was performed with the mann-
Whitney u test. P < 0.05 was considered significant. * = P < 0.05.
CXCL8, GMCSF and IL6 mRNA levels in Hfl-1, not the increase in PDGFB mRNA (figure 2). 
SC-514 inhibited the thrombin-induced increase in CCL2, CXCL8, GMCSF, IL6 and PDGFB 
mRNA levels in both cell lines. 
Glucocorticoid receptor mRNA expression by ARPE-19 and HFL-1 cells
Because the above data indicate a relative unresponsiveness of ARpE-19 to dexamethasone 
we examined the mRNA expression level of the glucocorticoid receptor encoding gene 
NR3C1. This revealed that NR3C1 mRNA was expressed at a significantly (P < 0.05) higher 
level in Hfl-1 than in ARpE-19 (figure 3). This suggests that the unresponsiveness of 
ARpE-19 to dexamethasone may be related to low glucocorticoid receptor expression.
The effect of dabigatran on vitreous-induced cytokine, chemokine and growth factor 
mRNA expression by ARPE-19 
Vitreous samples from RDD patients that lacked detectable thrombin activity did not 
enhance CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expression by ARpE-19, which is in 
line with our previous observations 9. Nor was this affected by dabigatran (Figure 4A). 
Vitreous samples from pVR patients that contained thrombin activity clearly enhanced 
CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expression by ARpE-19, in line with our 
previous observations 9. Dabigatran did significantly (P < 0.05) reduce the capacity of 
the pVR vitreous to stimulate CCL2, CXCL8, IL6 and PDGFB mRNA expression by ARpE-19 
(figure 4B).      
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figure 4: ARpE-19 cells were stimulated for 2 hours with (A) 1/8 diluted vitreous without thrombin 
activity or (B) 1/8 diluted vitreous with thrombin activity in the absence or presence of dabigatran 
(dabi, 10-5 m). CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA expression levels were determined by RQ-
pCR and normalized against the control gene ABL. Data are presented as the mean value from 4 
independent experiments ± SEm. Statistical analysis was performed with the Kruskal-Wallis (One-
way ANOVA) test followed by the mann-Whitney u test when applicable. P < 0.05 was considered 
significant. * = P < 0.05 and ** = P < 0.01.
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Discussion 
There is accumulating evidence that elevated intravitreal thrombin activity is involved 
in the pathogenesis of PVR and that its contribution goes beyond fibrin formation. 
In pVR thrombin activates pAR-1 signaling in RpE cells resulting in production of the 
proinflammatory cytokines CCL2, CXCL8, GM-CSF, IL-6, the profibrotic mediator PDGF-BB 
and dedifferentiation of RPE cells into collagen producing myofibroblasts 12, 16. Inhibition 
of thrombin may thus represent an attractive therapeutic option for pVR treatment. 
Our current findings demonstrate  that dabigatran inhibits thrombin and PVR vitreous-
induced elevation of CCL2, CXCL8, GMCSF, IL6 and PDGFB mRNA levels in ARpE-19 cells. 
previously we found a positive correlation for these mRNAs with the actual protein 
production when ARpE-19 were stimulated with thrombin or pVR vitreous indicating that 
the mRNA results can be translated to the protein level 9, 16.    
Thrombin stimulates the production of CCl2, CXCl8, gm-CSf, Il-6 and pDgf-BB by RpE 
via PAR-1 induced NF-κB signaling 16. Remarkably the standard anti-inflammatory drug 
dexamethasone that blocks NF-κB-induced expression of inflammatory mediators by 
many cell types did not inhibit thrombin-induced cytokine/chemokine production by ARpE-
19, but did inhibit this in lung fibroblasts (HFL-1). Thrombin-induced PDGFB expression 
was not inhibited by dexamethasone in both ARpE-19 and Hfl-1 cells. In contrast the 
NF-κB inhibitor SC-514 did inhibit thrombin-induced cytokine/chemokine and PDGFB 
expression by ARpE-19 and Hfl-1 cells. The observed unresponsiveness of ARpE-19 to 
dexamethasone is most likely related to the low expression of glucocorticoid receptor, 
which was ~4 fold lower at the mRNA level than that observed in Hfl-1. Although not 
examined in the current study, low expression of glucocorticoid receptor transcripts 
have also been described in human primary RpE cells 19. Our data therefore suggest that 
dexamethasone likely is unable to inhibit powerful thrombin-induced responses by RpE 
cells. However RpE cells are important producers of cytokines, chemokines and growth 
factors that shape the inflammatory environment in PVR, which stresses the need for 
compounds that inhibit inflammatory mediator production by RPE cells 16, 20. 
Recently we demonstrated that thrombin activity is increased in vitreous from pVR 
patients where it is a major factor contributing to vitreous-induced production of CCl2, 
CXCl8, gm-CSf and Il-6 by ARpE-19 cells. Here we demonstrate that dabigatran inhibits 
pVR vitreous-induced CCL2, CXCL8, GMCSF and IL6 mRNA expression in ARpE-19. Therefore 
we consider inhibition of intravitreal thrombin activity with dabigatran as treatment 
option to reduce the pro-inflammatory activation of RPE cells in PVR. 
Dedifferentiation of RPE cells into contractile extracellular matrix synthesizing 
myofibroblasts is a key event in the formation of fibrotic membranes in PVR 8, 20. Thrombin 
is an important driver of this dedifferentiation process which depends on autocrine 
release of pDgf-BB and subsequent pDgf-receptor activation 12. Here we found that 
dabigatran inhibits thrombin and pVR vitreous-induced expression of PDGFB mRNA in 
ARPE-19, suggesting that dabigatran may prevent thrombin-induced fibrotic responses 
in RpE cells.  
Taken together our data suggest that thrombin inhibition with a DTI as dabigatran may 
be an interesting therapeutic option in the prevention of pVR development. It should 
however be taken into account that the use of a compound as dabigatran, with potential 
side effects including hemorrhages, should be introduced with great precaution 21-23. 
moreover in case of pVR prevention the optimal clinical window of opportunity as well 
as route of administration (oral vs local) remain to be determined. 
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General discussion
The development of proliferative vitreoretinopathy (pVR) is characterized by 
inflammation followed by the formation of contractile fibroproliferative membranes 
which can cause the retina to detach 1, 2. In most cases pVR is the result of an unsuccessful 
retinal detachment surgery in patients with a rhegmatogenous retinal detachment 
(RRD) 3. Approximately 10% of the RRD patients develop pVR and have to undergo retinal 
detachment surgery at least once more 3. To date the cause of pVR development remains 
unclear. previous studies demonstrated that retinal pigment epithelial (RpE) cells are key 
players in PVR pathogenesis and that (myo)fibroblasts, glial cells and macrophages are 
important contributors as well 3. Also, increased levels of platelet-derived growth factor 
(PDGF), transforming growth factor (TGF)-β and vascular endothelial growth factor 
(VEgf) in vitreous of patients are important contributors to pVR pathogenesis, as they 
have been demonstrated to drive the processes which result in the formation of these 
contractile fibroproliferative membranes 3. A better understanding of the processes 
involved in pVR development  may provide better treatment options or even prevent 
pVR from developing.    
In the eye the non-pigmented cells of the ciliary epithelium and the endothelium of the 
iridal capillaries constitute the blood-aqueous barrier, whereas the RpE and endothelial 
cells of the retinal vessels form the blood-retinal barrier (BRB) 4. Breakdown of the 
BRB is part of RRD pathophysiology and subsequently serum constituents can gain 
access to the inner eye in higher than usual concentrations 5. Breakdown of the BRB 
in patients with RRD was found to result in some degree of intra-ocular activation of 
the coagulation cascade 5. By others it was demonstrated that the coagulation proteins 
activated factor X (FXa) and thrombin induce inflammatory and fibrotic responses in liver, 
kidney and lung 6-9. Since similar processes may occur in the eye after BRB breakdown it 
is hypothesized in this thesis that fXa and thrombin induce pVR associated processes like 
cytokine and growth factor production, proliferation, and differentiation by RPE cells. 
The studies in this thesis used the human RpE cell line ARpE-19 but also primary human 
RpE cultures. The ARpE-19 cell line may display limitations as these cells may show some 
differences compared to primary RPE for instance on gene expression profiles, but also 
on biological behavior like trans-epithelial resistance development 10-12. However, the 
studies performed with primary RpE generally showed similar responses to fXa and 
thrombin 13, 14. Therefore the studies performed in this thesis support the hypothesis and 
demonstrate that fXa and thrombin can play a comprehensive role in pVR development, 
by inducing inflammatory and fibrotic responses by RPE cells as depicted in figure 1 13-15.
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figure 1:  In pVR development the coagulation cascade is activated. The coagulation proteins fXa 
and thrombin induce inflammatory and fibrotic responses by RPE in a PAR-dependent manner. The 
inflammatory response is characterized by increased production of pro-inflammatory cytokines, 
chemokines and adhesion molecules. The increased cytokine/chemokine levels contribute to 
recruitment and activation of monocytes  followed by their differentiation into growth factor 
producing macrophages. This latter process involves at least the adhesion molecules CD18 and 
ICAM-1. The induced fibrotic response includes de-differentiation of RPE into ECM and growth 
factor producing myofibroblasts. The combined effect of the inflammatory and fibrotic responses 
results in the formation of contractile fibroproliferative membranes, which represent the 
pathological end-stage of pVR, and can cause further retinal (re)detachment. 
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Breakdown of the BRB has been associated with RRD suggesting that BRB breakdown 
is an early event in pVR pathogenesis 5, 16-18. However, no difference was observed in 
intravitreal thrombin activity between patients with RRD who don’t develop pVR after 
surgery and patients with RRD who do develop pVR after surgery. Only the vitreous of 
patients with established pVR contained elevated levels of intravitreal thrombin activity, 
suggesting that BRB breakdown or increased BRB breakdown is a late event in pVR 
pathogenesis 15. Indeed, the value of anterior chamber laser flare measurements (as a 
measure of BRB breakdown) to predict which patients with RRD are at risk for developing 
pVR, is far from clear (mulder et al, ARVO 2015). BRB breakdown as late event in pVR 
pathogenesis may be explained by the formed fibroproliferative membranes which, 
due to their contractile properties, cause more severe BRB breakdown of the retinal 
vessels, whereas breakdown of the BRB at the level of RpE is caused by the progressive 
accumulation of cytokines. It can also be suggested that local production of thrombin 
in the retina is involved, as was demonstrated in the cornea as well as in monocytes 
and macrophages under pathological conditions 19-24. Therefore it remains unclear 
whether RpE activation by coagulation proteins is the initiator for pVR development or a 
contributor to the progression of pVR development. 
The presence of macrophages in pVR membranes may be indicative for their 
contribution to pVR pathogenesis via their capacity to produce large amounts of growth 
factors 3, 25-28. Chemokines produced by the thrombin-activated RpE likely contribute to 
monocyte/macrophage recruitment which subsequently contribute to the inflammatory 
and fibrotic processes 14, 15. However, thrombin itself has also been described to be a 
chemoattractant for fibroblasts, monocytes, neutrophils and RPE 29-33. Nevertheless, it 
has been demonstrated before that co-culturing monocytes and RpE results in increased 
chemokine production and that when thrombin is added to the monocyte-RpE co-
cultures, chemokine production increases 34. In addition to these findings, the findings in 
Chapter 4 suggest that thrombin regulates the differentiation of monocytes into growth 
factor producing macrophages, which most likely involves integrin mediated cellular 
interaction with RpE. 
How does this proposed series of events relate to the findings of numerous other studies 
on pathogenesis and treatment of pVR? In vitro studies and studies in animal models 
have suggested major roles for hepatocyte growth factor, PDGF, VEGF and TGF-β 
35-43. 
Analysis of patients’ subretinal fluid and vitreous has shown increased concentrations 
of many cytokines and growth factors, and studies in patients have identified genetic 
polymorphisms in loci related to TNF-α, TGF signaling and apoptosis pathways as risk 
factors for pVR 44-50. However, the findings in all these studies fit our hypothesis as the 
far majority of these described mediators and processes are regulated in RpE upon 
thrombin-activation. Therefore, the studies in this thesis and their subsequent target 
(thrombin) have the elegance of simplicity: thrombin may be an early or late, initiating or 
contributing molecule and is compatible with many of the downstream effects reported 
in other studies. 
Discussion
7
144
Clinical applications
To influence the development of PVR multiple steps of the process could be targeted, 
with a preference for interfering with initiating steps rather than later manifestations. It 
remains hard to be sure that the initiator can be targeted, but the studies in this thesis 
suggest that interference with thrombin is a feasible choice. Targeting the coagulation 
cascade is of particular interest because this process is an early manifestation of retinal 
detachment, can initiate multiple subsequent steps, and can be influenced with blocking 
agents which are already clinically available 5, 51, 52. 
However, in five clinical trials to prevent PVR with heparin or low molecular weight 
heparins (LMWH) in combination with steroids or 5-fluorouracil (5-FU), there was a 
measurable reduction in pVR in only one 53-57. There are several explanations for this lack 
of effectivity. First, for heparin and LMWH to function properly, antithrombin III (ATIII) is 
necessary as a catalyst to inactivate fXa and/or thrombin 58. It remains unclear whether 
there is sufficient ATIII present in the vitreous for these anti-coagulants to be effective 
(below detection limit, unpublished data, Bastiaans et al). Second, heparin could only be 
used as a peroperative perfusion, and a single hour of anti-thrombin action is unlikely to 
influence a fibrotic process that occurs over a period of several weeks. A third explanation 
may be that the heparin (dalteparin) used in these studies, is more effective against FXa 
than against thrombin, the more potent inducer of fibrotic changes 59. However, it is 
to be expected that fXa inhibition results in decreased thrombin generation and thus 
decreased pAR signaling.
for most of these reasons a direct thrombin-inhibitor would be more preferable. 
Dabigatran (pradaxa) is a clinically available direct thrombin-inhibitor with hirudin-like 
properties 60-62. In Chapter 6 it was demonstrated that the effects of PVR vitreous on RPE 
can be inhibited by dabigatran. These findings make the use of dabigatran an interesting 
therapeutic strategy for treatment or prevention of pVR development. 
However, two important issues need to be addressed: 
1. The use of anticoagulants needs to be considered carefully, since side effects 
like hemorrhages in the brain and other organs have been reported 63. Systemic 
administration of anticoagulants like dabigatran to all patients at risk for pVR 
development may expose many patients to these side effects. It would be desirable 
to be able to select patients at high risk for pVR only. A reliable biomarker for this 
purpose remains to be found. But the  data from Chapter 5 suggest that CCl4 may 
represent such a biomarker since this was found elevated in vitreous of patients 
who developed pVR 6 months after vitrectomy, compared to those patients who 
did not develop pVR after vitrectomy. Therefore more research regarding the role 
of CCl4 in pVR development may be of interest.  
2. Thrombin has a relatively short half-life. In normal human plasma the half-life of 
thrombin is ~56.4 ± 4.7 seconds. In antithrombin-deficient plasma the half-life of 
thrombin is ~168.2 ± 14.9 seconds 64. Since the duration of BRB breakdown is at least 
three weeks, patients should be treated during that period 65. The same arguments 
would be applicable for therapeutically targeting pARs or tyrosine-kinase inhibitors 
to prevent them from signaling. 
Various intravitreal proteins have been suggested to contribute to pVR development. 
These proteins and the processes they regulate implicate that pVR pathogenesis 
comprises more than one variable. Therefore a multivariable therapeutic approach may 
be most favourable. The studies in this thesis demonstrate that many of the processes 
involved in pVR pathogenesis, including the upregulated expression of cytokines and 
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growth factors, are downstream of pAR signaling 13-15. pARs cannot only be activated by 
thrombin but by many other proteases as well, of which numerous have been found in 
vitreous of patients with vitreoretinal disorders. 66, 67. Studies in this thesis and others also 
clearly demonstrate an important role for pDgf-receptor signaling 13, 41, 68. The elevated 
levels of different PDGF isoforms induce fibrotic responses via PDGFR-α and PDGFR-β 
activation 68-71. In addition, VEGF and FGF have been described to activate PDGFR-α 
through transactivation via their own receptors 72, 73. In fibroproliferative membranes 
from patients with PVR mostly PDGFR-α was found activated 71. Therefore, combined 
targeting of receptors like PAR and PDGFR may be even more efficient in preventing PVR 
development. Vorapaxar (Zontivity) is a new and clinically available pAR1 inhibitor which 
has so far showed limited side effects 74-76. Tyrosine-kinase inhibitors like imatinib (glivec), 
dasatinib (Sprycel) and nintedanib (Vargatef) may be efficient PDGFR blockers which are 
already clinically available. The last one (nintedanib) also blocks VEgf-receptors and fgf-
receptors 77-79.  
The role of coagulation proteins in other vitreoretinal disorders
The fibrotic processes induced by thrombin do not only occur in PVR development, but 
in other vitreoretinal disorders like exudative age-related macular degeneration (ARmD) 
and proliferative diabetic retinopathy (pDR) as well 80-83. Components of the coagulation 
cascade have been found in vitreous of these patients as well and as such it is likely that 
in these disorders thrombin also contributes to pathogenesis 84-88.
The exudative or wet form of ARmD is associated with severe vision loss that can 
occur rapidly 89. This form of ARmD is characterized by choroidal neovascularization, 
stimulated by VEgf 89,90. These newly formed vessels leak blood and fluid, which can 
result in coagulant protein-driven activation of pARs expressed on the various cell types 
in the retina. Studies in histological specimens from both humans and animals have 
demonstrated the presence of macrophages as the main infiltrating inflammatory cells 
in ARmD lesions, particularly in the choroidal neovascular membranes (CNVm) 91. The 
precise role of macrophages in ARmD is still unclear. However, it can be expected that 
they exert similar effects as in PVR membranes. This is supported by the finding that 
the macrophages in the CNmV are capable of expressing pro-angiogenic factors such as 
VEGF and pro-inflammatory molecules, as in PVR 92.
The vitreous of patients with pDR contains elevated levels of prothrombin and ATIII 
compared to patients without diabetes mellitus and diabetes with no apparent diabetic 
retinopathy 93. pDR is characterized by retinal neovascularization resulting in increased 
retinal haemorrhages and increased levels of VEgf in the vitreous. These processes result 
in the formation of fibrovascular membranes. In these membranes endothelial cells and 
macrophages are prominently present 94, 95. Also, these fibrovascular membranes can 
cause retinal detachment by contraction. 
Collectively, both ARmD and pDR are characterized by increased levels of locally 
produced and serum-derived proteins like VEgf in the vitreous, membrane formation and 
macrophage accumulation causing choroidal (ARmD) or retinal (pDR) neovascularization. 
In ARmD and pDR, similar to pVR development, macrophage accumulation and membrane 
formation are part of fibrovascular tissue. Apart from the mainstay of treatment: anti-
VEGF, inhibition of thrombin may therefore be of some benefit in these patients as well, 
possibly to modify the fibrotic part of the fibrovascular process. 
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A role for other coagulation proteins in  PVR development
The coagulation proteins fXa and thrombin have widely been discussed for their 
activating properties. However, other components from the coagulation cascade, 
including fibrinogen, fibrinopeptides and fibrin fragments, have been described to induce 
cellular responses as well. In bronchial epithelial cells fibrinogen has been described to 
induce CCl2, CCl3 and CCl4 production by macrophages in a Toll-like receptor (TlR)4-
dependent manner and fibrinopeptides to induce IL-5 and IL-13Rα1 expression in a TLR4-
dependent manner 96, 97. fibrinopeptides are side products generated by the cleavage of 
fibrinogen by thrombin. These side products consist of 16 amino acids long fibrinogen 
α chains and 14 amino acids long fibrinogen β chains 98. RpE cells also express TlR4 
which suggests that formed fibrinopeptides, as the result of intra-ocular activation of 
the coagulation cascade, may induce TlR4-mediated activation of RpE. Also activated 
protein C, a natural anticoagulant, has been described to induce cellular responses which 
are associated with neovascularization and wound healing in a pAR-dependent manner 
99-102.
During fibrinolysis, a counter regulatory mechanism for activation of the coagulation 
cascade, fibrin is cleaved by plasmin, resulting in clot lysis and an accompanied generation 
of fibrin fragments such as D and E fragments 103. These fragments are chemotactic for 
leukocytes, but can also induce leukocyte migration by induction of cytokine/chemokine 
production 103. Other components of the fibrinolytic system like protease-activated 
receptor-1 and the plasmin-a2-antiplasmin-complex have been found elevated in vitreous 
of patients with pVR as well 16. However, whether these components affect the earlier 
described inflammatory and fibrotic properties of coagulation proteins remains to be 
investigated. 
Collectively these findings suggests additional roles for other components of the 
coagulation cascade in the activation and continuation of inflammatory and fibrotic 
responses by RpE which have not been investigated so far. Some of these interactions, 
though, may have occurred in the experiments with vitreous of patients. As such, 
dampening thrombin action continues to be a plausible approach. 
Concluding remarks
The development of pVR remains the major cause of unsuccessful retinal detachment 
surgery. Vitreoretinal surgeons have managed to improve their surgical skills and are 
relatively successful in reattaching the retina, with, however, unfortunately very modest 
functional results. No improvement has been made with anti-proliferative agents, 
steroids and heparin to prevent or treat pVR. The use of new direct thrombin-inhibitors, 
possibly in combination with new and more efficient receptor tyrosine-kinase inhibitors 
to target growth factor effectors, or even more speculatively antibodies to individual 
growth factors, cytokines or receptors may contribute to a prevention treatment for 
pVR development. 
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Summary
The pathogenesis of proliferative vitreoretinopathy (PVR) comprises inflammatory and 
fibrotic processes which result in the formation of fibrotic epiretinal, intraretinal and/or 
subretinal  membranes. These membranes can cause the retina to detach with resultant 
loss of vision. pVR develops in approximately 10% of the patients with a rhegmatogenous 
retinal detachment or can develop as a result of trauma. To date, surgery is the only 
treatment option for pVR, but this is not always successful. A better understanding of 
the molecular and cellular processes involved in the pathogenesis of pVR may lead to 
better treatment options. 
The role for coagulation proteins in inflammatory and fibrotic responses in organs 
including the lungs and kidneys is well established. Here, they stimulate proliferation 
and the production of cytokines and extracellular matrix molecules by several cell types, 
including (myo)fibroblasts. PVR development is associated with breakdown of the blood-
retinal barrier, which results in intraocular activation of the coagulation cascade and 
subsequent exposure of retinal pigment epithelial (RpE) cells to coagulation proteins. 
RpE cell activation is considered to represent a central event in the development of pVR. 
Activated RpE cells can produce chemokines and cytokines, involved in immune cell 
recruitment, activation and differentiation. They produce extracellular matrix proteins, 
including collagen, and are abundantly present in fibroproliferative membranes. In 
contrast to what is known about the role for coagulation proteins in inflammatory 
and fibrotic responses in organs such as the lungs and kidneys, the contribution of 
coagulation proteins to RpE cell activation in pVR is still poorly understood. In this thesis 
it was hypothesized that the coagulation proteins activated factor X (fXa) and thrombin 
contribute to PVR development via the induction of pro-inflammatory and pro-fibrotic 
processes in RpE cells. These coagulation proteins may thus represent an attractive 
therapeutic target to prevent or treat pVR. 
Chapter 2 of this thesis describes that fXa and thrombin stimulate the production of 
several cytokines, chemokines and growth factors by RpE cells. many of these (e.g. 
IL-6, CCL2 and PDGF) have previously been linked to inflammation and fibrosis in PVR. 
Both FXa and thrombin established this effect via protease-activated receptor-1 induced 
activation of the Nf-κB signaling pathway. Remarkably, differences existed between 
regulation of the production of the cytokines, chemokines and growth factors by fXa 
and thrombin in the RpE cells. It was found that thrombin generally appeared to exert 
stronger stimulatory effects than FXa. 
Chapter 3 demonstrates that thrombin induces de-differentiation of RPE cells into 
myofibroblasts, expressing α-smooth muscle actin and producing collagen. This is 
associated with loss of typical epithelial characteristics such as expression of the tight 
junction protein zonula occludens-1. In addition, the data in this chapter demonstrate 
that this thrombin induced process of epithelial-mesenchymal transition of RpE cells into 
myofibroblasts, involved the induction of autocrine PDGFR signaling. 
Chapter 4 shows that thrombin enhances monocyte-to-macrophage differentiation in 
monocyte-RPE co-cultures. This differentiation process most likely depends on direct 
physical interaction between monocytes/macrophages and RpE cells and involves at 
least the adhesion molecules CD18 and ICAm-1. The thrombin enhanced monocyte-to-
macrophage differentiation resulted in increased production of the pro-fibrotic mediators 
PDGF-BB, TGF-β2 and VEgf-A, which may suggest that the newly formed macrophages 
obtained an m2-phenotype. 
Chapter 5 demonstrates that vitreous of patients with established pVR contains elevated 
thrombin-activity, in contrast to vitreous of patients with rhegmatogenous retinal 
detachment, macular puckers or macular holes. moreover, this enhanced thrombin-
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activity in PVR vitreous was found to represent a major activator of pro-inflammatory 
and pro-fibrotic pathways in RPE cells. 
Altogether the data presented in Chapter 2-5 implicate a comprehensive role for 
especially thrombin in the pathogenesis of pVR. Thrombin may thus represent an 
attractive therapeutic target to treat or prevent pVR from developing, especially since 
direct thrombin inhibitors are clinically available. Chapter 6 describes the effects of the 
clinically available direct thrombin inhibitor dabigatran (pradaxa) on thrombin and pVR-
vitreous-induced   activation of RPE cells. The effect of dabigatran was compared to 
that of dexamethasone. Dabigatran efficiently blocked thrombin-induced production of 
cytokines, chemokines and growth factors by RpE cells, while dexamethasone largely 
failed to do so. This latter may be related to low glucocorticoid receptor expression in 
RpE cells. Importantly, dabigatran also inhibited cytokine, chemokine and growth factor 
production by RpE cells induced by (thrombin containing) pVR-vitreous, indicating that 
dabigatran is able to block thrombin-activity within the vitreal matrix.  
In conclusion, the studies described in this thesis provide important new insight into 
the contribution of especially thrombin to the induction of pro-inflammatory and pro-
fibrotic events in RPE cells during PVR pathogenesis. Inhibition of intravitreal thrombin-
activity may thus represent an attractive therapeutic option to treat or prevent pVR 
development, and future studies into this are therefore warranted. 
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Samenvatting
De ontwikkeling van proliferatieve vitreoretinopathie (pVR) wordt gekenmerkt door 
inflammatoire en fibrotische processen die uiteindelijk resulteren in de ontwikkeling 
van fibroproliferatieve membranen. Deze membranen kunnen er voor zorgen dat het 
netvlies loslaat wat vervolgens kan resulteren in zichtvermindering. pVR ontwikkelt 
zich bij ongeveer 10% van de patiënten die zijn geopereerd i.v.m. een rhegmatogene 
netvliesloslating of als gevolg van trauma. Tot de dag van vandaag is een nieuwe operatie 
nog altijd de enige optie om pVR te behandelen. Een beter inzicht in de moleculaire en 
cellulaire processen die plaatsvinden zowel voor als tijdens de ontwikkeling van pVR, zou 
kunnen resulteren in betere behandelingsmogelijkheden. 
De rol van stollingseiwitten in inflammatoire en fibrotische processen in organen als de 
long en lever is breed erkend. In deze organen stimuleren stollingseiwitten proliferatie en 
de productie van cytokinen en extracellulaire matrixmoleculen in verschillende celtypen, 
waaronder (myo)fibroblasten. De ontwikkeling van PVR is geassocieerd met schade aan 
de bloed-retina barrière, gevolgd door intra-oculaire activatie van de stollingscascade. 
Dit resulteert  vervolgens in blootstelling van retinaal pigment epitheel (RpE) cellen 
aan stollingseiwitten. Van RpE cellen, die zich tussen de fotoreceptoren en het choroïd 
bevinden, wordt aangenomen dat ze een belangrijke rol spelen in pVR ontwikkeling, 
omdat ze dominant aanwezig zijn in pVR membranen. Bovendien produceren ze na 
activatie cytokinen, chemokinen en groeifactoren die bijdragen aan (myo)fibroblast-
differentiatie, de productie van extracellulaire matrixmoleculen en activatie en rekrutering 
van immuuncellen. In tegenstelling tot de rol van stollingseiwitten in inflammatoire en 
fibrotische processen in organen als de long en lever, is nog maar weinig bekend over de 
bijdrage van stollingseiwitten aan RpE activatie bij pVR ontwikkeling. In dit proefschrift 
is gehypothetiseerd dat de stollingseiwitten geactiveerde factor X (fXa) en trombine 
bijdragen aan PVR ontwikkeling via inflammatoire en fibrotische processen in RPE. Deze 
stollingseiwitten zouden daardoor mogelijk interessante therapeutische targets zijn 
voor de voorkoming of behandeling van pVR.  
Hoofdstuk 2 van dit proefschrift beschrijft dat fXa en trombine de productie van 
diverse cytokinen, chemokinen en groeifactoren door RpE stimuleren. Deze cytokinen, 
chemokinen en groeifactoren (zoals Il-6, CCl2 en pDgf) zijn al vaker geassocieerd met 
inflammatoire en fibrotische processen in PVR ontwikkeling. Het effect van zowel FXa als 
trombine verloopt via protease-geactiveerde receptor-1 geïnduceerde activatie van de 
Nf-κB signalerings-pathway. Opvallend is dat er verschillen zijn tussen fXa en trombine 
in regulatie van de productie van cytokinen, chemokinen en groeifactoren door RpE. 
In deze studie bleek trombine de meest potente regulator te zijn van de productie van 
cytokinen, chemokinen en groeifactoren.
Hoofdstuk 3 laat zien dat trombine de-differentiatie induceert van RPE cellen tot (myo)
fibroblasten die verhoogd α-smooth muscle actine tot expressie brengen en collageen 
produceren. Dit proces is geassocieerd met verlies van epitheliale karaktereigenschappen 
zoals de expressie van het tight junction eiwit zonula occudens-1. Daarnaast laat de data 
in dit hoofdstuk zien dat de door trombine geïnduceerde de-differentiatie van RPE cellen 
gereguleerd wordt via autocrine pDgfR-signalering. 
Hoofdstuk 4 beschrijft dat trombine de differentiatie van monocyten tot macrofagen 
in monocyt-RPE co-kweken versterkt. Dit differentiatieproces lijkt afhankelijk te zijn van 
een directe interactie tussen de monocyten/macrofagen en de RpE cellen, waarbij in 
ieder geval de adhesiemoleculen CD18 en ICAm-1 betrokken zijn. Deze door trombine 
versterkte macrofaagdifferentiatie resulteert in verhoogde productie van pro-fibrotische 
mediatoren als PDGF-BB, TGF-β2 en VEgf-A. Dit suggereert dat de gevormde macrofagen 
mogelijk fibrotische M2-macrofagen zijn. 
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Hoofdstuk 5 demonstreert dat het glasvocht van patiënten met pVR een verhoogde 
hoeveelheid aan trombine-activiteit bevat. Dit is niet het geval voor glasvocht van 
patiënten met macula gaten, macula puckers en rhegmatogene netvliesloslatingen. 
De verhoogde trombine-activiteit in pVR-glasvocht is een sterke activator van pro-
inflammatoire en pro-fibrotische routes in RPE cellen. 
Alles bij elkaar laat de data in Hoofdstuk 2 t/m 5 zien dat er een belangrijke rol is voor 
trombine in pVR ontwikkeling. Om ontwikkeling van pVR te voorkomen, zou trombine 
dan ook een therapeutische target van interesse kunnen zijn, temeer omdat er directe 
trombine remmers klinisch beschikbaar zijn. 
Hoofdstuk 6 beschrijft de effecten van de klinisch beschikbare directe trombine remmer 
dabigatran (pradaxa) op door trombine en pVR-glasvocht geïnduceerde activatie 
van RPE cellen. Dit effect van dabigatran is vergeleken met dat van dexamethason. 
Dabigatran remt de door trombine geïnduceerde productie van cytokinen, chemokinen 
en groeifactoren door RpE, in tegenstelling tot dexamethason. Dit zou kunnen worden 
verklaard door de relatief lage expressie van de glucocorticoïd receptor in RpE cellen. 
Belangrijk is dat dabigatran ook door pVR-glasvocht (met verhoogde trombine activiteit) 
geïnduceerde productie van cytokinen, chemokinen en groeifactoren door RpE remt. 
Dit geeft de indicatie dat dabigatran intravitreale trombine activiteit kan remmen in een 
glasvochtmatrix. 
In conclusie voorzien de studies beschreven in dit proefschrift in belangrijk nieuw inzicht 
in de bijdrage van vooral trombine bij de inductie van inflammatoire en fibrotische 
processen door RpE cellen tijdens de ontwikkeling van pVR. Inhibitie van intravitreale 
trombine activiteit zou daarom mogelijk een interessante therapeutische strategie zijn 
om de ontwikkeling van pVR te voorkomen of te behandelen. Verdere studies naar 
dergelijke behandelmethoden zijn daarom gewenst.
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Abbreviations
6Ckine  Secondary lymphoid tissue chemokine/CCl21
ApC  Allophycocyanin/antigen presenting cell
ApC-EpCR Activated protein C – endothelial (activated) protein C receptor
AR  Androgen receptor 
ARmD  Age-related macular degeneration
ATIII  Antithrombin III
Axl  AXl receptor tyrosine kinase
BDNf  Brain-derived neurotrophic factor 
bFGF  Basic fibroblast growth factor 
BlC  B-lymphocyte chemoattractant/CXCl13
Bmp  Bone morphogenic protein
BRB  Blood-retinal barrier
BSA  Bovine serum albumin
BTC  Betacellulin
CCl  Chemokine (C-C-motif) ligand
CCR  Chemokine (C-C-motif) receptor
CD  Cluster of differentiation
cDNA  Copy deoxyribonucleic acid
CRAlBp  Cellular retinaldehyde-binding protein 
Ct  Cycle threshold
CTACK  Cutaneous T-cell-attracting chemokine/CCl27
CTgf  Connective tissue growth factor
CXCl  Chemokine (C-X-C-motif) ligand
CXCR  Chemokine (C-X-C-motif) receptor
DApI  4’,6-diamidino-2-phenylindole 
DMEM/F-12 Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 
DTI  Direct thrombin inhibitor
ECm  Extracellular matrix
EDTA  Ethylenediamine tetra-acetate
Egf  Epidermal growth factor
ElISA  Enzyme-enzyme linked immunosorbent assay
EmT  Epithelial-to-mesenchymal transition
ENA-78  Epithelial-derived neutrophil-activating protein 78/CXCl5
fACS  fluorescence activated cell sorter
fCp  fibrinogen cleavage product
fCS  fetal calf serum
fII (a)  (activated) factor II/(pro)thrombin
fITC  fluorescein isothiocyanate
fX(a)  (activated) factor X
gCp-2  granulocyte chemotactic protein 2/CXCl6
GDF  Growth differentiation factor
gDNf  glial cell derived neurotrophic factor 
gH  growth hormone
gm-CSf  granulocyte macrophage colony-stimulating factor
gRO  growth-regulated alpha protein/CXCl1
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HAT  Transmembrane protease serine 11D
HB-Egf  Heparin-binding Egf-like growth factor 
HCC  Thyroid carcinoma, hurthle cell
Hgf  Hepatocyte growth factor 
HplC  High-performance liquid chromatography 
HRp  Horseradish peroxidase
I-309  Inflammatory cytokine-309/CCL1
ICAm  Intercellular adhesion molecule
IFN-γ  Interferon gamma
Igf  Insulin-like growth factor
IgfBp  Insulin-like growth factor binding protein
IKK2  Nuclear factor kappa-B kinase subunit beta 
Il  Interleukin
I-TAC  Interferon-inducible T-cell alpha chemoattractant/CXCl11
KlK  Kallikrein
lDH  lactate dehydrogenase
lIf  leukemia inhibitory factor 
lIgHT  Tumor necrosis factor (ligand) superfamily, member 14
mAC-1  macrophage-1 antigen
mASp-1  mannon binding lectin serine peptidase 1
mCp  monocyte chemotactic protein
m-CSf  macrophage colony-stimulating factor
mDC  macrophage-derived chemokine/CCl22
mDm2  mouse double minute 2 homolog 
mET  mesenchymal-to-epithelial transition
mIf  macrophage migration inhibitory factor 
mIg  monokine induced by gamma interferon
MIP  Macrophage inflammatory protein
mmp  matrix metalloproteinase
mpIf-1  myeloid progenitor inhibitory factor 1/CCl23
mRNA  messenger ribonucleic acid
mSp  macrophage-stimulating protein
mTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAp-2  Napsin B aspartic peptidase
Nf-kB  Nuclear factor-kappa B
NT-3  Neurotrophin 3
OD  Optical density
Opg  Osteoprotegerin
OpN  Osteopontin
pAI  plasminogen activator inhibitor
pAR  proteinase-activated receptor
pARC  pulmonary and activation-regulated chemokine/CCl18
pBmC  peripheral blood mononuclear cell
PBS  Phosphate-buffered saline
pDgf  platelet derived growth factor
pDgf-R  platelet derived growth factor receptor
pDR  proliferative diabetic retinopathy
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pE  phycoerythrin
pEDf  pigment epithelial derived growth factor
pen C 13  penicillium citrinum 13
perCp  peridinin chlorophyl protein
pf4  platelet factor 4
pIgf  phosphatidylinositol glycan anchor biosynthesis, Class f
pmA  phorbol-12-myristate-13-acetate
pOS  photoreceptor outer membrane segments
ppV  pars plana vitrectomy
pTX3  pentraxin 3 
pVR  proliferative vitreoretinopathy
RANKl  Receptor activator of nuclear factor kappa-B ligand
RANTES  Regulated on activation, normal T-cell expressed and secreted/CCl5
RpE  Retinal pigment epithelium
RpmI-1640 Roswell park memorial institute-1640 medium
RQ-pCR  Real-time quantitative polymerase chain reaction
RRD  Rhegmatogenous retinal detachment
RVO  Retinal vein occlusion
SCf  Stem cell factor
SDf-1a  Stromal cell-derived factor-1A/CXCl12
SDS-pAgE Sodium dodecyl sulphate-polyacrylamide gel electrophorese
SEm  Standard error of the mean
SmAD7  mothers against decapentaplegic 7
TARC  Thymus and activation-regulated chemokine/CCl17
TBS  Tris-buffered saline
TECK  Thymus expressed chemokine/CCl25
Tf   Tissue factor
Tgf  Transforming growth factor
TImp  Tissue inhibitor of metalloproteinase
TJp1  Tight junction protein-1
TlR  Toll-like receptor
TmpRSS2 Transmembrane protease serine 2
TNf  Tumor necrosis factor
Tp53  Tumor protein 53
tpA  Tissue plasminogen activator
TRAIl  TNf-related apoptosis inducing ligand 
TSlp  Thymic stromal lymphopoietin 
upA  urokinase plasminogen activator
VEgf  Vascular endothelial growth factor
ZO-1  Zonula occludens-1
α-SMA  alpha-smooth muscle actin
β-NGF  beta-nerve growth factor 
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Dankwoord
Wie had tot een paar jaar geleden ooit nog gedacht dat ik het dankwoord van mijn 
proefschrift zou schrijven? En toch is het inmiddels zover. Zo zie je maar waar een hoop 
inspirerende en motiverende mensen om je heen toe kunnen leiden. Ik zal dan denk ik 
ook wel één van de laatste zijn die zal beweren dit alles alleen voor elkaar te hebben 
gekregen. Tijdens dit promotietraject waren er hoge pieken maar ook diepe dalen, en dit 
alles heb ik kunnen delen met geweldige vrienden en collega’s. Het succesvol afronden 
van mijn promotie heb ik te danken aan een hoop mensen, en omdat het altijd de vraag 
is waar te beginnen, begin ik maar gewoon in chronologische volgorde.
Dan mag ik meteen beginnen bij een zeer gewaardeerde onderzoeker binnen de afdeling 
Immunologie. Beste Dr. van den Burg, beste mirjam, bij jou had ik initieel gesolliciteerd 
voor een positie als analist in de pID werkgroep. Al vrij snel werd voor ons beiden duidelijk 
dat de hoeveelheid diagnostiek die bij deze functie hoorde, niet voor mij was weggelegd. 
Desalniettemin heb je mijn C.V. bewaard en deze later doorgegeven aan Wim, bij wie een 
plek voor een research analist vrij kwam. Als jij dat destijds niet had gedaan, had ik hier 
nu niet gestaan. Heel erg bedankt hiervoor.
Beste Dr. Dik, beste Wim, jij gaf me de gelegenheid om me als analist verder te ontwikkelen 
binnen jouw groep, en later gaf je me zelfs de kans om aan dit promotietraject te 
beginnen; een beslissing die een risico voor ons beiden met zich meebracht. Bedankt 
dat je me deze keuze hebt gegeven. Daarnaast wil ik je ook zeker bedanken voor de 
geboden kansen waarbij ik mezelf nog verder en breder kon ontwikkelen, waaronder de 
mogelijkheid om relatief veel (inter)nationale congressen te bezoeken. Voor mij waren 
dit belangrijke momenten waar ik vaak het meeste leerde. Hierop aansluitend wil ik ook 
graag prof. dr. Hooijkaas bedanken voor de mogelijkheid om aan dit promotietraject te 
beginnen. Beste Herbert, bedankt voor de goede zorgen. Ik wens je het allerbeste voor 
de toekomst.
Beste prof. dr. van meurs, beste Jan, u ook bedankt voor het vertrouwen en de 
mogelijkheid voor mij om aan dit promotietraject te mogen beginnen. Onze korte 
overleggen waren voor mij altijd erg motiverend. Het feit dat u wat verder van het 
laboratorium af staat, was voor mij een goede stimulans om mijn onderzoek binnen de 
oogheelkunde op een andere manier te leren uitleggen, zodat het ook begrijpelijk wordt 
voor mensen die niet op een laboratorium werkzaam zijn.
Beste prof. dr. van Hagen, beste martin, ook jou wil ik graag bedanken voor het 
vertrouwen en je bijstand met raad en daad. Jouw wijsheid is van unieke waarde. Ook 
onder jouw vleugels heb ik me breder mogen en kunnen ontwikkelen; eerst op het fcRn-
project met Kiki en later binnen mijn eigen promotietraject. 
Beste Prof. dr. Vingerling, Prof. dr. Hofland en Prof. dr. Kijlstra bedankt dat jullie plaats 
wilden nemen in de kleine commissie ter beoordeling van mijn concept proefschrift. 
Verder ook dank aan de overige leden van de grote commissie voor jullie bijdrage.
Beste Verena, als promovendi binnen hetzelfde project waren we deels op elkaar 
aangewezen, ook al was het mijn taak een ‘laboratory-based’ rationale te vinden en was 
het jouw taak om die rationale te gebruiken voor het vervolg van jouw studies, waaronder 
de trials. Ondanks dat er soms maar weinig van het hele invries- en opslagsysteem klopte, 
waardeerde ik onze discussies bij de -80oC vriezer zeer. Ik wens je nog heel veel succes bij 
het afronden van jouw studies.
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Ook veel dank aan de collega’s van de afdeling Oogheelkunde voor jullie bijdrage. In 
het bijzonder Joeri en Emine, het door jullie verzamelde patiëntenmateriaal is van grote 
waarde geweest.
Kim en leendert, jullie hebben waarschijnlijk geen idee hoe dankbaar ik jullie ben. Als 
kantoorgenoten hebben we heel veel gedeeld (waarvan een groot deel in snoeppotten 
zat) en vooral veel gelachen. Toen ik de kans kreeg om aan dit promotietraject te 
beginnen, waren jullie voor mij van onschatbare waarde. Ik kon me geen betere 
rolmodellen voorstellen. Hard werkend, flexibel en succesvol. Als ik bij jullie (en deels 
ook Marten en Jan Willem) de kunst van het promoveren niet had kunnen afkijken, weet 
ik niet of alles zo was gelopen zoals het gedaan heeft.
My sweet Asian invader Prayer. We shared the same office for the last three years. 
Together we were the odd ones out at the department of Immunology, since actual 
immunology was missing in both our projects. I take a deep bow for your endurance with 
all the Thai jokes we made, and I have deep respect for your perseverance to come to 
Holland for your PhD. The cultural and climate differences must have had a huge impact 
on you. your grown (and enforced) admiration for B-Brave was maybe a bit too much, 
but for you we accepted it. I wish you all the best in your future career and life. Rock the 
Boat! 
Then my other sweet Asian invader Rina. Also for you I have so much respect. It takes a 
lot of dedication to leave your sons and husband behind (for limited periods) to do your 
studies in our lab. luckily there is Skype, so you all could stay in touch. Thank you so 
much for your support. for me it was of great help to have an ophthalmologist so close 
by. Also to you, I wish all the best in your future career and life. gangnam on!!!
lieve Hanna, wat heb ik toch veel aan jou gehad. Bij elkaars ‘crisis’ momenten naar 
Doppio rennen om daar alles te relativeren en tot rust te komen. gelukkig voor ons 
waren die er niet zo veel en hadden we het vooral vaak heel gezellig. Je bent een topper!
Jorn, toen jij als AIO op het lab kwam, was het aantal mannelijke AIO’s behoorlijk beperkt 
en waren we op dat vlak op elkaar aangewezen. gelukkig ging dat meer dan prima en 
hebben we er een mooie tijd van gemaakt. Samen in de fC (alhoewel, hoe fC ben je als je 
tijdens de labdag in Thailand op het strand ligt?), organisatie van WK voetbal en Tour de 
france poules, of een lekker ‘bakkie’ in Den Haag buiten werktijd. Het resultaat van mijn 
waardering hiervoor pronkt nog altijd in A0 formaat op de 12de verdieping. Ik wens je heel 
veel succes met alles wat nog gaat komen. Jij gaat het maken! 
Ook een woord van dank naar alle andere AIO’s binnen de afdeling Immunologie. 
Britt(y), wat heb je een heerlijke humor. Ik zal ons hoekje voor ‘special people’ op 
de NVvI missen. gelukkig hebben we ons motto nog: oog om oog, tand(vlees) om 
tand(vlees). En gewoon omdat het kan, nog één keertje in Koos Alberts stijl van boven 
naar beneden: oog, tandvlees, nier en ‘iets met langerhanscellen’. Als we het dan toch 
over humor hebben dan kan ik H.K.H. martine natuurlijk niet vergeten. Zonder in te veel 
details te treden over alle momenten waarop we hebben zitten gieren: KlAp! fabi, my 
friend, never have I met someone with such a drive for a huge career in medicine and 
science as you. luckily, you also know how to enjoy life. So keep rocking it! Chris, mati 
and Karin, although you have left the department a while ago, I also want to thank you 
for some really great moments. Verder ook dank aan alle andere AIO’s waarmee ik de 
afgelopen 4 jaar heb mogen delen: Alice, Anna, Armanda, Chris, Christina, Diana, Dew, 
Ewout, ferry, Hessel, Iris, Jenna, Joey, Jojanneke, Karim, Karin, Kiki, lieke, lisa, lizenka, 
lucy, maarten, magda B, magda R, malou, marieke, marjolein, marlieke, Naomi, Nicole, 
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Odilia, prisca, Sandra, Simar, Wendy, Wida, Willem Jan, Wouter B, Wouter vdB en Zana. 
Ik wens jullie allen het allerbeste!
Dan is het toch echt tijd voor de twee grootste toppers van het lab: (puzzz) Nicole 
en (tante) Conny. Wat had ik zonder jullie gemoeten en wat ben ik jullie ontzettend 
dankbaar!!! Niet alleen voor jullie keiharde werk, inzet en flexibiliteit, maar ook om wie 
jullie zijn. Zonder jullie had dit proefschrift er een stukje dunner uitgezien, en waren de 
afgelopen jaren vast en zeker veel moeizamer verlopen. Of het nou ging om (on)gein 
uithalen, in canon het kuikentjes lied zingen in de lAf-kasten, het jaarlijks herhalen van 1 
april grappen, studenten ondervragen CSI-stijl, ‘Nederlands’ leren aan onze buitenlandse 
collega’s of de loze conversaties. Alles kon en alles mocht. Het meest bijzondere vond ik 
nog wel dat jullie bij een half woord al voor me klaar stonden. Dan pas ga je beseffen wat 
collegialiteit, flexibiliteit en inzet echt inhouden. Weet dat ik het oprecht waardeer! Het 
kan natuurlijk ook niet anders dan dat ik met jullie aan mijn zijde mijn promotietraject wil 
afsluiten. Bedankt dat jullie mijn paranimfen willen zijn. 
En dan de rest van het warme nestje waarin ik belandde: de IRD werkgroep. In geen 
enkele werkgroep zijn diagnostiek en research zo strikt gescheiden als bij ons, en toch 
wisten we elkaar te vinden. marja en marion, onze labmoeders en dynamisch duo. Jullie 
ook ontzettend bedankt voor jullie hulp en inzet. Ik waardeer het zeer dat jullie telkens 
maar weer tijd wilden inruimen voor mijn multiplex analyses. Verder wil ik uiteraard ook 
Benjamin, Corrien, Dagmar, Dicky, gemma, marten, Nicoline en Jan Willem bedanken 
voor de gezelligheid en talloze mooie momenten op het lab. De studenten die hebben 
bijgedragen aan dit project: Nada, pauline, peter en Rosanne, jullie ook heel erg bedankt 
voor jullie inzet en bijdrage. En ook de andere studenten in onze werkgroep Irma, Judith, 
Jacolien, Kees, marloes, Simon, Vilma en alle anderen, bedankt voor de gezelligheid.
gellof, patricia, maaike en Barbara, ook jullie wil ik heel graag bedanken voor de vele 
zeer mooie momenten. Wat zal ik die gaan missen. Of het nou ging om borrels, feestjes, 
festiviteiten buiten werktijd of al het andere wat met gezelligheid te maken heeft, we 
wisten elkaar te vinden. Op het moment dat het even niet zo goed ging, waren jullie 
er ook en dat is mij meer dan goud waard! En lieve patries, intern ook wel bekend als 
mevrouw Bastiaans, wie weet zal het in de toekomst misschien toch nog…???
monique, mijn lieve p.A., wat ben je toch een heerlijk mens. Recht voor z’n raap en dat 
alles heerlijk op z’n Haags. Wat is het toch mooi als je kunt communiceren zonder ook 
maar één woord te zeggen. Wat hebben we een hoop afgelachen en wat zullen we dat 
nog vaak gaan doen. Want of we nou op het lab zijn of in Den Haag om met o.a. Edward 
een ‘bakkie’ te doen, het is altijd gezellig. Bedankt voor wie je bent en bedankt voor het 
feit dat je altijd voor me klaar staat. 
uiteraard wil ik alle andere collega’s ook ontzettend bedanken voor al die mooie 
momenten in de afgelopen jaren. mensen van de AIZ, bedankt dat jullie ons als klein 
researchgroepje wilden adopteren. Jullie input wordt zeer gewaardeerd. Diana, zowel 
de BBQ’s als de carnavalsoptochten in prinsenbeek waren iedere keer weer top! De 
vrijmibo’s en lunches met de mensen van de AID waren ook altijd leuk. marco, jij in het 
bijzonder nog bedankt voor het feit dat je af en toe back-up begeleider wilde zijn. Je 
weet het: ‘we do make the difference!’. Ingrid Pico, zoals jij overal een feestje van weet 
te maken, dat kan er maar één. Vooral blijven doen! Dames bij de frontservice, we zagen 
elkaar niet heel vaak maar we hebben ook heel wat afgelachen samen. Keep up the 
good work! Dames van het secretariaat, jullie ook bedankt voor alle goede zorgen en 
behulpzaamheid. mJ’s, ook jullie bedankt voor de gezelligheid en hulpvaardigheid. Aan 
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alle anderen waarvan ik de naam niet heb genoemd, weet dat ik heel erg genoten heb 
van mijn tijd bij de afdeling Immunologie en daar heb jij zeker aan bijgedragen.
Ook wil ik nog graag mijn vrienden bedanken voor alle steun en support de afgelopen 
jaren. Of we elkaar nou veel zagen of niet, op jullie kon ik rekenen! Bedankt voor die 
talloze mooie momenten. Jullie zijn allemaal kanjers. Het is niet mogelijk om iedereen 
hier te noemen maar een paar mensen wil ik toch graag in het bijzonder bedanken. lieve 
Suus en miek, in 2001 werden we huisgenoten en later inwoners van Den Haag. Inmiddels 
hebben we alles wel van elkaar gezien, gehoord en meegemaakt, en dat schept een hele 
sterke band. Suus, hoe onze carrières ook zullen gaan verlopen, ons ‘navelstrengetje’ zal 
ons altijd blijven binden. miek, als rotsen in de branding hebben we veel voor onze kiezen 
gehad maar we staan nog steeds overeind. En hoe!! Jeroen, wij delen eenzelfde interesse 
in optimale vrijetijdsbesteding. Zo ervaren als jij zal ik nooit worden maar dat zal de pret 
absoluut niet drukken. lieve Kaat, door dik en dun, je was er altijd wanneer ook nodig. 
Zelfs nu je in België woont, weten we elkaar nog genoeg te vinden. Dergelijke afstanden 
zijn maar relatief en je bent het meer dan waard! Karolina, Tsutsie, ooit begonnen we als 
collega’s bij Add2X en nu kom ik niet meer van je af. gelukkig maar, want je bent er één 
uit duizenden. flip, pretletter, heerlijk zoals jij in het leven staat: All-in en gaan met die 
banaan! Stiekem benijd ik je daar wel eens om. Vanaf nu kan ik meer tijd investeren in het 
afkijken van deze kunst. Anne Marie, jouw enthousiasme en drive werken zo aanstekelijk. 
Recht op je doel af en het lukt je steeds weer. Tegenwoordig zien we elkaar niet zo vaak 
meer maar gelukkig hebben we nog steeds onze culinaire en culturele uitstapjes die dat 
meer dan goed maken. Bas, ooit begonnen we als bestuursgenoten bij SSR-W en over tig 
jaar eindigen we, daar waar we ooit begonnen zijn, op de vloer naast de bar, dan van je 
eigen brouwerij die je gegarandeerd nog eens gaat opzetten. Beter zouden we het haast 
niet kunnen treffen. 
En tot slot mijn familie met in het bijzonder mijn lieve muti. Al begrijp je helemaal niets 
van alles wat ik de afgelopen jaren heb gedaan, zonder jouw support had ik nooit kunnen 
bereiken wat ik nu heb bereikt. Zeker het afgelopen jaar, wat voor ons beiden erg zwaar 
was, stond je voor me klaar. Het was een lange rit, maar ik ben er! Bedankt!
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